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Structural heart disease comprises a spectrum of non-coronary based cardiac 
pathologies, including valvular heart disease and primary hypertrophic cardio-
myopathy (HCM). Valvular heart disease involves myopathy secondary to pres-
sure loading (e.g. aortic stenosis) or volume loading (e.g. mitral regurgitation). 
In primary HCM the myocardium is primarily affected by mutation of sarcomeric 
protein encoding genes. Both forms of structural heart disease are characterized 
by structural and functional myocardial changes that ultimately impose a risk of 
arrhythmia, heart failure and (sudden) death, if left untreated.1, 2 Thorough risk 
stratification has therefore become mainstay for decision making concerning the 
need, timing, and type of therapeutic interventions. In addition adequate patient 
selection is crucial as these interventions tend to become less invasive, includ-
ing transcatheter approaches. In this regard, the myriad of non-invasive cardiac 
imaging modalities and techniques, as well as clinical surrogates, provides unique 
opportunities for risk stratification and patient selection.
Due to its wide availability, versatility and non-invasive nature, echocardiography 
remains the first line modality for risk stratification and patient selection for trans-
catheter therapies. 3-Dimensional (3D) echocardiography offers superior valvular 
anatomical and structural information compared to 2-dimensional echocardiog-
raphy and its accuracy to quantify left ventricular ejection fraction is superior to 
2-dimensional echocardiography when compared to magnetic resonance imaging 
as reference standard.3, 4 Echocardiographic deformation imaging (strain, strain 
rate) can depict early and preclinical functional alterations of the myocardium.5 
With the advent of advanced automatization, increasing measurement reproduc-
ibility, both advanced echocardiographic techniques may fuel further advances to 
establish their role in the clinical arena of structural heart disease management.6 
PATIENT SELECTION FOR TRANSCAThETER VALVE ThERAPIES: RISk SCORES 
AND 3-DIMENSIONAL EChOCARDIOgRAPhy
Significant valvular heart disease, mainly aortic stenosis and mitral regurgitation, 
affects 3% of the general population, and is associated with increased morbidity 
and mortality.7 The coincidence of population ageing with valvular heart disease 
prevalence raising over 8% in patients older than 65 years, makes that the global 
burden of valvular heart disease is expected to grow significantly.7 Due to inherent 
clustering of co-morbidities, however, many of these patients are at high or even 
prohibitive risk for conventional valve surgery, the gold standard treatment. Sur-
veys have confirmed that such patients are often denied surgery, associated with 
dismal outcome.8, 9 Transcatheter valve therapies provide a valuable therapeutic 
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alternative for symptomatic patients with severe valvular heart disease that are 
at high or prohibitive surgical risk. Transcatheter aortic valve implantation (TAVI) 
comprises the insertion of a self or balloon-expandable bioprosthetic valve within 
the stenotic native aortic valve via percutaneous route. (Figure 1) Percutaneous 
mitral valve repair using Mitra-Clip involves placement of a cobalt-chromium clip 
to attach both mitral leaflets at the origin of the regurgitant jet. This procedure 
significantly reduces mitral regurgitation severity by creating a double orifice 
valve and is performed via transfemoral venous access. (Figure 2) Both therapies 
relief symptoms and are associated with improved functional status, quality of life, 
reduced heart failure hospitalizations and, in case of TAVI, improved survival when 
compared to optimal medical therapy.10-12 Although an attractive option for many 
patients, the outcome of transcatheter therapies critically depends on adequate 
patient selection (including risk stratification and technical eligibility assessment) 
and procedural guidance. Clinical evaluation and 3D cardiac imaging have become 










Transcatheter aortic valve implantation (TAVI). Panel A: The balloon-expandable Sapien 3 prosthesis (Edwards Life-
sciences). Panel B: The self-expandable Evolut R Corevalve prosthesis (Medtronic). Panel C: Procedural principles 
of TAVI.1: degenerative calcified aortic valve stenosis. 2: arterial transfemoral access. 3: balloon dilatation of dis-
eased native aortic valve. 4: meticulous positioning of a balloon-expandable prosthesis. 5: balloon expansion of 









Surgical risk scores including EuroSCORE and Society of Thoracic Surgeons (STS) 
score have been widely adopted as a simple tool to calculate 30 day surgical 
mortality risk and categorize patients into high or prohibitive risk for conventional 
surgery.13, 14 Importantly, however, being at increased surgical risk does not imply 
beneficial outcome when transcatheter therapy is provided. In addition, these sur-
gical risk scores have not been developed nor validated for patients undergoing 
percutaneous valvular interventions. Apart from procedural related factors, patient 
related factors including advanced age, renal dysfunction and frailty amongst oth-
ers may independently relate to outcome after transcatheter therapies. Clinical 
risk scores, based on preprocedural patient related factors, to predict outcome in 
case of transcatheter valve therapy are an unmet clinical need that may represent 
a valuable additional tool for decision making and patient management.2







Transcatheter mitral valve repair (Mitra-Clip). Panel A: The cobalt-chromium Mitra-Clip (Abbott Vascular). Panel B: 
Procedural principles of Mitra-Clip.1: venous transfemoral access. 2: transseptal insertion of clip delivery system. 
3: Mitra-Clip positioning perpendicular to coaptation line of dysfunctional mitral valve. 4: insertion of clip into 
left ventricle at site of maximal regurgitation. 5: grasping and clipping of both anterior and posterior mitral valve 
leaflet with significant regurgitation reduction. 6: double orifice mitral valve.
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3-dimensional echocardiography
Tremendous advances have been made by the introduction of matrix-array 
transducers that allow for acquisition of a 3D pyramidal volume during one or 
more cardiac cycles while holding breath. Apart from more accurate and reli-
able semi-automated quantification of ventricular volumes, mass, and ejection 
fraction compared to conventional echocardiography, 3D-echocardiography has 
revolutionized cardiac valve assessment, in particular of the mitral valve.4, 15 The 
technique permits simultaneous visualization of multiple transsections through a 
region of interest (multi-plane imaging), allows to cut and examine the 3D volume 
at any desired level or plane and, even more important, provides the surgical or en 
face view of the valve. These properties translate into unique, superior and repro-
ducible morphological and structural evaluation of the diseased mitral valve, even 
for novice readers.4, 16 (Figure 3) In addition quantification of valve area and (func-
tional) regurgitation can be performed more reliably.4 Further software analysis 
also permits to create 3D models of the mitral valve complex to derive a multitude 
of geometric indices and measures, thereby providing unique pathophysiological 
insights into mitral valve disease.4 (Figure 3) Of note, acquisition quality of 3D 
datasets to avoid artifacts or low temporal resolution, subject to learning curve, is 
critical for reliable use.
In patients undergoing transcatheter valve therapies, including TAVI and Mitra-
Clip, 3D-echocardiography is becoming mainstream for patient selection and 
procedural guiding.17 3D-imaging by echocardiography or computed tomography 
shows the typical oval shape of the aortic annulus which critically determines 
the choice of adequate valve prosthesis size in patients undergoing TAVI. In ad-
dition 3D transesophageal echocardiography may be useful to assist in adequate 
positioning of the valve prosthesis during the procedure, an important outcome 
A B C 
Figure 1.3
Three-dimensional echocardiography of the mitral valve. Panel A: Surgical view with P2 scallop flail (arrow) due to 
chordal rupture. Panel B: Double orifice valve after central Mitra-Clip. Panel C: 3-dimensional model of complex 









determinant.18 3D-echocardiography is even more indispensible in patients 
undergoing Mitra-Clip therapy.17 Technical eligibility for Mitraclip includes a mul-
titude of anatomic criteria that can easily be assessed by 3D-echocardiography: 
central (non-commissural) jet origin, mitral valve area > 3.5-4.0 cm², no calcifi-
cation, cleft or significant leaflet thickening in the grasping area, non rheumatic 
disease, sufficient mobile leaflet length, minimal residual leaflet coaptation length 
and non extensive tethering (coaptation depth) for functional regurgitation and 
non extensive flail width and gap for organic regurgitation.19 Equally important 
3D-echocardiography is the cornerstone during procedural guidance as, contrary 
to TAVI, fluoroscopic imaging has a very limited role to depict the mitral valve.
DEFORMATION IMAgINg IN STRuCTuRAL hEART DISEASE: ECg AND 
EChOCARDIOgRAPhIC SuRROgATES OF CARDIAC FIBROSIS
Myocardial Fibrosis
Myocardial fibrosis refers to increased collagen content in the myocardium. Focal 
fibrosis comprises myocardial cell loss replaced by collagen (replacement fibrosis, 
scar), while diffuse fibrosis represents increased interstitial collagen without no-
table cell loss (interstitial fibrosis).20, 21 Diffuse fibrosis often precedes focal fibrosis 
and is predominantly found in non-ischemic mitral regurgitation patients.22 Focal 
fibrosis to a variable extent is found in 30-60% of patients with aortic stenosis 
and in 42-71% of primary HCM patients.23-27 Presence of fibrosis adversely af-
fects myocardial diastolic and later systolic function due to reduced myocardial 
compliance and increased stiffness and relates to structural remodeling. Moreover, 
it provides a substrate for re-entry tachyarrhythmia. Fibrosis has been linked to 
clinical translates such as symptom and arrhythmia onset, heart failure and even 
(sudden) death.23, 27 Identification of fibrosis therefore provides an attractive target 
that may hold the key for early risk stratification and hence decision-making in 
patients with structural heart disease.
ECg and fibrosis
Fragmentation of QRS complexes on surface ECG (comprising various RSR’ pat-
terns) has been related to fibrosis in both ischemic and non-ischemic cardio-
myopathy.28, 29 Moreover its presence was shown to be associated with adverse 
outcome in a variety of cardiomyopathies such as ischemic cardiomyopathy, 
arrhythmogenic right ventricular dysplasia, Brugada syndrome and idiopathic 
dilated cardiomyopathy.30-32 Abnormal ECG findings are noted in 75 up to 95% of 
primary HCM patients, however, no such abnormalities have consistently shown a 
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relationship to poor outcome in these patients. The presence and potential clinical 
value of QRS fragmentation, as a surrogate marker of fibrosis, has been poorly 
explored in this patient population.
Deformation imaging and fibrosis
Speckle tracking echocardiography involves frame by frame tracking of natural 
acoustic markers present in B-mode images, so called ‘speckles’, during the cardiac 
cycle. This technique measures displacement of myocardial segments and allows 
semi-automated quantification of velocity, relative myocardial length changes 
(strain) and the speed of these changes (strain rate) in longitudinal, circumferen-
tial and radial direction, due to its angle independency.33 In addition the wringing 
motion of the left ventricle with clockwise rotation of the base and anticlockwise 
movement of the apex, due to the helical myocardial architecture, can be assessed 
as rotation and twist (net rotation difference between base and apex).33 It is a 
robust imaging technique, validated against sono-micrometry, that offers great 
opportunities to study the complex myocardial atrial and ventricular function, far 
more sensitive than ejection fraction.34 The average peak systolic strain value of 
all segments of the left ventricle is expressed as global longitudinal strain and 
often represented by a color-coded bull’s eye plot. (Figure 4)
Longitudinal deformation is predominantly determined by endocardial fibers 
and explored most as the subendocardium is most vulnerable and early affected in 
the vast majority of cardiomyopathies. Longitudinal deformation is determined by 
intrinsic myocardial contractility, chamber structure, geometry, loading conditions 
and, importantly, fibrosis extent.35 Therefore it represents a valuable and sensitive 
marker yielding great potential as a biological signal related to multiple clinical 
endpoints in patients with structural heart disease, often regarded as a surrogate 
marker of fibrosis. As longitudinal dysfunction precedes overt left ventricular 
dysfunction in terms of reduced ejection fraction, it represents an ideal tool to 
detect subclinical dysfunction. Indeed, impaired left ventricular longitudinal de-
formation despite preserved left ventricular ejection has been consistently shown 
in patients with significant aortic stenosis, mitral regurgitation and hypertrophic 
cardiomyopathy.36-38 In valvular heart disease (early) impaired longitudinal de-
formation relates to symptom onset, heart failure, decreased survival and worse 
postoperative outcome.38-40 In primary HCM a relation with decreased survival and 
tachyarrhytmia has been shown.41 Although atrial remodeling is present in both 
mitral regurgitation and primary HCM, related to dismal outcome, the clinical value 









Objectives and outline of the thesis
In this thesis we explore the risk stratification and management of patients with 
structural heart disease, focusing on valvular heart disease and primary HCM. In 
particular the potential clinical role of advanced echocardiography including 3D-
echocardiography and deformation imaging (strain), as well as clinical surrogates 
are studied. Although risk often comprises a continuum rather than a dichotomous 
phenomenon, its assessment is a prerequisite for clinical decision making in daily 
practice.
Part I focuses on the potential role of 3-dimensional echocardiography. At first 
a clinical risk score model for prediction of outcome in patients undergoing TAVI 
is presented (Chapter 2). Second the role of 3D-echocardiography is explored in 
depth in patients with mitral valve disease. Different non-invasive cardiac imaging 
modalities to evaluate mitral valve function and anatomy are described and the 
use of 3D-echocardiography is put into perspective (Chapter 3). We then evaluate 
the role of the latter to gain insights in patients with functional mitral regurgitation 
(Chapter 4), to select patients and guide procedures regarding percutaneous mitral 
valve repair using Mitra-Clip (Chapter 5) and to assess the effect of Mitra-Clip on 
the mitral valve (Chapter 6).
In Part II we further elaborate the potential role of risk stratification by ECG and 
myocardial deformation imaging (strain), as surrogate markers of fibrosis. Surface 
ECG fragmentation in primary HCM is first evaluated (Chapter 7). The important 
future role of fibrosis imaging in valvular heart disease patients is then reviewed 
(Chapter 8). Finally the role of left atrial structure and function is evaluated in 





Left ventricular and atrial longitudinal strain. Panel A: Bull’s eye plot showing reduced left ventricular global longi-
tudinal strain (GLS) despite normal left ventricular ejection fraction (LVEF) in a patient with primary hypertrophic 
cardiomyopathy. Maximal hypertrophy in septal and anteroseptal region corresponds to most impaired longitudi-
nal deformation (blue and pink). Panel B: Left atrial longitudinal strain assessment.
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Value of the ‘TAVI2 -SCORe’ versus Surgical Risk 
Scores for Prediction of One Year Mortality in 511 
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A bed-side available transcatheter aortic valve implantation (TAVI)-dedicated 
prognostic risk score is an unmet clinical need. We aimed to develop such a risk 
score predicting 1-year mortality post-TAVI and to compare it to the performance 
of the logistic EuroSCORE I (LES-I) and II (LES-II) and the Society of Thoracic Sur-
geons (STS) score.
Methods and Results
Baseline variables of 511 consecutive patients undergoing TAVI that were inde-
pendently associated with 1-year mortality post-TAVI were included in the TAVI2-
SCORe. Discrimination and calibration abilities of the novel score were assessed 
and compared to surgical risk scores. One-year mortality was 17.0% (n=80/471). 
Porcelain Thoracic aorta (HR 2.56), Anemia (HR 2.03), left Ventricular dysfunction 
(HR 1.98), recent myocardial Infarction (HR 3.78), male Sex (HR 1.81), Critical 
aortic valve stenosis (HR 2.46), Old age (HR 1.68) and Renal dysfunction (HR 1.76) 
formed the TAVI2-SCORe (all p<0.05). According to number of points assigned (1 for 
each variable and 2 for infarction), patients were stratified into 5 risk categories: 
0, 1 (HR 2.6), 2 (HR 3.6), 3 (HR 10.5) and ≥4 (HR 17.6). TAVI2-SCORe showed best 
discrimination ability (Harrells`C statistic 0.715) compared to LES-I, LES-II and 
STS scores (0.609, 0.633 and 0.50, respectively). Cumulative 1-year survival was 
54% versus 88% for patients with TAVI2-SCORE ≥3 versus <3 points, respectively 
(p<0.001). Contrary to surgical risk scores, there was no significant difference 
between observed and expected 1-year mortality for all TAVI2-SCORe risk strata 
(all p>0.05, Hosmer-Lemeshow statistic 0.304), suggesting superior calibration 
performance.
Conclusions
The TAVI2-SCORe is an accurate, simple and bed-side available score predicting 










Current guidelines recommend transcatheter aortic valve implantation (TAVI) to 
improve symptoms and/or survival in symptomatic patients with severe aortic 
valve stenosis and high or prohibitive risk for surgical aortic valve replacement.1 
Candidate selection for TAVI is based on the heart-team decision.1 Current surgi-
cal risk scores, including the logistic EuroSCORE I (LES-I), the logistic EuroSCORE 
II (LES-II) or the Society of Thoracic Surgeons (STS) score predict 30 day survival 
after conventional surgery and are used to identify high or prohibitive surgical risk 
patients.1, 2 These risk scores, however, are not designed nor validated to assess 
mortality risk for TAVI. In particular, a few studies that have evaluated the value of 
conventional surgical risk scores to predict 1-year mortality after TAVI concluded 
that the heart-team evaluation remains the cornerstone in decision-making in the 
absence of a TAVI-dedicated risk score that might have superior discrimination or 
calibration properties than conventional surgical risk scores.3-6 Accordingly, a risk 
score to predict outcome after TAVI and thereby optimize the selection of patients 
remains an unmet clinical need.7, 8 The aim of the current study was to test and 
compare the performance of LES-I, LES-II and STS score to a newly developed TAVI-
dedicated clinical risk score to predict 1-year mortality post-TAVI. We hypothesized 
that a TAVI-dedicated risk score based on baseline preprocedural patient character-
istics might be superior to conventional surgical risk scores in predicting survival.
METhODS
Patient population
Patients with symptomatic severe aortic stenosis (valve area <1.0 cm² and/or <0.6 
cm²/m² and/or mean gradient ≥40 mmHg) who underwent TAVI at the Leiden Uni-
versity Medical Center (Leiden, the Netherlands) and Centro Cardiologico Monzino 
IRCCS (Milan, Italy) between November 2007 and November 2012 were included. 
All patients were considered to be at high or prohibitive surgical risk, according to 
the heart-team decision. Baseline patient demographic data, cardiovascular risk 
factors, symptoms, medication, laboratory variables and 2-dimensional transtho-
racic echocardiographic data were retrospectively analyzed.
Echocardiography
Baseline transthoracic 2-dimensional echocardiography was performed using 
commercially available ultrasound systems (Vivid 7 and E9, GE Medical Systems, 
Horten, Norway and iE33, Philips Medical systems). Standard gray-scale and Dop-
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pler ECG-triggered cine-loop images were acquired and transferred to a worksta-
tion for off-line analysis (EchoPAC version 110.0.0 or 112.0.0). Left ventricular 
(LV) assessment was performed as recommended, including LV linear dimensions 
measured at the parasternal long-axis view and LV mass calculated using the 
Devereux’s formula and indexed to body surface area.9 LV volumes and ejection 
fraction were measured according to the Simpson’s method. Similarly, left atrial 
volume was determined. All volumes were indexed to the body surface area. Early 
mitral inflow velocity (E) was measured on pulsed wave Doppler recordings with 
the sample volume located at the tips of the mitral leaflets and the early septal 
mitral annular velocity (E’) was assessed on apical 4-chamber tissue-Doppler ac-
quisitions.10 Subsequently the E/E’ ratio was calculated. Mitral, aortic and tricuspid 
valve regurgitation were evaluated using spectral and color-Doppler images and 
semi-quantitatively graded as trivial, mild, moderate and severe, as recommend-
ed.11 Aortic valve area was assessed using the continuity equation and indexed to 
the body surface area.12 On continuous wave Doppler acquisitions in the apical 
5-chamber view the mean transaortic valve gradient was measured.12 Maximal 
tricuspid regurgitant jet velocity combined with inferior caval vein respiratory 
variation was used to calculate systolic pulmonary arterial pressure.13 
Mortality risk factors
Baseline patient data were used to calculate individual values of conventional 
surgical risk scores that assess the probability of 30 day mortality after cardiac 
surgery: LES-I, LES-II and STS score. Parameters were entered according to the web-
site definitions. Additional baseline factors, potentially relating to increased risk of 
mortality after TAVI, were also collected. These included laboratory findings such 
as hemoglobin, C-reactive protein (CRP), serum albumin, aspartate transaminase 
(AST), alanin aminotransferase (ALT) and total bilirubin. Poor mobility and neuro-
logic dysfunction were defined in accordance with website definitions applied in 
the LES-II. Frailty was present when evidence existed of a syndrome of decreased 
reserve and resistance to stressors, resulting from multiple declines across multiple 
physiologic systems, leading to vulnerability to adverse outcomes.14, 15 Cognitive 
dysfunction or dementia was noted if mentioned in the medical history. Porcelain 
aorta and hostile chest were defined in accordance with recent VARC-2 consensus 
definitions.16 Urgent procedural need comprised patients requiring intervention 
on current admission for medical reasons.
TAVI procedure
The vast majority of TAVI procedures (n=499, 98%) were performed using a 








oof 23, 26, or 29 mm. A minority of patients (n=12, 2%) received a self-expandable 
CoreValve prosthesis (Medtronic, Minneapolis, USA), using similar sizes. Prosthesis 
sizing was based on aortic annulus measurements using 3-dimensional imaging 
techniques (multidetector row computed tomography [preferably] or transesopha-
geal echocardiography). The transfemoral route was used in 268 patients (52%), 
while a transapical route was chosen in 243 subjects (48%) because of unsuit-
able anatomy or intervention/surgery of the arterial vascular tree or in case of 
porcelain aorta.7 All procedures were performed during general anaesthesia under 
fluoroscopic and transesophageal echocardiography guidance.
Study endpoint
All-cause mortality 1-year after TAVI was the primary study endpoint. Survival and 
causes of death were assessed for all patients by consulting the patient’s medical 
files and the official Dutch National Survival Registry.
Statistical analysis
Continuous variables, reported as mean ± SD if normally distributed and as me-
dian with interquartile range if non-normally distributed, were compared with the 
Student-T test and Mann Whitney U test, respectively. Categorical data are given 
as percentages and compared by χ2-test or Fisher exact test as appropriate. First, 
performance of conventional surgical risk score models to predict 1-year mortal-
ity was evaluated.17, 18 Discrimination (ability to correctly identify high versus low 
mortality risk) was evaluated by Harrell`s C statistic. The cumulative survival was 
assessed with the Kaplan Meier method dichotomizing the patients into high ver-
sus low mortality risk, using >20% versus ≤20% for LES-I, >8% versus ≤8% for 
LES-II and >10% versus ≤10% for STS-score, respectively.19 Calibration (ability to 
match patients’ expected versus observed mortality) was determined by binomial 
testing of expected versus observed overall mortality and according to risk score 
quartiles. In addition Hosmer-Lemeshow goodness of fit statistic was calculated for 
all surgical risk scores. A value <0.05 indicates significant difference in expected 
versus observed mortality.
Second, a new TAVI-dedicated 1-year mortality risk prediction model was de-
veloped, restricted to demographic, clinical, biochemical and echocardiographic 
patient factors present at baseline. Exploratory categorizing of baseline param-
eters into nominal variables by different cut-off levels was performed and tested 
at univariate Cox regression analysis. Categorical baseline parameters available 
in approximately all study patients and achieving univariate significance level of 
p<0.05, were entered in a multivariate Cox regression model, using a backward 
elimination approach. Multivariate analysis identified risk factors independently 
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related to 1-year mortality after TAVI. These risk factors were assigned 1 or 2 points, 
proportional to their respective hazard ratios, to create a simple scoring system, 
the TAVI2-SCORe (porcelain Thoracic aorta, Anemia, Ventricular dysfunction, recent 
myocardial Infarction, male Sex category, Critical aortic valve stenosis, Old age and 
Renal dysfunction). According to the number of points assigned, patients were 
divided into different risk categories.
Third, the performance of the newly developed TAVI2-SCORe model was evalu-
ated using identical discrimination and calibration statistics as described above. 
In addition internal validation of the model’s discriminatory power was performed 
by bootstrap validation of Harrell`s C statistic on 100 samples drawn from the pa-
tient cohort. The mean difference in performance between each bootstrap sample 
and its corresponding performance in the original patient sample (optimism) was 
used to correct the initial Harrell’s C statistic of the original patient cohort for the 
TAVI2-SCORe model.
Fourth, the performance of the new TAVI2-SCORe to predict 1-year mortality after 
TAVI versus that of the conventional surgical risk scores was evaluated based on 
available results of discrimination and calibration for the respective scores.
SPSS version 20.0. (SPSS Inc., Chicago, Illinois) was used for statistical analysis. 
A p-value of <0.05 was considered statistically significant for all tests that were 
2-sided.
RESuLTS
A total of 511 patients (median age 82 [77-86] years, 38% male) were included, 
of which 207 (41%) were treated in Leiden and 304 (59%) in Milan. A total of 
36 patients were excluded because of incomplete data to calculate respective 
conventional surgical risk scores. Baseline characteristics are listed in Table 1. All 
patients were at high or prohibitive surgical risk as indicated by mean LES-I, LES-II 
and STS score. No patients were lost to follow-up for evaluation of the study end-
point. Within 30 days, 29 (5.7%) died, mainly from cardiovascular causes (n=25, 
86%), as summarized in Table 2. Peri-procedural death occurred in 12 patients. 
In addition 51 individuals died between 30 days and 1-year, resulting in overall 
1-year mortality of 17.0% (n=80/471). Mortality between 30 days and 1-year was 
attributed to cardiovascular cause in 47% (n=24) of patients. One year mortality 
rates were similar between both centers (p=0.88). Patients were further dichoto-
mized based on 1-year mortality status, as shown in Table 1. Patients who died 
within 1-year after TAVI showed significantly higher LES-I and LES-II than patients 









Baseline characteristics of overall study population and stratified according to survival status one year post trans-








 (n=80) p value
Age ( years) 82 (77-86) 82 (77-86) 83 (78-87) 0.28
Men 194 (38%) 135 (35%) 40 (50%) 0.009
Body surface area (m2) 1.77±0.21 1.76±0.20 1.77±0.23 0.68
Body mass index (kg/m2) 26±4 26±4 25±4 0.16
Sinus rhythm 393 (77%) 303 (78%) 58 (73%) 0.34
Hypertension 423 (83%) 319 (82%) 66 (83%) 0.85
Diabetes mellitus II 141 (28%) 106 (27%) 23 (29%) 0.76
Smoker 175 (35%) 134 (34%) 23 (30%) 0.34
Hypercholesterolemia 309 (61%) 225 (58%) 50 (63%) 0.41
Medications
β-blocker 267 (52%) 201 (51%) 42 (53%) 0.86
Diuretics 375 (73%) 285 (73%) 64 (80%) 0.19
Spironolactone 102 (20%) 76 (19%) 21 (26%) 0.17
Angiotenisn converting enzyme 
inhibitor and/or angiotensin II 
receptor blocker
302 (59%) 240 (61%) 44 (55%) 050
Statin 247 (48%) 180 (46%) 41 (51%) 0.40
Insulin 77 (15%) 55 (14%) 14 (18%) 0.43
Inotrope(s) 22 (4%) 17 (4%) 4 (5%) 0.77
New York Heart Association class 0.009
I 17 (3%) 14 (4%) 1 (1%)
II 132 (26%) 106 (27%) 12 (15%)
III 252 (50%) 196 (50%) 40 (5%)
IV 109 (21%) 75 (19%) 27 (34%)
Syncope 105 (21%) 83 (21%) 16 (20%) 0.81
Angina pectoris 180 (35%) 140 (36%) 26 (33%) 0.57
Logistic Euroscore I (%) 18.3 (12.1-27.7) 17.8 (12.1-26.1) 22.6 (14.3-34.5) 0.002
Logistic Euroscore II (%) 6.4 (4.0-10.6) 6.1 (3.9-10.1) 9.1 (5.5-14.1) <0.001
STS score (%) 16.6 (12.5-22.1) 16.4 (12.5-21.9) 17.8 (12.9-23.5) 0.14
Dialysis 4 (0.8%) 4 (1%) 0 (0%) 1.00
Chronic obstructive pulmonary disease 148 (29%) 107 (27%) 31 (39%) 0.042
Peripheral artery disease 242 (47%) 179 (46%) 44 (55%) 0.13
Porcelain aorta 58 (11%) 36 (9%) 17 (21%) 0.002
Prior stroke/transient ischemic attack 74 (14%) 58 (15%) 9 (11%) 0.40
Recent myocardial infarction (<90 days) 12 (2%) 6 (2%) 5 (6%) 0.025











Prior percutaneous coronary 
intervention
121 (24%) 90 (23%) 20 (25%) 0.84
Poor mobility 140 (28%) 110 (28%) 24 (30%) 0.75
Neurologic dysfunction 42 (8%) 35 (9%) 7 (9%) 0.95
Frailty 98 (21%) 74 (20%) 20 (26%) 0.22
Cognitive dysfunction/dementia 55 (11%) 43 (11%) 12 (15%) 0.31
Ascites 4 (1%) 2 (1%) 2 (3%) 0.14
Cirrosis 15 (3%) 11 (3%) 4 (5%) 0.30
Hostile chest 93 (18%) 70 (18%) 14 (18%) 0.92
Creatinine clearance (ml/kg/min) 49 (36-61) 49 (36-61) 44 (31-58) 0.07
Hemoglobin (g/dl) 12.1±1.6 12.1±1.6 11.7±1.6 0.047
C reactive protein (mg/dl) 4.0 (2-10) 3.4 (1.8-8.8) 7.0 (2.7-15.1) 0.010
Albumin (g/dl) 3.8±0.5 3.8±0.5 3.6±0.6 0.030
Total bilirubin (μmol/l) 0.81 (0.63-1.20) 0.80 (0.61-1.10) 0.98 (0.67-1.40) 0.009
Aspartate transaminase (U/l) 23 (18-29) 22 (18-28) 25 (20-34) 0.009
Alanin aminotransferase (U/l) 17 (13-23) 17 (13-22) 19 (14-26) 0.06
Left ventricular end-diastolic diameter 
(mm)
48±8 48±8 48±8 0.78
Left ventricular end-systolic diameter 
(mm)
31±9 31±9 32±10 0.53
Left ventricular mass index (g/m2) 145±40 146 ± 40 150±41 0.37
Left ventricular end-diastolic volume 
index (ml/m2)
52 (42-68) 53 (42-68) 50 (41-70) 0.45
Left ventricular end-systolic volume 
index (ml/m2)
21 (15-34) 21 (15-34) 24 (15-37) 0.37
Left ventricular ejection fraction (%) 58 (46-66) 58 (48-66) 54 (39-61) 0.008
Left atrial volume index (ml/m2) 54±23 55±24 52±16 0.32
E/e` 26 (18-37) 26 (17-37) 32 (20-40) 0.18
Systolic pulmonary arterial pressure 
(mmHg)
39 (30-46) 39 (31-46) 42 (32-49) 0.009
Aortic regurgitation ≥ grade 3 25 (5%) 19 (5%) 1 (4%) 1.00
Mitral regurgitation ≥ grade 3 33 (7%) 26 (7%) 5 (7%) 1.00
Tricuspid regurgitation ≥ grade 3 32 (6%) 22 (6%) 7 (9%) 0.29
Aortic valve mean gradient (mmhg) 47±17 48±16 47±20 0.43
Aortic valve area indexed (cm2/m2) 0.38±0.10 0.38±0.10 0.38±0.09 0.87
Urgent procedural need 45 (9%) 28 (7%) 14 (18%) 0.003
Hypertension: history of high blood pressure and/or on antihypertensive treatment. Hypercholesterolemia: history 









Surgical risk scores and 1-year mortality
The Harrell’s C statistic for LES-I, LES-II and STS score to predict 1-year mortality 
after TAVI was 0.609 (p=0.002), 0.633 (p<0.001) and 0.500 (p=0.14), respectively. 
Kaplan Meier survival analysis showed significantly worse cumulative 1-year sur-
vival in patients with LES-I >20% compared to ≤20% (79 versus 89%, p=0.002) 
and LES-II >8% versus ≤8% (77 versus 89%, p=0.001), but not when stratified by 
STS score >10% versus ≤10% (84 % versus 89%, p=0.36) (Figure 1). These results 
suggest that LES-II has overall reasonable ability to discriminate between patients 
at high versus low risk for 1-year mortality after TAVI, and better compared to LES-I 
and STS score.
Overall the STS score showed good calibration with no significant difference 
between the number of predicted and observed deaths during 1-year follow-up 
Table 2.2 








Cardiovascular 25 (86%) 24 (47%) 49 (61%)
Cardiogenic shock/heart failure 11 (38%) 10 (20%) 21 (26%)
Vascular access problems 7 (24%) 0 7 (14%)
iliac dissection 3 (10%) 0 3 (4%)
aortic dissection 4 (14%) 0 4 (5%)
Sudden death 2 (7%) 3 (6%) 5 (6%)
Stroke 0 5 (10%) 5 (6%)
Myocardial infarction 0 1 (2%) 1 (1%)
Aortic annulus rupture 1 (3%) 0 1 (1%)
Left main coronary occlusion 1 (3%) 0 1 (1%)
Interventricular septum rupture 1 (3%) 0 1 (1%)
Acute bowel ischemia 1 (3%) 1 (2%) 2 (3%)
Intestinal bleeding 1 (3%) 2 (4%) 2 (3%)
Pulmonary embolism 0 2 (4%) 2 (3%)
Non cardiovascular 4 (14%) 27 (53%) 31 (39%)
Infection 1 (3%) 6 (12%) 7 (9%)
Traffic accident 1 (3%) 1 (2%) 2 (3%)
Unknown 2 (3%) 11 (22%) 13 (16%)
Renal failure 0 2 (4%) 2 (3%)
Respiratory failure 0 2 (4%) 2 (3%)
Liver failure 0 2 (4%) 2 (3%)
Femur fracture 0 1 (2%) 1 (1%)
Oncologic 0 2 (4%) 2 (3%)
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(Figure 2). The STS-score however, significantly overestimated 1-year mortality for 
the lowest risk category (first STS score quartile). In contrast, the LES-I and LES-II 
showed significant differences in predicting 1-year mortality compared to the ob-
served deaths. In particular, LES-I overestimated mainly high risk patients (fourth 
quartile) and LES-II significantly overestimated survival within all risk categories 
(all 4 quartiles). Hosmer-Lemeshow statistics (8 degrees of freedom) confirmed 
the superior calibration ability of the STS score (0.844) compared to the LES-I 
(0.457) versus LES-II (0.185).
Development of the TAVI2-SCORe
Several baseline parameters that are included in the conventional surgical risk 
scores were associated with 1-year mortality after TAVI (Table 3 and in supple-
mental Table 1). Interestingly, other baseline parameters, not included in LES-I, 
LES-II or STS score, were also associated with 1-year mortality post-TAVI: porcelain 
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Figure 2.1 
Percentage of expected versus observed mortality 1-year after TAVI for surgical risk scores (and quartiles) and 









thoracic aorta, hemoglobin <10 g/dl (anemia), CRP >10 mg/dl, serum albumin <3.0 
g/dl, total bilirubin level and mean aortic valve gradient ≥70 mmHg (critical aortic 
valve stenosis). Univariate baseline predictors available in the vast majority of the 
study population (509/511 patients) were entered in the multivariate analysis that 
identified 8 baseline parameters with independent relation to 1-year mortality 
after TAVI: porcelain Thoracic aorta, Anemia, Ventricular dysfunction (LV ejection 
fraction <35%), recent myocardial Infarction (<90 days prior to TAVI), male Sex 
category, Critical aortic valve stenosis, Old age (>85 years) and Renal dysfunction 
(creatinine clearance <30 ml/kg/min). These parameters comprise the TAVI2-SCORe. 
All parameters were individually weighted by assignment of 1 point for the major-
ity of the variables and 2 points for recent myocardial infarction, proportional to 
hazard ratios noted. According to the number of points assigned (0, 1, 2, 3 or ≥4), 
patients were divided into 5 different risk categories (Figure 3).
Log rank p=0.002 
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LES-I >20 % 













                       Patients at risk                                             
                    by LES-I stratum       30d             120d                    240d                    365d     Events 
 
                       ≤20 %        284        274               269                      254                      231          32 
                       >20 %        227        208               199                      180                      160          48 
                        













Follow up (days after TAVI) 
                       Patients at risk                                             
                  by LES-II stratum       30d             120d                    240d                    365d     Events 
 
                       ≤8 %         311        300               295                      279                      253          34 
                       >8 %         200        182               173                      155                      138          46 
                        
 LES-II ≤8 % 
 LES-II >8 % 













Follow up (days after TAVI) 
                       Patients at risk                                             
            by STS score stratum       30d             120d                    240d                    365d     Events 
 
                        ≤10 %         53          51                 51                        46                        41            6 
                        >10 %       458        431               417                      388                      350          74 
                        
STS score ≤10 % 













Log rank p<0.0001 
Follow up (days after TAVI) 
                       Patients at risk                                             
      by TAVI2-SCORe stratum     30d              120d                    240d                    365d     Events 
 
                       <3 points     448    428                419                      393                     359           52 
                      ≥3 points       61      52                  47                        39                       31           28 
                        
   TAVI2-SCORe < 3 points 
     TAVI2-SCORe ≥ 3 points 
Figure 2.2
Cumulative 1-year survival after TAVI stratified into high versus low risk categories of surgical risk scores and TAVI2-
SCORe (discrimination ability).
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TAVI2-SCORe and 1-year mortality
The Harrell’s C statistic for prediction of 1-year mortality after TAVI in the original 
patient cohort applying the TAVI2-SCORe was 0.720 (p<0.001). Internal bootstrap 
validation indicated limited optimism of the model (0.005), an expected low value 
for a single predictor model. The final corrected Harrell’s C statistic therefore was 
0.715, indicating high discriminatory performance. In addition, the Kaplan Meier 
analysis indicated highly significant differences in cumulative survival for patients 
when stratified according to different TAVI2-SCORe risk strata (Figure 3). In par-
ticular, a TAVI2-SCORe of ≥3 points versus <3 indicates significantly worse 1-year 
cumulative survival after TAVI (54 versus 88%, p<0.0001). Figure 4 indicates that a 
TAVI2-SCORe of 3 or ≥4 points, compared to 0 points, was associated with a respec-
tive 10-fold and 17-fold increased mortality risk within 1-year after TAVI. These 
data indicate that the TAVI2-SCORe is accurate in discriminating patients at high 
versus low risk for 1-year mortality after TAVI.
In addition, no significant difference in expected versus observed mortality 
1-year after TAVI was observed for the TAVI2-SCORe, stratified according to the dif-
ferent risk categories. Hosmer-Lemeshow statistic for the TAVI2-SCORe was 0.304 
(2 degrees of freedom). These data underscore accurate calibration of the TAVI2-
SCORe model.
Table 2.3 
Univariate and multivariate cox regression analysis. Baseline parameters available in the majority of study patients 
(n=509/511) and reaching significance level <0.05 at univariate level only are shown. Results of univariate analy-
sis including all factors tested is available as supplemental file.
Univariate Multivariate
HR p value 95% CI HR p value 95% CI
Age >85 years 1.63 0.035 1.04-2.56 1.68 0.030 1.05-2.69
Male gender 1.70 0.018 1.10-2.64 1.81 0.012 1.14-2.87
New York Heart Association class III or IV 2.24 0.008 1.23-4.05 1.82 0.06 0.98-3.38
Chronic obstructive pulmonary disease 1.62 0.037 1.03-2.53 1.54 0.08 0.96-2.47
Porcelain aorta 2.39 0.001 1.34-4.08 2.56 0.001 1.46-4.48
Recent myocardial infarction (<90 days) 3.58 0.006 1.15-8.87 3.78 0.005 1.50-9.54
Creatinine clearance <30 ml/kg/min 1.95 0.011 1.16-3.26 1.76 0.036 1.04-2.97
Hemoglobin <10 g/dl 1.89 0.031 1.06-3.36 2.03 0.022 1.11-3.73
Left ventricular ejection fraction <35 % 2.05 0.015 1.15-3.66 1.98 0.028 1.08-3.63
Systolic pulmonary arterial pressure >45 mmHg 1.58 0.049 1.01-2.49 1.39 0.19 0.85-2.28
Aortic valve mean gradient ≥70 mmHg 2.10 0.012 1.18-1.73 2.46 0.004 1.33-4.56
Urgent procedure 2.22 0.007 1.25-3.96 1.67 0.10 0.91-3.05








oTAVI2-SCORe versus LES-I, LES-II and STS score
Higher bootstrap validation corrected Harrell`s C statistic and the Kaplan Meier 
survival analyses showed that the TAVI2-SCORe had better discriminatory per-
formance to predict 1-year mortality after TAVI than conventional surgical risk 
scores. Moreover, no significant difference between observed and expected 1-year 
mortality for all TAVI2-SCORe risk strata suggested better calibration performance 
compared to LES-I, LES-II and STS score.










                       Patients at risk                                             
       by TAVI2-SCORe stratum     30d               120d                      240d                     365d         Events 
 
                       0 points     119       118                116                        108                       103                6 
                       1 points     210       200                197                        185                       167              26 
                       2 points     119       110                106                        100                         90              20 
                       3 points       49         43                  40                          33                         26              21 
                     ≥4 points       12           9                    7                            6                           5                7   














Cumulative 1-year survival after TAVI, stratified according to the different TAVI2-SCORe risk strata. Different risk 
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Figure 2.4 
Hazard ratio for 1-year mortality after TAVI according to different TAVI2-SCORe risk strata. Ref: reference category.
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DISCuSSION
This study indicates that TAVI2-SCORe is a simple and novel risk model for accurate 
prediction of 1-year mortality after TAVI, based on preprocedural baseline patient 
characteristics. Moreover, the TAVI2-SCORe outperforms discriminatory and calibra-
tion abilities of conventional surgical risk scores, including LES-I, LES-II and STS-score.
Surgical risk scores and TAVI outcome
Cumulative 30 day and 1-year mortality observed in our registry is in line with the 
respective mortality of 7.4-9.7% and 24% reported in the 2 largest real-world 
registries including >3000 patients treated with TAVI.19, 20 In addition, the high LES-I 
and STS scores in our series, comparable to the scores previously reported, reflect 
appropriate selection of patients for TAVI that were at high or prohibitive surgical 
risk.1, 8, 19, 20 Estimation of operative risk with the LES-I, LES-II, and STS scores are 
used worldwide.21-23 These scores however, have not been developed to predict 
the operative risk of elderly patients with symptomatic severe aortic stenosis and 
associated co-morbidities who are currently referred for TAVI. In addition, these 
scores, and recently more TAVI-dedicated risk scores, are intended to predict 30 day 
mortality.8 Although this is an important acute clinical endpoint, 1-year mortality 
might be preferred for purposes of patient selection and evaluation of cost-benefits 
for a given treatment. A limited number of studies have reported on the value of 
conventional surgical risk scores to predict 1-year mortality after TAVI and have com-
pared the performance of different surgical risk scores.3-6, 19 Predictive performance 
of a risk model relies both on discrimination (ability to identify patients at high 
versus low mortality risk) and calibration (ability to match observed versus expected 
mortality).17, 18 Both characteristics are not mutual exclusive and should be reported 
to assess the value of a prognostic risk model.17 In patients undergoing TAVI, higher 
LES-I and STS score have been associated with increased 1-year mortality risk.6, 19 
Another study including 426 TAVI patients suggested that STS score but not LES-I or 
LES-II were independently related to this endpoint.3 Furthermore, Sedaghat et al. re-
ported on model performance statistics of different conventional surgical risk scores 
to predict 1-year mortality after TAVI in 206 patients undergoing TAVI with CoreValve 
prosthesis.4 The authors showed better discrimination abilities for LES-I compared 
to LES-II and STS score with Harrell’s C statistic of 0.72, 0.70 and 0.70 respectively. 
In addition both LES-I and LES-II were well calibrated for 1-year mortality contrary 
to STS score with a Hosmer-Lemeshow statistic of 0.36, 0.32 and 0.08, respectively. 
In contrast, the present study showed reasonable discrimination abilities for LES-II 
score (≤8 % low risk versus >8 % high risk) and superior and good calibration for 








oTAVI2-SCORe and TAVI outcome
Based on preprocedural patients’ baseline characteristics that showed indepen-
dent association with 1-year mortality after TAVI, we developed the TAVI2-SCORe. 
LV systolic dysfunction, recent myocardial infarction, sex, age and renal dysfunc-
tion, incorporated in conventional surgical risk scores, also showed a relation to 
outcome after TAVI in several reports.14, 21-27 Porcelain thoracic aorta and anemia 
might represent risk factors more specifically related to outcome after TAVI.28 
Interestingly, several additional factors such as hypoalbuminemia and a rise of 
inflammatory markers (CRP) were related to the study endpoint. These factors 
should be explored in larger patient cohorts and might prove to be useful to 
further refine the TAVI2-SCORe. The present study demonstrated accurate and 
superior discrimination and calibration properties of the TAVI2-SCORe compared to 
conventional surgical risk scores.
LIMITATIONS
Some important limitations should be acknowledged. First, prospective valida-
tion of the TAVI2-SCORe in a large external cohort of patients treated with TAVI is 
needed. Second, the current study findings cannot be extrapolated to patients 
treated with TAVI prosthesis other than the Edwards SAPIEN system. Third, pro-
cedural and postprocedural factors, including the access (transfemoral versus 
transapical, direct aortic or transsubclavian) and paravalvular leak post-TAVI also 
determine outcome post-TAVI and might further improve predictive performance, 
but do not allow for clinical decision making prior to the TAVI procedure.20, 26, 29, 30 
Finally, frailty, a potential key factor in TAVI outcome, did not relate to the study 
endpoint in the current series. A more objective definition to define frailty by us-
ing multidimensional geriatric assessment including prospective assessment of 
mobility, cognitive function, nutritional status and instrumental and basic daily 
live activities might be more appropriate.
CONCLuSION
TAVI2-SCORe is a risk score predicting 1-year mortality after TAVI, based on prepro-
cedural baseline patient characteristics. Simplicity, bed-side availability and bet-
ter predictive ability compared to conventional surgical risk scores are the main 
strengths. Awaiting prospective external validation, TAVI2-SCORe might become a 
valuable clinical tool for decision making and patient selection for TAVI.
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SuPPLEMENTAL TABLE
Univariate 1-year mortality cox regression analysis for all baseline parameters tested and categorized to their best 
performing cut-off values.
Available in 
N patients HR p value 95% CI
Age (years) 511 1.01 0.56 0.98-1.05
Age >85 years 511 1.63 0.035 1.04-2.56
Male gender 511 1.70 0.018 1.10-2.64
Body surface area (m2) 511 1.13 0.82 0.39-3.31
Body mass index (kg/m2) 511 0.96 0.17 0.91-1.02
Body mass index >25 kg/m2 511 0.76 0.22 0.49-1.18
Sinus rhythm 511 0.78 0.32 0.48-1.27
Hypertension 511 1.01 0.97 0.57-1.80
Diabetes mellitus II 511 1.09 0.73 0.67-1.77
Smoker 500 0.78 0.32 0.48-1.27
Hypercholesterolemia 511 1.13 0.59 0.72-1.78
β-blocker 511 1.04 0.88 0.67-1.60
Diuretics 511 1.48 0.16 0.86-2.56
Spironolactone 511 1.44 0.15 0.87-2.37
Angiotensin converting enzyme inhibitor and/or 
angiotensin II receptor blocker
511 0.81 0.36 0.52-1.26
Statin 511 1.19 0.45 0.76-1.84
Insulin 510 1.26 0.44 0.71-2.24
Inotrope(s) 511 1.17 0.76 0.73-3.21
New York Heart Association class III-IV 511 2.24 0.008 1.23-4.05
Syncope 511 0.94 0.82 0.54-1.62
Angina 511 0.89 0.63 0.58-1.42
Angina pectoris class IV 511 1.46 0.52 0.46-4.64
Dialysis 511 0.05 0.58 0.00-1882
Chronic obstructive pulmonary disease 511 1.62 0.037 1.03-2.53
Peripheral artery disease 511 1.39 0.14 0.89-2.16
Porcelain aorta 510 2.39 0.001 1.34-4.08
Prior stroke/transient ischemic attack 511 0.73 0.37 0.36-1.46
Recent myocardial infarction (<90 days) 511 3.58 0.006 1.15-8.87
Prior cardiac surgery 511 1.20 0.74 0.73-196
Prior percutaneous coronary intervention 511 1.10 0.72 0.66-1.82
Poor mobility 510 1.11 0.67 0.69-1.79
Neurologic dysfunction 511 1.07 0.86 0.49-2.33
Frailty 478 1.38 0.22 0.83-2.30
Cognitive dysfunction/dementia 511 1.52 0.18 0.82-2.81
Ascites 511 3.09 0.12 0.76-12.6











N patients HR p value 95% CI
Hostile chest 509 0.92 0.77 0.52-1.64
Creatinine clearance (ml/kg/min) 511 0.99 0.13 0.98-1.01
Creatinine clearance ≤ 30 ml/kg/min 511 1.95 0.011 1.16-3.26
Hemoglobin (g/dl) 510 0.87 0.038 0.76-0.99
Hemoglobin <10 g/dl 510 1.89 0.031 1.06-3.36
C reactive protein (mg/dl) 327 1.01 0.38 0.99-1.01
C reactive protein >10 mg/dl 327 2.03 0.013 1.16-3.53
Albumin (g/dl) 373 0.63 0.023 0.43-0.94
Albumin <3.0 g/dl 373 3.45 0.001 1.71-7.13
Total bilirubin (μmol/l) 433 1.45 0.021 1.06-2.00
Total bilirubin >2.0 μmol/l 433 1.95 0.12 0.84-4.49
Aspartate transaminase (U/l) 464 1.01 0.19 0.99-1.01
Aspartate transaminase >70 U/l (2x ULN) 464 2.66 0.06 0.97-7.29
Alanin aminotransferase (U/l) 464 1.01 0.62 0.96-1.01
Alanin aminotransferase >90 U/l (2x ULN) 464 1.74 0.44 0.73-7.08
Left ventricular end-diastolic diameter (mm) 502 0.99 0.91 0.97-1.03
Left ventricular end-systolic diameter (mm) 429 1.01 0.47 0.99-1.03
Left ventricular mass index (g/m2) 502 1.01 0.30 0.99-1.01
Left ventricular mass index >130 g/m2 502 1.43 0.15 0.88-2.31
Left ventricular end-diastolic volume index (ml/m2) 511 0.99 0.67 0.99-1.01
Left ventricular end-diastolic volume index ≥75 ml/m2 511 1.24 0.46 0.71-2.17
Left ventricular end-systolic volume index (ml/m2) 511 1.01 0.30 0.99-1.02
Left ventricular end-systolic volume index ≥31 ml/m2 511 1.43 0.13 0.90-2.25
Left ventricular ejection fraction (%) 511 0.98 0.004 0.96-0.99
Left ventricular ejection fraction <35 % 511 2.05 0.015 1.15-3.66
Left atrial volume index (ml/m2) 505 0.99 0.38 0.98-1.01
Left atrial volume index >34 ml/m2 505 1.41 0.38 0.65-3.07
E/e` 185 1.01 0.26 0.99-1.02
Systolic pulmonary artery pressure (mmHg) 511 1.02 0.039 1.01-1.04
Systolic pulmonary artery pressure >45 mmhg 511 1.58 0.049 1.01-2.49
Aortic regurgitation ≥grade 3 511 0.74 0.61 0.23-2.35
Mitral regurgitation ≥grade 3 511 1.03 0.95 0.42-2.55
Tricuspid regurgitation ≥grade 3 511 1.52 0.29 0.70-3.30
Aortic valve mean gradient (mmHg) 511 0.99 0.48 0.98-1.01
Aortic valve mean gradient >70 mmhg 511 2.10 0.012 1.18-1.73
Aortic valve index (cm2/m2) 511 0.58 0.65 0.06-5.78
Aortic valve index <0.6 cm2/m2 511 20.7 0.41 0.02-2.63
Urgent procedural need 511 2.22 0.007 1.25-3.96
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Mitral valve (MV) disease is highly prevalent. Accurate characterization of normal 
anatomy and function of the MV is crucial to understand the pathophysiology 
of MV disease. This review summarizes recent advances on noninvasive cardiac 
imaging to assess normal MV anatomy and function and provides an overview of 
the clinical applications of these novel imaging techniques in the evaluation of 
patients with MV disease.
Summary 
Echocardiography remains the first imaging technique for evaluation of the 
anatomy and function of the MV. However, advances in minimally invasive and 
transcatheter valve repair/replacement procedures demand high spatial resolution 
images to accurately assess the anatomy of the MV and its surrounding structures. 
Three-dimensional echocardiography improves 2-dimensional echocardiography 
morphological and functional MV evaluation. Furthermore, computed tomogra-
phy provides high spatial resolution 3-dimensional data and may constitute the 
modality of choice for additional morphological or geometrical study of the MV 
and surrounding structures. In addition, cardiac magnetic resonance (CMR) permits 
accurate assessment of anatomy and function of the mitral valve and is considered 
the method of reference to quantify mitral flow.
Conclusions 
Any abnormality in any of the components of the MV (annulus, leaflets, subvalvular 
apparatus, left ventricle and left atrium) may lead to MV dysfunction. Current non-
invasive cardiac imaging modalities permit accurate assessment of MV anatomy 
and function. These imaging techniques refine our diagnostic performance, pro-
vide additional (patho)physiological insights and help to design new strategies for 










Mitral valve (MV) disease is one of the most prevalent valvular heart diseases. De-
spite the dramatic decrease in rheumatic valve disease in industrialized countries, 
the increased lifespan of the population has led to an increase in degenerative MV 
disease, fueling the number of MV interventions.1,2 Echocardiography is used as a 
first-line imaging technique to study MV disease. However, more recently, advanced 
imaging techniques such as 3-dimensional (3D) echocardiography, multidetector 
row computed tomography (MDCT) and cardiac magnetic resonance (CMR) were 
added to the diagnostic armentarium to study the MV.3,4 These imaging techniques 
are sequentially applied (1) to identify MV dysfunction, (2) to study the etiology, 
morphological lesions and mechanism of MV dysfunction (Carpentier triad), (3) 
to assess hemodynamic, morphological and functional cardiac consequences of 
MV disease and (4) to select, guide and evaluate the therapeutical approach.5,6 
To answer all these questions, thorough knowledge of the normal morphological, 
geometrical and functional appearance of the MV is crucial. Moreover, this knowl-
edge is basic to design and develop novel treatment strategies for MV dysfunction 
that aim at restoring normal MV anatomy and function.
This review focuses on the use and clinical value of different imaging modalities 
to assess normal MV anatomy and function.
IMAgINg NORMAL MITRAL VALVE
The normal MV is a functional complex that consists of mitral annulus, leaflets, 
subvalvular apparatus, left ventricle (LV) and left atrium (LA).7,8 Any abnormality 
in any of these components may cause MV dysfunction (stenosis/regurgitation). 
Structural MV abnormalities are referred to as organic MV disease. Functional MV 




1 The normal MV is a functional complex that relies on normal morphology, geometry and function 
of all its constituents.
2 3D-echocardiography improves morphological MV evaluation and mitral annular structural and 
functional evaluation.




The mitral annulus consists of a discontinuous fibrous D-shaped ring between the 
LV and LA to which the MV leaflets are anchored.7,8 The anterior part of the mitral an-
nulus is in close relationship with the aortic annulus at the level of the left and non-
coronary aortic valve cusps. This part is enforced by a fibrous continuity, so-called 
aorto-mitral valvular continuity, which ends laterally in the left and right fibrous 












Surgical view of the mitral valve. Panel A: Schematic representation of mitral valve anatomy (with permission from 
reference [9]). Panel B: Surgical exposition of Barlow degenerated mitral valve. Panel C: 3-Dimensional echocar-
diography of structural normal mitral valve. Panel D: Same patient as panel C, now post mitral annuloplasty for 
functional mitral regurgitation. Note the morphologic resemblance of the valve on 3-dimensional echocardiogra-
phy and peroperatively. A: anterior mitral valve with scallops A1, A2 and A3, ALC: antero-lateral commissure, AMF: 
aortic-mitral fibrosa, LAA: left atrial appendage, LCC: left coronary cusp of aortic valve, LFT: left fibrous trigone, NCC: 
non coronary cusp of aortic valve, P: posterior mitral valve leaflet with scallops P1, P2 and P3, PMC: postero-medial 









more muscular and lacks a firm fibrous cord. Consequentially, this site is prone to 
dilatation and calcification.8 The 3D-shape of the mitral annulus resembles a saddle 
with peaks located anteriorly and posteriorly and nadirs at the postero-medial 
and antero-lateral commissures.10 This 3D-geometry optimizes stress distribution 
over the mitral leaflets.10 Assessment of mitral annular dimensions is important to 
determine appropriate annuloplasty ring or mitral prosthesis size.
Noninvasive imaging modalities permit end-systolic quantification of the 
maximal antero-posterior diameter (minor axis) and the inter-commissural diam-
eter (major axis) in appropriate reconstruction planes, characterizing the planar 
D-shaped morphology of the mitral annulus (Table 1).5,11 Based on 2-dimenisonal 
(2D) echocardiographic measurements, an antero-posterior annular diameter >35 
mm measured at end-systole or an annular to end-diastolic anterior mitral leaflet 
length ratio >1.3 define mitral annulus dilatation.12 3D-imaging modalities permit 
accurate alignment of multiplanar reformation planes through the mitral annulus 
and increase the accuracy of the measurements of the annular dimensions.11,13,14 
In a series of 17 patients undergoing 2D transthoracic echocardiography and 
MDCT, mitral annulus measurements performed on conventional 2D echocar-
Table 3.1
Geometric indices of clinical interest for the functional mitral valve complex. See text for explanation.
Annulus
Antero-posterior diameter (minor axis) 
Inter-commissural diameter (major axis) 
Annular area and circumference 
Annular width-to-height-ratio 
Aortic-mitral annular angle 
Left atrium 




Tenting area or volume 
Posterior and anterior mitral leaflet angle (A2-P2 level) 
Posterior and anterior mitral leaflet length (A2-P2 level) 
Subvalvular apparatus 
Chordal length 
Interpapillary muscle distance 
Papillary muscle tethering length 
Papillary muscle anterior and posterior angle 
Left ventricle 
Sphericity index (length-to-width ratio) 
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diographic views overestimated the antero-posterior diameter by 23% and 
underestimated the inter-commissural diameter by 12% compared with MDCT. 
In contrast, echocardiographic measurements performed on correct anatomical 
views resulted in improved agreement with MDCT measurements with an under-
estimation of the antero-posterior diameter by 1% and an overestimation of the 
inter-commissural diameter by 0.9%.11 Subsequently, head-to-head comparison 
between 3D-transesophageal echocardiography (TEE) and MDCT measurements 
of mitral annular dimensions showed good agreement between both techniques.14 
These 3D-imaging techniques have refined the analysis of mitral annular geom-
etry and have provided several parameters (annular height, minimal and maximal 
width, height-to-commissural-width ratio, annular circumference, annular area and 
aortic-mitral annular angle) that may help to understand the pathophysiology of 
MV disease and to design tailored MV repair techniques (Figure 2).13,15,16
In percutaneous MV interventions, the assessment of the anatomic relationship 
of the mitral annulus and its surrounding structures is crucial, especially the coro-
nary circumflex artery and the coronary sinus with MDCT and CMR (Figure 3).17-20 
This is of major interest as the coronary sinus is a new target for percutaneous 
indirect annuloplasty devices that aim to reduce the antero-posterior diameter of 
the mitral annulus.5 In patients with structurally normal hearts and in patients with 
heart failure and mitral regurgitation, MDCT and CMR showed that the coronary 
sinus is frequently located above the mitral annulus.18,19 In addition, the circumflex 
coronary artery was located between the coronary sinus and the mitral annulus in 
68 to 80% of patients.18-20 These findings highlight the limited patients` eligibil-
ity for percutaneous indirect annuloplasty: the technique may be ineffective in 
reducing mitral regurgitation if the coronary sinus is not aligned with the mitral 
annulus or may imply a high risk of myocardial ischemia if the coronary sinus 
courses above the circumflex artery.21 Furthermore, MDCT provides the highest 
spatial resolution to characterize mitral annulus calcification, a potential limitation 
for coronary sinus-based annuloplasty procedures.
Additionally to the anatomical characterization, the function of the mitral annu-
lus can be studied. The mitral annular area decreases approximately 25% at mid-
systole due to atrial and ventricular myocardial forces imposed upon the mitral 
annulus and its normal translational motion towards the LV apex.10 Mitral-aortic 
valvular coupling can be studied by evaluating changes of the aortic-mitral angle 
throughout the cardiac cycle.15 These 3D dynamic properties of the mitral annulus 
reduce MV leaflet stress, enhance mitral leaflet coaptation and contribute to atrial 
and ventricular performance by optimizing filling and ejection flow dynamics.7,10 
Assessment of mitral annular function may help to optimize surgical techniques 










The MV consists of the anterior and the posterior leaflets that converge at the 
antero-lateral and postero-medial commissures (Figure 1). The anterior mitral leaf-
let is rounded and occupies one third of the annular circumference whereas the 
posterior mitral leaflet is elongated and narrow and is hinged to the remaining two 
thirds of the annulus. Despite having comparable surface areas, this anatomic fact 
explains that the anterior mitral leaflet forms the greatest part of the atrial floor 
(Figure 2). Based on the presence of 2 indentations, the posterior mitral leaflet 
is usually divided into a lateral P1 scallop (close to the left atrial appendage), a 
bigger central P2 and a medial P3 scallop.22 The opposing segments of the anterior 
mitral leaflet are similarly named A1, A2 and A3 scallop.7-9 Of note, indentations 
between the leaflets never reach the mitral annulus in normal MV.7 
3D-model
annular diameters  annulus area
annular height posterior leaflet area  posterior leaflet angle
saddle-shaped annulus
tenting volume anterior leaflet area anterior leaflet angle
A B C














Real time three-dimensional echocardiography to assess mitral valve geometry. Panel A: Indication of anatomic 
landmarks on 3-dimensional reformation planes is performed, using Mitral Valve Quantification software. Panel B: 
A 3-dimensional model of the mitral valve is generated by the software. The saddle-like shape of mitral annulus 
is appreciated. Panel C: Several geometric indices of clinical interest can be measured. A: anterior, AL: antero-
lateral, Ao: aorta, LA: left atrium, LV: left ventricle, P: posterior, PM: postero-medial, 2-ch: two-chamber, 3-ch: three-
chamber, 3D: three-dimensional. Red arrow: antero-posterior annular diameter (minor axis), Yellow arrow: inter-
commissural annular diameter (major axis).
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The segmental anatomical identification is of paramount importance when 
studying and reporting on the morphology and function of the MV.6 The location 
and extent of prolapsing segments in organic mitral regurgitation or the exact 
localization of the restriction characteristic of functional mitral regurgitation (usu-
ally postero-medial segments) are essential for therapeutic management strate-
gies.5,12 Protocols for standardized approach using 2D- and 3D-transthoracic or 
TEE, MDCT and CMR have been reported.3,12,13,23,24 3D-echocardiography provides 
the possibility of simultaneous 3D-display “en face” view of the MV leaflets from 
the ventricular or atrial perspective (‘surgical view’) (Figure 1 and 4). This increases 
the accuracy of MV evaluation by novice readers, improves the evaluation of the 

















Peri-annular anatomy by computed tomography and cardiac magnetic resonance. Panels A-C: computed tomogra-
phy, panel D: cardiac magnetic resonance. Panel A: Volume-rendered reconstruction showing presence of coronary 
sinus (CS) in atrio-ventricular groove close to the mitral annulus (upper panel). Short axis view of mitral annulus 
showing close proximity of CS (lower panel). Anatomic eligibility for percutaneous indirect mitral annuloplasty is 
likely. Panel B: CS courses superiorly of mitral annulus and left circumflex coronary artery (LCX) runs inferior of 
CS (upper panel). Short axis view points out risk of LCX impingement in case of percutaneous indirect mitral an-
nuloplasty (lower panel). Panel C: Mitral annular calcification is seen on long-axis view of the left ventricle (arrows) 
and short axis mitral annular view (detail). Panel D: LCX partly overlaps with CS at level of mitral annulus (with per-
mission form reference 20). Ao: aorta, LA: left atrium, CS-GCV: coronary sinus-great cardiac vein, LAD: left anterior 









the cardiac surgeon/interventionalist and cardiac imager.13,25 2D-TEE, 3D-TEE and 
MDCT provide the best spatial resolution to study mitral leaflet morphology and 
geometry.3 Attempts using CMR steady state free precession (cine) images are 
increasingly reported with reasonable results, but they suffer from suboptimal 
spatial resolution (Figure 4).26-28
Normal leaflet length can be assessed in mid-diastole from the hinge point at 
the mitral annulus towards the leaflet tips. Its assessment can be used for index-
ation of geometric MV measurements in functional MV disease and can influence 
surgical management strategies in hypertrophic cardiomyopathy patients with 
increased LV outflow tract gradient and systolic anterior movement of the anterior 
















Multimodality morphologic study of a patient with Barlow degenerated mitral valve leaflet. Panel A: 2-Dimensional 
echocardiographic 2-chamber view shows thickened leaflets and prolapse of anterior mitral valve leaflet (arrow). 
Panel B: 3-Dimensional echocardiography surgical view illustrates complex Barlow degeneration with A2-A3 scal-
lop prolapse and flail A1 scallop (arrow) Panel C: 3-Dimensional long-axis view indicates flail anterior leaflet. Panel 
D: cardiac magnetic resonance (CMR) reveals prolapse of mitral valve on 2-chamber view. Panel E: CMR suggests 
A2 prolapse on 4-chamber view, although caution is warranted when diagnosing prolapse in this view because 
misinterpretation may occur due to the saddle-shaped mitral annulus. Ao: aorta, LA: left atrium, LAA: left atrial ap-
pendage, LV: left ventricle, RA: right atrium, RV: right ventricle
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The parasternal and apical long-axis views of the left ventricle allow quantifica-
tion of the MV leaflet geometry (Table 1). At mid-systole the coaptation distance 
or height (4-6 mm from coaptation point to mitral annulus plane) and the anterior 
and posterior angles formed between the mitral annulus plane and the respective 
anterior and posterior mitral leaflets can be measured at the A1-P1, A2-P2 or A3-
P3 level (Figure 5).3,12,30 A triangular tenting area or volume comprised between 
the mitral annulus plane, the leaflet surfaces and the coaptation line can be identi-
fied.12 Increased tenting area and increased posterior and distal anterior leaflet 
angle are important determinants of mitral regurgitation severity and are related 
to adverse outcome after mitral surgery for functional mitral regurgitation.12,31,32 
The coaptation length refers to the length between the tips of the leaflets and 
their coaptation point that is formed by the systolic overlap of the leaflets (6-10 


















Segmental anatomy and geometric indices of mitral valve by computed tomography. Panel A: Interpapillary muscle 
distance on 2-chamber plane. Panel B: Short-axis view of mitral valve with A1-A2-A3 scallops, P1-P2-P3 scallops, 
antero-lateral commissure (ALC) and postero-medial commissure (PMC). Panel C: Short-axis view at level of mitral 
annulus to measure minor and major axis annular diameters (arrows). Panels D, E, F: Reconstruction planes at 
A1-P1, A2-P2 and A3-P3 level, respectively. The mitral valve coaptation height (MVCht), anterior angle (Aα) and 
posterior angle (Pα) can be quantified. Ao: aorta, LCX: left circumflex coronary artery, LV: left ventricle, LVOT: left 









MV function.3,7 Its assessment should be an integral part of the evaluation of per-
operative success of mitral repair. With the use of multiplanar reformation planes, 
3D-echocardiography and MDCT permit accurate assessment of these parameters 
(Figure 5).14 
Functionally, normal leaflet mobility throughout the cardiac cycle (1) protects 
from systolic backflow of blood towards the left atrium, (2) forms an essential 
component of the funnel shaped LV outflow tract during ejection and (3) enables 
diastolic blood flow towards the LV without a significant forward gradient.7 A 
mitral valve area of 4-5 cm2 is considered normal.7,8 The assessment of mitral 
leaflet mobility is pivotal to define the mechanism of MV regurgitation according 
to the Carpentier classification: normal, excessive (prolapse or flail) or restricted 
(rheumatic or functional MV disease) leaflet mobility.12 
Finally, spectral- and color-Doppler echocardiographic methods can identify the 
presence of regurgitation or stenosis and provide the cornerstone of quantita-
tive functional MV assessment (Table 2). Alternatively, mitral regurgitation can be 
detected as low signal intensity (signal void) on bright-blood steady state free 
precession-cine images and subsequently quantified by blood flow imaging using 
velocity-encoded phase-contrast CMR.27 Except for mitral valve planimetry, MDCT 
currently does not allow quantitative MV function assessment as it lacks blood 
flow data and suffers low temporal resolution. Quantification of MV function by 
different imaging modalities and applications will be extensively discussed in 
other articles included in this issue.
Table 3.2
Usefulness of multimodality imaging to study mitral valve anatomy and function. CMR: cardiac magnetic reso-
nance, Echo: echocardiography, MDCT: multidetector computed tomography, 2D: two-dimensional, 3D: three-di-
mensional.
Mitral valve 2D-echo 3D-echo MDCT CMR
Anatomy
Annulus ++ +++ ++ ++ 
Left atrium ++ ++ ++ ++ 
Leaflets +++ +++ + +/- 
Subvalvular apparatus +++ + +++ +/- 
Left ventricle +++ +++ +++ +++ 
Function     
Mitral regurgitation +++ ++ - ++ 
Mitral stenosis +++ +++ +/- ++ 
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Subvalvular apparatus and left ventricle
The subvalvular apparatus consists of fibrous tendinous chords and the papillary 
muscles. The antero-lateral papillary muscle usually arises from the apico-lateral 
third of the LV and the postero-medial papillary muscle originates from the middle 
third of the LV inferior wall, avoiding the interventricular septum.7,8 Both papillary 
muscles give rise to several dozens of tendinous chords that attach to the ipsilat-
eral half of the anterior and posterior mitral leaflets. Commissural chords however 
originate only from the papillary muscle in closest proximity beneath.7,8 Tendinous 
chords remain at the same length throughout the cardiac cycle and give rise to 
several branches of chords that can attach to the edges of the mitral leaflets (pri-
mary chords) or to the ventricular surface of the leaflet bodies (secondary chords). 
Few tertiary chords can be identified originating directly from the posterior LV wall 
to the posterior mitral leaflet only.7,8 
With 2D transthoracic echocardiography, the basal and mid short-axis as well as 
long-axis bi-commissural views of the left ventricle allow systematic morphologi-
cal evaluation of the subvalvular apparatus and end-diastolic measurement of the 
chordal length and various geometrical indices (Table 1).8 Chordal elongation can 
be encountered in fibro-elastic deficiency and Marfan’s disease for example.33 The 
90º (transgastric) 2-chamber view on TEE provides a clear view on the subvalvular 
apparatus.13 Furthermore, MDCT has demonstrated the highly variable anatomy of 
the subvalvular apparatus.3 While the antero-lateral papillary muscle usually has 1 
or 2 heads and a single trabecularized insertion on the LV wall, the postero-medial 
papillary muscle has multiple anatomic variations with 1 to 3 heads and multiple 
trabecularized ventricular insertions.3 
The normal geometric relations of the MV leaflets described above depend on 
the geometry of the subvalvular apparatus. The inter-papillary muscle distance 
refers to the distance in between the base or the heads of the papillary muscles in 
systolic short-axis mid-ventricular view or in a LV longitudinal view, respectively 
(Figure 5).3,34 This parameter reflects the displacement of the papillary muscles 
in patients with dilated left ventricles. Similar to the mitral leaflets, the anterior 
and posterior angles and length between the tip of the papillary muscles and 
the mitral annulus can be quantified as a measure of mitral leaflet tethering. 3D-
imaging techniques provide optimal assessment of all these geometrical indices. 
Acquisition of a full volume of the left ventricle with 3D-echocardiography and 
subsequent image post-processing displays best the entire subvalvular apparatus 
from the LV perspective.13
Functionally, the subvalvular apparatus ensures adequate leaflet mobility 
throughout the cardiac cycle by synchronous papillary muscle contraction in con-









are transmitted to the valvular leaflets by the primary chords to ensure leaflet 
coaptation. Secondary chordae permit limited bulging of the leaflet bodies, which 
reduces leaflet stress in concert with the 3D-shape of the mitral annulus. The 
secondary ‘strut’ chordae only attach to the anterior mitral leaflet and are part of 
a ventriculo-valvular fibrous loop, essential to suspend the aorto-mitral angle and 
maintain normal LV shape, geometry and function.7 Normal LV shape (sphericity in-
dex, end-diastolic volume index, end-systolic volume-index) and systolic function 
(ejection fraction, (dys)synchrony) are major determinants of normal geometric 
relations and function of the subvalvular apparatus.3
CLINICAL IMPLICATIONS 
Studies of the normal MV by different noninvasive cardiac imaging modalities 
contributed to a wealth of (patho)physiological insights and clinical applications 
in patients with MV dysfunction. Echocardiography remains the first-line imaging 
technique of choice for evaluation of MV dysfunction (Table 2). 3D-echocardiog-
raphy provides additional information to study function and anatomy of the mitral 
annulus, quantify mitral valve dysfunction and evaluate MV morphology, given by 
the ease of segmental anatomy recognition. However, 3D-image quality depends 
on 2D-image quality and still the temporal and spatial resolution are lower than 
2D-echocardiography.13 MDCT is highly suited to study MV anatomy (morphology 
and geometry), given its optimal spatial resolution. Radiation exposure, use of 
iodinated contrast agents, limited temporal resolution and current lack of applica-
tions to quantify blood flow are current drawbacks to systematically apply MDCT 
for MV evaluation.35 As MDCT-angiography is increasingly performed to evaluate 
coronary artery disease, the report should mention when abnormal mitral mor-
phology or geometry is encountered. CMR is a valid alternative for quantitative 
functional evaluation of the MV in case of suboptimal acoustic window and contra-
indication for TEE, but lacks spatial resolution to optimally address MV anatomy.28 
The costs, availability and high technical expertise needed for appropriate imaging 
additionally hamper the wide clinical use of CMR to image the MV.
Current surgical and percutaneous techniques or devices rely on careful noninva-
sive cardiac imaging for patient selection, planning, guiding and evaluation of the 
intervention. Morphologic MV characteristics determine MV reparability in organic 
MV disease, while geometric indices of the leaflets and subvalvular apparatus 
have shown to determine severity of MV dysfunction, reparability and outcome 
after repair in functional mitral regurgitation.12,31 The importance of geometrical 
indices in functional MV disease enforced the idea of targeting therapeutically 
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the subvalvular apparatus, resulting in different surgical possibilities such as LV 
remodeling techniques (Coapsys® system, external balloon patch, etc.), use of 
neo-chordae and translocation or reconstruction of papillary muscles.10 MDCT may 
become useful to evaluate the subvalvular apparatus prior to abovementioned 
complex repair procedures.3 Moreover, there is a growing interest in percutane-
ous techniques to treat mitral regurgitation. Devices for direct or indirect mitral 
annuloplasty (via coronary sinus approach), direct edge-to-edge leaflet repair and 
percutaneous mitral valve replacement have been introduced into clinical practice 
or are currently under development.5 MDCT as well as CMR enable the study of the 
surrounding anatomy of the mitral annulus which is of major interest in the selec-
tion of candidates for percutaneous annuloplasty interventions via the coronary 
sinus, for example.4-6 
CONCLuSION
The normal MV is a functional complex that relies on normal morphology, geometry 
and function of all its constituents. The role of 3D-imaging techniques to study the 
MV is increasingly recognized. Further development in this field of multimodality 
imaging will undoubtedly lead to novel (3D) applications and improved spatial and 
temporal resolution to study the (normal) mitral valve. This knowledge will ulti-
mately refine our diagnostic performance, provide additional (patho)physiological 
insights and help to design new strategies for interventional or surgical treatment 
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Recently it has been hypothesized that mitral leaflet remodeling may play a role 
in the pathophysiology of functional mitral regurgitation (FMR). We investigated 
the characteristics, determinants and relation of mitral leaflet remodeling to FMR 
severity.
Methods and Results
3-dimensional transesophageal echocardiographic data of the mitral valve (MV) 
were studied in 30 patients with FMR ≥grade 3 (≥3), 24 patients with FMR <grade 
3 (<3) and 22 controls with normal MV. FMR <3 and ≥3 patients showed leaflet 
remodeling compared to control subjects with larger overall MV leaflet areas 
(11.47±3.16 and 9.58±1.99 vs. 7.30±1.57 cm2/m2, respectively; all p<0.01). Tent-
ing volume (r2=0.55), LV ejection fraction (r2=0.20), annulus area (r2=0.87) and 
LV sphericity index (r2=0.25) were correlated with overall MV leaflet area (all 
p<0.001). Although these correlates were similar between FMR <3 and ≥3 patients 
(all p>0.05), the overall MV leaflet area was smaller in FMR ≥3 compared to FMR<3 
patients (p=0.01), indicating less remodeling despite similar tethering degree. 
Particularly, coaptation/overall MV leaflet area ratio ≤0.24, reflecting insufficient 
leaflet remodeling, was associated with FMR ≥3 (area under ROC curve=0.93, sen-
sitivity 90% and specificity 91%). This ratio was independently associated with 
FMR ≥3 (OR 61.3, 95%CI 9.4-399.9, p<0.001) and showed significant correlation 
with effective regurgitant orifice area (r2=0.38, p< 0.001).
Conclusion
MV leaflet remodeling in FMR is common and relates to LV function, LV sphericity, 
MV tenting volume and annulus dilatation. Insufficient leaflet remodeling relative 










Functional mitral regurgitation (FMR) affects approximately 30% of patients with 
ischemic heart disease or dilated cardiomyopathy and yields a dismal prognosis.1 
FMR is a complex problem, comprising dysfunction of a structurally normal mitral 
valve (MV) secondary to local or global left ventricular (LV) dysfunction with dis-
torted LV geometry.2 Recent data, however, have challenged the idea of the MV 
being only an “innocent bystander” in FMR patients. In particular, it was shown 
that the MV in patients with end-stage heart failure exhibits extracellular matrix 
changes proportional to annular, atrial and ventricular dimensions and function, 
including increased fibrosis (collagen), deoxyribonucleic acid (DNA, cellularity) 
and glycosaminoglycan extent.3 These alterations coincided with increased leaflet 
thickness and length, reflecting structural leaflet remodeling.3 Animal studies have 
also shown an up-regulation of the extracellular matrix and mitral leaflet adaptation 
(increased area) as a compensatory response to LV dilatation or loading.4, 5 More 
recent studies, using 3-dimensional (3D) echocardiography which is ideally suited 
for detailed evaluation of MV anatomy and morphology, have shown the presence 
of MV leaflet remodeling in patients with LV dysfunction and have suggested that 
inadequate leaflet remodeling may be related to the presence of significant FMR.6-8 
Data on characteristics, potential determinants and the relationship of MV leaflet 
remodeling to FMR severity are scarce, however. Therefore, the hypothesis of the 
present evaluation was to demonstrate whether inadequate leaflet remodeling on 
3D echocardiography, expressed as lack of leaflet coaptation relative to annular or 
LV changes, relates to presence of significant FMR.
METhODS
Patients
Patients with FMR who underwent 3D transesophageal echocardiography were in-
cluded. FMR was defined as MR due to local or global LV dysfunction and/or remod-
eling in the absence of macroscopic morphologic abnormalities of the mitral valve. 
Clinical reasons for transesophageal echocardiography in FMR patients comprised 
evaluation of severity of valvular dysfunction and specific underlying mechanism 
(n=35/54), screening for transcatheter mitral valve repair eligibility (n=17/54) or 
diagnostic work-up before ventricular tachyarrhytmia ablation (n=2/54). A control 
group included patients with macroscopically normal structural and functional 
MV who underwent clinically indicated 3D transesophageal echocardiography to 
exclude cardiac embolism source (n=19/22) or endocarditis (n=3/22). Patients 
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with aortic valve stenosis, MV stenosis, prior left-sided valve surgery, organic MV 
disease (prolapse, flail, cleft, rheumatic disease), congenital heart disease, active 
endocarditis, LV assist device or hypertrophic cardiomyopathy and patients with 
insufficient image quality were not included.
Clinical characteristics, medication use and heart failure etiology (ischemic ver-
sus non-ischemic, including location of prior myocardial infarction) were retrieved 
from the departmental Cardiology Information System (EPD-Vision®, Leiden 
University Medical Center, Leiden, the Netherlands). Patients with FMR were di-
vided into two groups according to the mitral regurgitation grade (FMR<3 versus 
FMR≥3). MV apparatus geometry and mitral leaflet remodeling were evaluated and 
compared between groups.
The institutional ethical committee approved this evaluation and waived the 
need for patient written informed consent for retrospective analysis of clinically 
collected data.
2D echocardiography
All patients underwent 2-dimensional (2D) transthoracic echocardiography in the 
left lateral decubitus position using commercially available ultrasound machines 
(Vivid-5, Vivid-7 and E9, GE-Vingmed, Milwaukee, WI) equipped with 3.5 MHz and 
M5S transducers. 2D-gray-scale and Doppler images were acquired in cine-loop 
format with ECG-triggering. Off-line analysis of these images was performed on 
a workstation (EchoPAC 112.0.0, GE Medical Systems, Horten, Norway). LV and 
left atrial dimensions were assessed as recommended.9 LV end-diastolic and end-
systolic diameters were measured at the parasternal long-axis view. The Simpson’s 
biplane method was applied to quantify LV volumes and to calculate LV ejection 
fraction. Left atrial volume was also measured according to the biplane method. All 
volumes were indexed to body surface area. LV sphericity index was defined as the 
ratio of end-diastolic mid-ventricular width to length of the LV. Early (E) and late 
(A) diastolic mitral inflow velocities as well as deceleration time were assessed by 
pulsed-wave Doppler, placing the sample volume at the tips of the mitral leaflets. 
Septal mitral annulus velocities (E`) were derived from tissue Doppler recordings 
and used to calculate the E/E` ratio. In line with current recommendations, inte-
gration of all available qualitative and (semi-)quantitative parameters assessed 
with 2D echocardiography, including vena contracta width and effective orifice 
area (EROA) by proximal isovelocity surface area method were evaluated to grade 
FMR as trivial (1), mild (2), moderate (3) or severe (4).10, 11 A vena contracta width 
between 3-4 mm, 5-6 mm and ≥7 mm defined grade 2, 3 and 4 FMR, respectively. 
In addition, an EROA between 10.0-14.9 mm2, 15.0-19.9 mm2 and ≥20.0 mm2 










Patients underwent 3D transoesophageal echocardiography using a Philips iE33 
ultrasound machine (Philips Medical Systems). 3D datasets of the MV were ac-
quired using full-volume or 3D-zoom mode, comprising a pyramidal volume of ap-
proximately 60º by 60º. In order to maximize frame rate, multi-beat (7-14 beats) 
full-volume acquisitions were performed during breath-hold whenever possible 
or 1-beat 3D-zoom acquisitions with the sector adjusted to include the MV if the 
patient could not hold the breath or when presenting with irregular heart rhythm 
such as atrial fibrillation.
3D mitral valve quantification
3D-volumetric datasets of the MV were studied off-line on a workstation (Qlab, 
Philips Medical Systems, version 9.0) using dedicated commercially available MV 
Quantification software (MVQ). To maximize spatial and temporal resolution, 3D-
full volume acquisitions were preferred over 3D-zoomed acquisitions and mean 
frame rate was 26 frames/s. Stepwise reconstruction of a 3D-model of the MV 
was performed by a single experienced operator, blinded to FMR severity (Figure 
1A). After selecting the end-systolic frame, multi-plane reformation (MPR) planes 
were automatically displayed and manually aligned to obtain a bicommisural, 
outflow tract and short-axis view of the MV. In addition, a 3D volume rendering 
of the MV is displayed and can be additionally used for identification of anatomic 
landmarks. The short-axis plane was set at the level of the mitral annulus. The 
antero-lateral and postero-medial mitral annulus were then indicated on the bi-
commissural view whereas the anterior and posterior mitral annulus as well as the 
mitral leaflet coaptation point and the aortic annulus were set at the outflow tract 
view. An initial 3D-model containing an annular ring and mitral leaflets was then 
automatically displayed. The mitral annulus on the 3D-model was subsequently 
refined by indicating additionally 8 pairs of annulus points on sequential MPR 
rotational cross-sections in the long-axis views and the mitral leaflet commissural 
points were set on the short-axis MPR image. Subsequently, the mitral leaflets and 
the coaptation length were manually traced on multiple cross-sections (between 
18 to 30) in the outflow tract view, orthogonal to the inter-commissural direction 
with a minimal distance of 0.17 cm between cross-sections. To correctly identify 
the coaptation point, the 3D-rendered volume of the MV (surgical en face view) 
was additionally used. Finally, the 3D model of the MV was displayed and several 
geometric measurements of the MV were automatically generated (Figure 1B). 
Lengths, areas and volumes were indexed to body surface area. In particular, the 
antero-posterior and inter-commissural annular diameter and circumferential an-
nular area were assessed. In addition, the exposed leaflet area of the total MV and 
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the respective anterior and posterior leaflets, representing the surface exposed 
to the left atrium, were derived. The overall leaflet area, including the exposed 
area and coaptation area of each mitral leaflet was also computed. The coaptation 
area was calculated as the overall leaflet area minus the exposed leaflet area of 
the total MV.8 Of note, the anatomic regurgitant orifice area is not excluded from 
the coaptation area as spatial resolution does not permit its adequate detection. 
The coaptation length at central level (A2-P2) and the tenting volume comprised 
between the leaflets and the annular surface area were also measured. Similar to 
prior reports, the ratio of overall total leaflet/annular area (leaflet/annular area) 
and coaptation/overall total leaflet area (coaptation/leaflet area) were assessed as 
measures of leaflet remodeling, relative to the mitral annulus and LV changes.6-8 
Statistical analysis
Continuous variables are presented as mean ± SD and compared with the Stu-
dent T-test or Mann-Whitney U-test, as appropriate. Categorical variables are 
presented as number and percentages and compared by Pearson chi-square 
test. Overall comparison among groups was performed by one-way ANOVA with 
Bonferroni post-hoc testing (for continuous variables with normal distribution), 









Mitral leaflet and annulus geometry by 3D transesophageal echocardiography. Panel A: A 3-dimensional (3D) mod-
el of the mitral valve is reconstructed after indicating mitral annulus landmarks, tracing leaflets and indicating the 
coaptation point on multi-plane reformation images that are manually aligned to obtain a bicommisural (green), 
outflow tract (red) and short-axis plane (blue) of the mitral valve. Panel B: Annulus area (1), tenting volume (2), an-
nulus diameters (3), total valve area (4), exposed valve area (5) and coaptation area (6), calculated as total minus 










chi-square (for categorical variables) tests. Correlates of overall total mitral leaflet 
area were explored with linear regression analysis. In addition binary logistic 
regression was performed to investigate the univariate associates of significant 
mitral leaflet remodeling (defined as ≥2 SD of the overall leaflet area of control 
subjects). A receiver operating characteristic (ROC) curve was subsequently con-
structed to evaluate the value of the coaptation/leaflet area to predict presence 
of FMR ≥3. Uni- and multivariate binary logistic regression analyses were in addi-
tion performed to identify independent correlates of FMR ≥3, using a backward 
elimination approach. Odds ratio (OR) and 95% confidence intervals (CI) were 
obtained. A significance level of p<0.10 qualified for entrance in the multivariate 
model. Finally the association between coaptation/leaflet area and FMR grade was 
further explored by linear regression analysis. Intra- and inter observer variability 
for overall and exposed mitral valve leaflet area was evaluated by intraclass cor-
relation for 15 randomly selected patients (5 control subjects, 5 FMR<3 and 5 
FMR≥3 patients). Statistical analyses were performed using the SPSS software ver-




Seventy-six patients were evaluated, including 22 controls (53±15 years old, 64% 
male), 24 patients with FMR<3 (61±16 years old, 50% male) and 30 patients 
with FMR≥3 (68±12 years old, 60% male). Characteristics of the control and FMR 
groups are outlined in Table 1. Control subjects were younger, more likely to be in 
sinus rhythm, had less diabetes mellitus and were using less cardiovascular medi-
cation. Patients with FMR≥3 had lower systolic and diastolic blood pressure and 
higher prevalence of ischemic heart failure etiology compared to patients with 
FMR<3. Location of myocardial infarction between patients with ischemic FMR<3 
vs. FMR≥3 was however, similar. Cardiovascular medication use was comparable 
between both groups.
FMR patients had significantly larger LV diameters, LV volumes, LA volume and 
showed significantly worse LV systolic and diastolic function with higher systolic 
arterial pulmonary pressures compared to controls.
Mitral leaflet remodeling 
Geometric and morphologic characteristics of the mitral annulus and leaflets are 









n=30 p value* p value†
Men, n (%) 14 (64) 12 (50) 18 (60) 0.17 0.46
Age, years 53 ± 15 61 ± 16 68 ± 12 0.001 0.22
BSA, m² 1.95 ± 0.2 1.90 ± 0.2 2.03 ± 0.2 0.08 -
Sinus rhythm, n (%) 22 (100) 19 (79) 19 (63) <0.001 0.21
Systolic BP, mmHg 130 ± 16 129 ± 26 112 ± 21 0.004 0.015
Diastolic BP, mmHg 75 ± 10 76 ± 15 65 ± 9 0.002 0.006
Arterial hypertension, n (%) 7 (32) 10 (42) 15 (50) 0.17 0.54
Diabetes mellitus, n (%) 1 (5) 4 (17) 11 (37) <0.001 0.10
Active/ex-smoker, n (%) 9 (45) 11 (46) 16 (53) 0.82 0.58
Hypercholesterolemia, n (%) 13 (59) 13 (54) 15 (50) 0.49 0.76
Ischemic FMR, n (%) - 12 (50) 25 (83) - 0.009
Prior myocardial infarction 
Anterior, septal and/or apical - 7/12 (58) 15/25 (60) 0.92
Inferior, posterior and/or lateral - 6/12 (50) 11/25 (44) 0.73
β-blocker, n (%) 5 (24) 18 (75) 23 (77) 0.036 0.89
ACE-inhibitor, n (%) 3 (14) 12 (50) 13 (43) 0.036 0.52
ARB II, n % 3 (14) 6 (25) 10 (33) <0.001 0.57
Diuretic, n (%) 2 (10) 17 (71) 28 (93) 0.014 0.09
Spironolactone, n (%) 1 (5) 6 (25) 11 (37) <0.001 0.41
Statin, n (%) 15 (75) 13 (54) 22 (73) 0.002 0.20
LVEDD, mm 45 ± 6 60 ± 9 65 ± 9 <0.001 0.64
LVESD, mm 26 ± 5 47 ± 9 50 ± 10 <0.001 0.45
LVEDVI, mL/m² 48 ± 15 99 ± 56 99 ± 41 <0.001 1.00
LVESVI, mL/m² 17 ± 6 67 ± 47 67 ± 37 <0.001 1.00.
LVEF, % 66 ± 6 36 ± 10 36 ± 14 <0.001 1.00
LVED sphericity index 0.47 ± 0.1 0.61 ± 0.1 0.62 ± 0.1 <0.001 1.00
LAVI, mL/m² 25 ± 5 51 ± 18 55 ± 20 <0.001 1.00
E/A 1.0 ± 0.3 1.7 ± 0.8 2.6 ± 1.0 <0.001 0.001
E/E’ 11 ± 5 30 ± 12 41 ± 23 <0.001 0.044
DecT, msec 206 ± 37 167 ± 48 146 ± 48 <0.001 0.29
MV mean gradient, mmHg 1.2 ± 0.4 1.8 ± 0.9 2.0 ± 1.1 0.008 1.00
MR grade, n (%) 0.003 <0.001
Grade 1 - 7 (29) 0 (0) 
Grade 2 - 17 (71) 0 (0) 
Grade 3 - 0 (0) 7 (23) 
Grade 4 - 0 (0) 23 (77) 
MR vena contracta, mm - 3.8 ± 0.7 8.1 ± 1.7 - <0.001
MR EROA (Pisa), cm² - 0.12 ± 0.1 0.40 ± 0.1 - <0.001
PAPsyst, mmHg 26 ± 5 37 ± 11 43 ± 14 <0.001 0.14
* for comparison between all patient groups
† for comparison of FMR <3 versus ≥3 patients
ACE: angiotensine converting enzyme, ARBII: angiotensine receptor bocker, BP: blood pressure, BSA: body surface 
area, DecT: deceleration time, ED: end-diatsolic, EDD: end-diastolic diameter, ESD: end-systolic diameter, EDVI: 
end-diastlic volume indexed to BSA, EF: ejection fraction, ESVI: end-systolic volume indexed to BSA, FMR: function-
al mitral regurgitation, LAVI: left atrial volume indexed to BSA, MV: mitral valve, MR: mitral regurgitation, PAPsyst: 









area compared with controls. The presence of leaflet remodeling was identified 
in both FMR groups showing larger overall leaflet area compared to controls. 
Patients with FMR <3 and ≥3 had a respective relative increase of overall total 
leaflet area of 57% and 31% compared to controls (both, p<0.001). Significant 
leaflet remodeling, defined as ≥2 SD overall total leaflet area of control subjects, 
was respectively observed in 67% (n=16/24) and 37% (n=11/30) of patients with 
FMR<3 and FMR≥3. The pattern of relative leaflet remodeling was symmetrical for 
the anterior and posterior mitral leaflets. In patients with FMR<3 the anterior and 
posterior mitral leaflet areas were increased by 53% and 62% whereas in patients 
with FMR≥3 these increments were of 31% and 32%, respectively. In addition, 
symmetrical leaflet remodeling was also noted in patients with infero-posterior 
myocardial infarction (n=17), showing a 35% and 39% relative increase of the 
posterior and anterior MV leaflet respectively.
Table 4.2






n=30 p value* p value†
ANNULUS
AP diameter, mm/m2 14.3 ± 1.8 18.0 ± 2.5 16.9 ± 2.3 <0.001 0.18
IC diameter, mm/m2 18.8 ± 2.8 21.1 ± 3.1 19.6 ± 2.0 <0.001 0.12
Annulus area, cm2/m2 4.6 ± 1.0 6.7 ± 1.6 6.1 ± 1.2 <0.001 0.21
LEAFLETS
Exposed leaflet area, cm2/m2
AMVL 3.12 ± 0.65 4.81 ± 1.15 4.37 ± 0.80 <0.001 0.23
PMVL 2.15 ± 0.52 3.62 ± 1.23 3.16 ± 0.84 <0.001 0.21
Total (AMVL + PMVL) 5.27 ± 1.12 8.42 ± 2.30 7.53 ± 1.54 <0.001 0.18
Overall leaflet area, cm2/m2
AMVL 4.13 ± 0.86 6.33 ± 1.59 5.39 ± 1.03 <0.001 0.016
PMVL 3.17 ± 0.74 5.14 ± 1.62 4.18 ± 1.03 <0.001 0.013
Total (AMVL + PMVL) 7.30 ± 1.57 11.47 ± 3.16 9.58 ± 1.99 <0.001 0.012
Coaptation area, cm2/m2 2.03 ± 0.50 3.04 ± 0.97 2.04 ± 0.51 <0.001 <0.001
A2-P2 coaptation L, mm/m2 2.8 ± 0.7 3.2 ± 0.9 2.1 ± 0.40 <0.001 <0.001
Leaflet /annular area 1.57 ± 0.09 1.70 ± 0.14 1.59 ± 0.17 0.004 0.013
Coaptation/ leaflet area 0.28 ± 0.02 0.26 ± 0.03 0.21 ± 0.02 <0.001 <0.001
Leaflet/exposed area 1.38 ± 0.05 1.36 ± 0.06 1.27 ± 0.03 <0.001 <0.001
Tenting volume, mL/m2 0.74 ± 0.29 2.09 ± 1.13 1.87 ± 1.1 <0.001 1.00
* for comparison among all patient groups
† for comparison of FMR <3 versus ≥3 patients
AMVL: anterior mitral valve leaflet, AP: antero-posterior, A2: AMVL medial scallop, IC: inter-commissural, L: length, 
PMVL: posterior mitral valve leaflet, P2: PMVL medial scallop 
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Correlates of mitral leaflet remodeling 
Potential determinants of mitral leaflet remodeling were explored by logistic and 
linear regression analysis. Larger MV tenting volume (OR 10.04, 95% CI 3.52-28.68, 
p<0.001), LV sphericity index ≥0.65 (OR 17.00, 95% CI 4.76-60.77, p<0.001) and 
increased mitral annulus area (OR 1.04, 95% CI 1.02-1.07, p<0.001), all reflecting 
increased tethering forces, significantly correlated with the presence of significant 
leaflet remodeling and overall mitral leaflet area (Figure 2). In addition LV ejection 
fraction was significantly and inversely associated with the presence of significant 
leaflet remodeling (OR 0.94, 95% CI 0.91-0.97, p<0.001) and overall MV leaflet 
area (Figure 2).
Leaflet remodeling and mitral regurgitation severity
Significant mitral leaflet remodeling was present in both FMR groups. Importantly, 
a similar degree of tethering was noted in both groups, shown by comparable 
MV tenting volumes, annulus dilatation and LV size, shape and function (Table 1 
and 2). Less extensive leaflet remodeling, however, was observed in patients with 






















































tenting volume (mL/m2) LVEF (%)
LV end-diastolic sphericity index
r2=0.55, p<0.001 r2=0.20, p<0.001
r2=0.87, p<0.001 r2=0.25, p<0.001
Figure 4.2









area (Table 2; Figure 3). This difference was mainly attributed to smaller coaptation 
area in patients with FMR≥3 compared with patients with FMR<3, as both groups 
had comparable exposed leaflet area. The coaptation/leaflet area was preserved 
(proportional to increased leaflet size) in patients with FMR<3, however, it was 
significantly decreased in patients with FMR≥3 compared with control patients, re-
flecting insufficient leaflet remodeling (lack of coaptation reserve) to compensate 
for the requirements of the dysfunctional dilated LV (Figure 4).
The ROC curve analysis showed that coaptation/leaflet area was an accurate 
predictor of the presence of FMR≥3 with AUC=0.925 (p<0.001) (Figure 5A). In 
particular a coaptation/leaflet area ≤0.24, indicating a coaptation area ≤24% of 
the overall total leaflet area, had a sensitivity and specificity of 90% and 91% to 
predict the presence of FMR≥3, respectively.
As shown in Table 3, the multivariate regression analysis demonstrated that 
coaptation/leaflet area ≤0.24 is strongly related to the presence of FMR≥3, inde-
pendently of degree of LV tethering or infarct location in case of ischemic FMR. 
Coaptation/leaflet area showed a significant inverse correlation with FMR severity 
(r2=0.38, p<0.001) (Figure 5B).
Additionally, the leaflet/annular area ratio of patients with FMR≥3 was signifi-
cantly smaller than patients with FMR<3, suggesting insufficient leaflet remodel-
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*  p<0.05 vs controls
†  p<0.05 vs FMR 1-2
Figure 4.3
Mitral valve remodeling among different groups. Patients with functional mitral regurgitation (FMR) show larger 
total mitral leaflet area than control subjects (leaflet remodeling). Leaflet area in patients with FMR ≥3 versus <3, 
however, is smaller, mainly due to smaller coaptation area rather than exposed leaflet area. Insufficient leaflet 
remodeling resulting in lack of coaptation reserve might prohibit adequate systolic leaflet closure and facilitate 








Coapt area / MVA ratio 0.27
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Coapt area / MVA ratio 0.20
Figure 4.4
Examples of mitral valve leaflet remodeling in representative subjects. Panel A: control patient without functional 
mitral regurgitation (FMR). Patients with mild (Panel B) and severe FMR (Panel C), both secondary to inferior infarc-
tion. Note larger mitral valve area (MVA) and coaptation area to MVA ratio in patient with mild versus severe FMR. 




















Relation of coaptation to mitral valve leaflet area and severity of functional mitral regurgitation. Panel A: ROC-
curve analysis, coaptation/leaflet area ratio ≤0.24 predicts FMR ≥ grade 3 with sensitivity of 90% and specificity 
of 91%. Panel B: Reduced coaptation/mitral leaflet area ratio correlates linearly to FMR severity. Red dashed line 
indicates the ROC-curve derived cut-off point of ≤0.24. AUC: area under the curve, EROA: effective regurgitant 










Intraclass correlation coefficients for overall (total) leaflet area were 0.903 (intra-
observer) and 0.947 (inter-observer). For exposed leaflet area measurements, the 
intraclass correlation coefficients were 0.955 and 0.947 for intra-observer and 
inter-observer reproducibility, respectively.
DISCuSSION
The present evaluation demonstrated that MV leaflet remodeling is common in 
FMR, showing a symmetrical involvement of both leaflets, and relates to MV teth-
ering and closing forces. In addition, insufficient MV leaflet remodeling to com-
pensate for annular and LV changes is strongly and independently associated with 
FMR severity, reflecting a potential therapeutic target for patients with functional 
MV disease.
Leaflet remodeling evidence
FMR results from an imbalance between valvular closing (LV dysfunction, LV and 
papillary muscle dyssynchrony and reduced annular contraction) and tethering 
forces (LV sphericity, papillary muscle displacement, annular dilatation and MV 
tenting).2, 12 This imbalance causes relocation of the MV coaptation point more api-
Table 4.3
Independent associates to functional mitral regurgitation ≥ grade 3.
Univariate Multivariate
OR 95% CI p value OR 95% CI p value
Age, per year 1.06 1.02-1.10 0.004 1.01 0.93-1.08 0.96
Male gender 1.15 0.45-2.94 0.76
Ischemic FMR 5.00 1.43-17.5 0.012 3.19 0.50-20.5 0.22
Infarct location
 Ant, sept and/or apical 1.07 0.26-4.34 0.92
 Inf, post and/or lateral 0.79 0.19-3.12 0.73
LVEF, per % 0.95 0.92-0.98 0.001 0.98 0.91-1.06 0.61
LVED sphericity index ≥0.65 3.63 1.27-10.4 0.016 1.04 0.15-7.12 0.97
Annulus area, per mm2/m2 1.01 0.99-1.01 0.68
Tenting volume, per mL/m2 1.45 0.93-2.25 0.10
Leaflet/annulus ratio 0.07 0.01-2.23 0.13
Coaptation/leaflet ratio ≤0.24 93.3 17.5-496.6 <0.001 70.0 11.7-419.9 <0.001
CI: confidence interval, LVED: left ventricular end-diastolic, LVEF: left ventricular ejection fraction,MR: mitral regur-
gitation, OR: odds ratio
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cally and/or posteriorly, thereby restricting the leaflets movement with secondary 
loss of coaptation and FMR.12 Therefore FMR is generally regarded as a ventricular 
problem leading to dysfunction of a structurally normal valve.2 Differences in FMR 
severity despite similar tethering degree, however, have been observed.6-8 For 
instance in patients with moderate to severe aortic regurgitation and significant 
LV remodeling, the prevalence of FMR is surprisingly low.6 Such observations 
enforce the idea that the MV itself might develop compensatory adaptations to 
the chronic stress imposed by the annular and LV changes.7, 13 Indeed, alterations 
in biochemical extracellular matrix and increased cellularity in mitral leaflets of 
humans with LV dysfunction have been reported.3 This ultra-structural remodeling 
coincides with increased stiffness and reduced leaflet stretch abilities.14 In addi-
tion, structural mitral leaflet remodeling, including increased mitral leaflet length, 
area and thickness in response to mitral annular and LV dilatation was observed in 
animal models of both ischemic and non-ischemic heart failure.5, 13, 15 Evidence of 
prospective increase in mitral leaflet size >30% in response to imposed stress and 
as the result of an active biological process was recently provided by longitudinal 
animal model studies.5, 15 The current evaluation also shows that patients with 
FMR have increased MV area of >30% compared to normal controls, indicating 
presence of leaflet remodeling. These findings are in line with previous reports on 
transthoracic or transesophageal 3D echocardiography of the MV, showing relative 
increases in mitral leaflet area of 23% to 35% .6-8 This evidence suggests that in 
patients with FMR the MV shows structural remodeling and should, therefore, not 
be regarded as `normal`.
Characteristics and determinants of leaflet remodeling
The present evaluation indicates that significant leaflet remodeling (defined as 
≥2 SD of the overall leaflet area of control subjects) is prevalent. In addition, a 
symmetrical pattern of relative enlargement of the posterior compared to the 
anterior MV leaflet was found, even in patients with ischemic cardiomyopathy 
with prior infero-posterior myocardial infarction. These findings are in line with 
a recent finite element analysis in a unique sheep model of the LV and MV after 
infero-posterior infarction, showing that both anterior and posterior mitral valve 
leaflets were subjected to similar extent of leaflet stress.16 As the posterior and 
anterior MV leaflet have comparable surface areas, one could anticipate that the 
leaflets show similar extent of enlargement, as shown in current study.17 Another 
study using an animal model of non-ischemic cardiomyopathy also reported simi-
lar relative increase of the anterior and posterior mitral leaflet area.13 Other factors 
than leaflet stress alone, however, might also determine leaflet remodeling. In a 









structural leaflet remodeling at follow-up was identified, suggesting that isolated 
MR is able to cause leaflet remodeling of the MV.18 
However, data on determinants of structural leaflet remodeling in humans are 
limited. Our findings suggest that both tethering (LV sphericity, annulus size and 
tenting volume) and closing forces (LV systolic function) are potential determi-
nants of leaflet remodeling. A preserved or higher leaflet/annular ratio in FMR 
patients compared to controls confirms the idea that leaflet size increases relative 
to annular dilatation. Other reports have shown similar findings.6-8 These results 
indicate that leaflet remodeling occurs as an adaptive response to annular and 
LV changes that pose specific requirements to the mitral leaflet size to ensure 
adequate surface and leaflet coaptation area to prevent from significant FMR.
Leaflet remodeling and regurgitation severity
Despite similar tethering and LV remodeling degree, patients with FMR≥3 com-
pared to FMR<3 intriguingly showed less increase in MV area. These results point 
out that isolated LV remodeling fails to account for the observed FMR variability. 
The reported variability of FMR prevalence in ischemic patients may suggest that 
there are other associated pathophysiological factors than regional or global LV 
remodeling or dysfunction contributing to FMR.19, 20 In the present study, although 
ischemic etiology was significantly more frequent among FMR≥3 patients than in 
FMR<3 patients, the location of myocardial infarction was not significantly differ-
ent within the FMR≥3 group. In addition, there was significantly leaflet remodeling 
difference between groups that was attributed mainly to smaller coaptation area 
rather than exposed leaflet area. Hence, coaptation/leaflet area (coaptation index) 
was significantly smaller in FMR≥3 patients versus FMR<3 patients, similar to a 
prior report on 3D transesophageal echocardiography and comparable to two 
other studies that mentioned smaller leaflet/exposed (closure) area.6-8 These data 
suggest that leaflet remodeling in FMR≥3 patients is insufficient to compensate for 
the changes in MV annular and LV dimensions. In particular, the lack of coaptation 
reserve defined by the ratio coaptation/leaflet area was an independent associate 
of significant FMR. The presence of limited coaptation reserve <24 % of total MV 
area was independently related to FMR severity. These findings are in line with 
the study by Chaput et al. reporting a cut-off value for leaflet/closure area ratio of 
<1.7 to predict the presence of significant FMR, which reflects <30 % coaptation 
reserve .7 This absolute difference in cut-off value compared to our study might 
be due to the measurement of mitral valve area at a different time point during 
the cardiac cycle, to the use of different 3D quantification software and to the use 
of transthoracic 3D echocardiography characterized by lower spatial resolution, 
compared to transesophageal 3D echocardiography.21 
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Clinical significance 
The current data show, in line with previous reports, that the presence of larger MV 
leaflets for the same LV tethering degree may protect from FMR.6-8 These findings 
might have implications for the treatment of FMR patients, which remains a clinical 
challenge.2 
First, elucidating the mechanisms including signaling pathways and triggers that 
are responsible for leaflet remodeling may help to explain the variability in leaflet 
remodeling observed in patients despite similar LV dilatation. This knowledge 
might lead to identification of patients with LV dysfunction that are prone to inad-
equate MV leaflet remodeling. These patients would represent ideal candidates to 
undergo biological modification with specific drugs developed to block adverse or 
stimulate beneficial remodeling of mitral leaflets to prevent from significant FMR.
Second, results of restrictive mitral annuloplasty for FMR overall have been 
relatively disappointing with high recurrence rates at medium to long-term follow 
up. In addition, no robust survival benefit has been shown so far for FMR surgery.2 
Current data lend support to the principle of surgical mitral leaflet augmentation 
plasty, which involves insertion of a pericardial bovine patch into the anterior or 
posterior MV leaflet in addition to restrictive annuloplasty.22, 23 MV augmentation 
plasty increases MV leaflet area, reduces leaflet stress and increases coaptation 
reserve which might be of paramount importance as the underlying process of 
adverse LV remodeling potentially continues, imposing specific requirements to 
the MV area.22, 24 Given the importance of coaptation reserve that should ideally 
exceed 24% of the total MV area, as indicated by the current study, this alterna-
tive surgical MV repair technique might warrant further study. Small series using 
posterior (n=44) and anterior (n=25) leaflet augmentation have shown promising 
results, but long-term results are lacking.22, 23 The complexity of LV remodeling and 
FMR, however, probably precludes a single best option to treat FMR that rather 
requires a tailored approach to the individual patient and MV complex.25 
Limitations
FMR severity assessment is prone to well-known limitations and challenges as-
sociated with the functional nature of the valvular regurgitation. Use of a multi-
integrative approach, as recommended, partly accounts for these limitations. 
Mitral leaflet area was assessed at end-systole to ensure evaluation of leaflet 
coaptation. Therefore a contribution of acute stretch to the measured leaflet area, 
known to potentially increase leaflet size, can not be excluded.26 Similar values for 
leaflet areas compared to our study measured during diastole, however have been 
reported.6, 7 In addition, leaflet remodeling in FMR occurs also independently of 









diographic data. Due to retrospective analysis in a limited number of patients, the 
present study should be interpreted as hypothesis generating analysis.
CONCLuSION
Mitral leaflet remodeling in patients with FMR is highly prevalent, symmetrical and 
determined by MV closing and tethering forces. Insufficient leaflet remodeling 
relative to the annular and LV dilatation causes lack of coaptation reserve and is 
independently associated with FMR severity. MV leaflets in FMR should not be re-
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Chapter 5
Tools and techniques: 3D-transesophageal 
echocardiography for selecting and guiding in 
percutaneous mitral valve repair using MitraClip 
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This report provides an illustrative and practical approach for screening of patients 
with mitral regurgitation who are candidates for MitraClip® therapy and for proce-
dural guidance using 3D-transesophageal echocardiography (3D-TOE), providing 
state-of-the-art practice for imagers (what and how to assess mitral valve with 
3D-TOE) and interventionalists (how to interpret and translate 3D-TOE images for 
the intervention).
Summary 
Superior anatomic performance and comprehensive evaluation of regurgitant jet 
characteristics represent cornerstones for eligibility assessment. Standardized 
mitral valve display, alternating 1-beat 3D full volume and bi-plane acquisitions, 
improves procedural guidance. Intensive communication between a skilled imager 
and a well-trained interventionalist with each understanding of 3D-TOE from a 
technical and practical point of view, respectively, are prerequisites to obtain high 
procedural success rates.
Conclusions
3D-TOE has become indispensable for optimal candidate selection and procedural 










Mitral valve repair using the MitraClip® system (Abott Vascular) consists of a per-
cutaneous approach to attach both leaflets of the mitral valve to each other by 
one or more cobalt-chromium clips where the regurgitant jet originates.1 Thereby 
it resembles the surgical Alfieri-stitch technique, creating a double-orifice mitral 
valve.2 This therapy has currently been adopted in over 15000 symptomatic pa-
tients with severe primary (organic) or secondary (functional) mitral regurgitation 
that are at high surgical risk or with contraindications for surgery. The EVEREST-II 
trial and large real-world registries have shown high feasibility (successful clip 
implantation achieved in >95%) and efficacy with reduction of mitral regurgi-
tation to grade 2 or less (acute procedural success) in at least 80% of treated 
subjects.1, 3-5 Adequate patient selection and procedural guidance is a prerequisite 
for procedural and clinical success of MitraClip® therapy. Although 2-dimensional 
transesophageal echocardiography (TOE) remains the reference standard to assess 
the anatomy of the mitral valve and the severity of mitral regurgitation of patients 
who are candidates for this therapy, 3-dimensional (3D) TOE has improved and 
standardized communication between interventionalists and imagers. This report 
provides a brief, illustrative and practical approach for screening of patients with 
mitral regurgitation who are candidates for MitraClip® therapy and for procedural 
guidance using 3D-TOE, providing state-of-the-art practice for imagers (what and 
how to assess mitral valve with 3D-TOE) and interventionalists (how to interpret 
and translate 3D-TOE images for the intervention), as summarized in Figure 1.
PATIENT SELECTION
Selection of patients who are candidates for MitraClip® therapy includes thorough 
analysis of the anatomy of the mitral valve and mechanism as well as severity 
of mitral regurgitation.6 Evaluation of anatomy requires high spatial resolution 
whereas accurate quantification of mitral regurgitation relies on high temporal 
resolution (high frame rate data). Using 3D TOE, anatomical and functional data 
can be obtained with 3 different acquisition modes (Figure 2):
·	 1-beat full volume: provides in one beat the 3D rendering of the mitral valve. 
The spatial resolution is high while avoiding stitching artifacts that may distort 
the anatomy.
·	 Multi-beat full volume: the 3D rendering of the mitral valve is created from 
several pyramidal subvolumes obtained during 2-7 beats. This mode provides 
high temporal and spatial resolution data. The patient, however, needs to hold 
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the breath to avoid stitching artifacts during compilation of the subvolumes. 
Similarly, the presence of irregular heart rhythms (atrial fibrillation) may create 
stitching artifacts that will limit the analysis and visualization.
·	 Bi-plane view: This mode provides simultaneous visualization of 2-dimensional 
orthogonal planes. Using the bicommissural plane as reference, the perpen-
dicular (left ventricular outflow tract) view can be displayed at specific levels 
of the mitral valve (anterolateral, central and posteromedial). This acquisition 
mode provides high temporal resolution data.
3D color Doppler data can be obtained with any of the above acquisition meth-
ods. However, high temporal resolution must prevail over spatial resolution and 
therefore, multi-beat color Doppler 3D full-volume and bi-plane view will be the 
acquisition modes of choice.
3D TOE for MITRACLIP
PATIENT SELECTION
PROCEDURAL GUIDANCE
Mitral Valve anatomy analysis
• High spatial resolution > temporal resolution
• 3D-zoom (to avoid stitching artefacts)
* careful with drop-outs
• 3D full-volume (if regular heart rhythm)
• Bi-plane (gives better temporal resolution)
Quantification of mitral regurgitation
• High temporal resolution > spatial resolution
• Color Doppler 3D full-volume
• Bi-plane (gives better temporal resolution)
Manipulation of catheters
• High temporal resolution > spatial resolution
• Fast imaging (no full-volume data acquisition)
• Transseptal puncture (Bi-plane)
• Steering guiding catheter in left atrium: 3D-zoom
• Positioning and aligning MitraClip to target lesion: Bi-plane and 3D-zoom
• Grasping leaflets: Bi-plane
Evaluation of procedural effects
• Attachment of MitraClip to leaflets: 3D-zoom (high spatial resolution)
• Reduction of mitral regurgitation: color Doppler 3D full-volume
• Residual mitral valve leaflet area: 3D-zoom
Figure 5.1










Analysis of mitral anatomy
The mitral valve ‘en face’ or ‘surgical view’ comprises 3D-visualization of the entire 
mitral valve as seen from the left atrium, including mitral annulus, all anterior (A1-
A2-A3) and posterior (P1-P2-P3) leaflet scallops as well as both anterolateral and 
posterolateral commissures (Figure 3). To orient the 3D volume rendering several 
anatomical landmarks need to be included: the left atrial appendage indicating 
the anterolateral region and the aorta indicating the anterior region of the mitral 
valve. By displaying the 3D volume rendering with the aortic valve at 12 o’clock 
position and left atrial appendage at lateral (left) side the communication between 
interventionalists and imagers may be facilitated. The mitral valve can be also 
analyzed using the bi-plane view using as reference the bicommissural mitral 
valve view, mostly found at about 60º, and bisecting each level of the mitral valve 
(from anterolateral – P1 scallop –, central – A2 scallop – and to posteromedial –P3 
scallop) to display the simultaneous left ventricular outflow tract view with the 
anterior and posterior scallops of the mitral valve at each level (Figure 4).
1-beat 3D full-volume multi-beat 3D full-volume 3D bi-plane
90°
A                        B                       C
Figure 5.2
Principles of 3D (transesophageal) echocardiography. A: 1-beat 3D full volume acquires pyramidal volume in single 
beat. B: multibeat 3D full volume acquires pyramidal volume stitching sub-volumes together over multiple heart 
beats. C: 3D bi-plane shows a reference image (left) with corresponding 90 degrees perpendicular view (right).
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Adherence to initial EVEREST-II criteria for technical feasibility (Table 1) yields 
high procedural success rates.1 Based on the underlying pathophysiological 
mechanisms, mitral regurgitation can be classified as organic or primary, when the 
lesion affects the mitral valve leaflets, or functional or secondary, when the mitral 
leaflets are anatomically normal but left ventricular remodeling and dysfunction 









L                                  M
Figure 5.3
Mitral valve anatomy on 3D ‘surgical’ or en ‘face view’ of mitral valve. A: schematic mitral valve anatomy. B: Cor-
responding 1-beat 3D full volume view. A: anterior, ALC: antero-lateral commissure, anterior mitral valve leaflet 
with lateral (A1), middle (A2) and medial (A3) scallop, AMF: aortic-mitral fibrosa, AoV: aortic valve with left (LCC), 
right (RCC) and non coronary (NCC) cusp, L: lateral, LFT: left fibrous trigonum, M: medial, P: posterior, PMC: postero-
medial commissure, posterior mitral valve leaflet with lateral (P1), middle (P2) and medial (P3) scallop, RFT: right 








Mitral valve anatomy on 3D bi-plane view, at bi-commissural level. A: schematic mitral valve and B: 
bi-plane view. The blue dashed line corresponds to the bi-commissural view on bi-plane (left panel) 
and the orange dashed line corresponds to the 90 degrees perpendicular antero-posterior view on 
bi-plane (right panel). This bi-plane view allows for simultaneous orientation in latero-medial direc-









restriction as well as coaptation failure. In patients with organic mitral regurgita-
tion, the exact location of the lesions (prolapse/flail) and numbers of leaflet scal-
lops involved should be assessed (Figure 5).
Table 5.1
Technical echocardiographic requirements for MitraClip® treatment, adapted from EVEREST-II trial.1 
Mitral valve assessment Measurements 3D acquisition
Anatomy
organic: flail width < 15 mm full-volume
flail gap < 10 mm bi-plane
functional: coaptation depth <11 mm bi-plane
coaptation length ≥ 2 mm bi-plane
excluding cleft, calcification in grasping area - full-volume, bi-plane
excluding asymmetrical leaflet thickness ≤ 5 mm full-volume, bi-plane
area (cm²) ≥ 4.0 cm² full-volume
mean gradient (mmHg) < 5 mmHg (Continuous wave) 
mobile leaflet length at jet origin ≥ 8 mm bi-plane
Regurgitation
jet location preferably A2-P2 color full-volume, bi-plane
severe functional, EROA ≥ 20 mm² color full-volume 
severe organic, EROA ≥ 40 mm² color full-volume 










Additional value of 3D mitral valve echocardiography for anatomic and morphologic assessment in screening for 
MitraClip® therapy. All patients presented with severe mitral regurgitation but are anatomically not eligible for 
MitraClip® therapy. A: Complex Barlow degeneration involving prolapse of all mitral segments. B: Posterior leaflet 
cleft. C: Anterolateral commissural prolapse. D: Severe rheumatic stenosis (*) with diffuse calcifications and com-
missural fusion (arrows). E: Loss of central coaptation during systole. F: A2 flail with chordal rupture (*), flail width 
17 mm. G: P2 flail with chordal rupture (*), flail width 22 mm. H: Complex Barlow with prolapse of A2, A3, postero-
medial commissure and P3 scallops.
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From 3D volume rendering, the type of lesion and number of valve segments 
involved are readily assessable. Using the multiplanar reformation planes, the 3D 
volume rendering can be analyzed and the flail width and gap can be measured. 
The flail width, comprising the width of the prolapsing segment(s), can be measured 
on the surgical view and should be ≤15 mm (Figure 6). The flail gap, reflecting the 
distance between both leaflet tips during mid-systole needs to be ≤10 mm (Figure 
6). In patients with functional mitral regurgitation a coaptation length (apposition 
of both leaflets in systole) of ≥2 mm should be present at the level of the mitral 
regurgitant jet origin during mid-systole to allow for grasping of both leaflets (Fig-
ure 6). In addition the coaptation height between the leaflet tips and the annular 
plane, reflecting leaflet tethering severity, should be ≤11 mm to avoid excessive 
Figure 5.6
Mitral valve geometric measurements for evaluation of technical feasibility for MitraClip® therapy in patients with 









tension in the system and mitral leaflets (Figure 6). Patients with rheumatic valve 
disease, calcification in the leaflet grasping area or cleft (congenital defect in or 
between leaflet scallops reaching the mitral annulus) are not ideal candidates for 
MitraClip® therapy (Figure 5). In addition, asymmetrical leaflet thickness at the 
origin of the regurgitant jet implies technical ineligibility due to risk of future clip 
detachment (Figure 7).
Second, the mitral valve area should be evaluated. MitraClip® therapy reduces 
mitral valve area about 25 to 50% and therefore mitral valve area should be ≥4.0 
cm² to avoid development of significant leaflet stenosis (Figure 8).7 Apart from 
2D-planimetry, mitral valve area can be assessed on 3D-planimetry at multi-plane 
reformation analysis at the maximal opening of the tip of the leaflets during 
systole. The mean valvular gradient should be <5 mmHg, assessed by tracing the 
diastolic mitral inflow on continuous wave Doppler acquisition.
Finally, the length of the mobile leaflet part of both anterior and posterior mitral 
leaflets at the origin of the regurgitant jet should be ≥8 mm to allow ability to 
grasp, to avoid inducing valvular stenosis and to prevent from later clip detach-
ment.
Quantification of mitral regurgitation
Quantification of the regurgitant orifice area (EROA), most often by the proximal 
isovelocity surface area method (PISA), is the gold standard for quantifying re-
gurgitation severity as it least depends on hemodynamic loading conditions.8 An 
EROA of ≥40 mm² and ≥20 mm² defines severe mitral regurgitation for organic and 
Figure 5.7
Mitral valve thickening. Panel A: Asymmetrical thickened A2 leaflet (arrow) with thickened subvalvular chordae 
(arrow) which challenges MitraClip® therapy. Panel B: 3D-color Doppler data showing severe mitral regurgitation.
– 92 –
functional mitral regurgitation, respectively. The EROA of patients with functional 
mitral regurgitation, however, is often not circular as in organic mitral valve disease, 
explaining lower thresholds when applying the PISA method. Particularly for these 
subjects, 3D quantification of the vena contracta area can be performed, compris-
ing direct anatomic measurement of the area of the vena contracta, namely the 
small neck of the regurgitant jet at the atrial level (Figure 9). This technique can 
also be applied in case of multiple jets by adding values obtained at the different 
jets (Figure 10).
Central regurgitant jet origin, at A2-P2 scallops, represents an ideal scenario 
for MitraClip® treatment. The origin, number and exact location of the regurgitant 
jet(s) is most easily evaluated on 3D-TOE, applying the ‘en face view’ as well as the 
bi-plane biplane mitral valve view (Figure 11). Building on experience by treatment 
of higher numbers of patients, more lateral or medial jet origins can be targeted, 
being the most challenging lesions those located at the commissures since they 
are associated with entangling into or rupturing of commissural mitral chords.
5.79 cm2 3.14 cm2 0.62 cm2+
A B
Figure 5.8
3D planimetry of mitral valve area before and after MitraClip® therapy. A: Mono-orifice valve before MitraClip® (up-
per panel) with valve area planimetry on multi-reformation planes (lower panel). B: Double-orifice valve after 
MitraClip (upper panel) with selective planimetry of lateral orifice (left lower panel) and medial orifice (right lower 











Comprehensive guiding of MitraClip® implantation procedure requires extensive 
use and switching between different 3D-TOE modalities; fluoroscopy guiding 
is limited since the non-calcified mitral valves are not well depicted. Catheter 
manipulation requires accurate visualization of the mitral valve and surrounding 
anatomical structures and high temporal resolution. One-beat 3D full volume and 
bi-plane acquisitions are the most common 3D modes of visualization (Figure 2). 
Figure 5.9
3D Vena contracta area assessment. After mid-systolic orthogonal alignment of the regurgitant jets on multi ref-
ormation planes (green and red planes) from a 3D color full-volume acquisition, the short axis plane (blue) is set 
at the level of the vena contracta. The non circular regurgitant orifice area of this functional mitral regurgitation is 
traced, measuring 45 mm², compatible with severe mitral regurgitation.
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Procedural results, reduction of mitral regurgitation severity and clip attachment, 
require high temporal and spatial resolution, respectively.
A                           B                           C
Figure 5.10
3D Vena contracta area assessment in multiple jets. A: Mitral regurgitation with a small centrolateral jet (yellow ar-
row) and large centromedial jet (white arrow). Selective assessment of the vena contracta area of the centromedial 





Assessment of regurgitant jet characteristics and location. A: central jet origin at A2-P2 level on en face mitral view. 
B: Double jet at centromedial (large) and centrolateral (small) level. C: Anterolateral commissural and lateral jet 
origin, unsuitable for MitraClip® therapy. D: Short axis transgastric 2D mitral view indicating posteromedial com-
missural jet origin, contra-indication for MitraClip® treatment. E: Bi-plane view at bicommissural level, displaying 











The location of the transseptal puncture is crucial as it determines further clip 
delivery system manipulations needed to obtain the optimal angle for subsequent 
alignment and grasping mitral valve leaflets. Ideally the puncture should target the 
middle to slightly superior part of the non-muscular part of the interatrial septum 
at a slightly posterior level (Figure 12). The bi-plane interatrial septal view allows 
for simultaneous posteroanterior and inferosuperior guiding on the short-axis 
aortic valve view and bicaval view respectively. By slightly pressing with the Brock-
enbrough or Verres needle on the targeted area, tenting of the interatrial septum 
can be observed which allows for subsequent measurement of puncture height 
from the mitral annular plane in 4-chamber TOE view. This height should ideally 




















Ideal location and guiding transseptal puncture. A: bi-plane view of interatrial septum showing short axis aortic 
valve (left panel, anteroposterior direction) and bicaval view (right panel, inferosuperior direction). The dashed 
orange line indicates the location of mitral leaflet coaptation. The blue arrow points out the ideal puncture side: 
slightly posterior and mid-to-slightly-superior. B: suboptimal (too anterior) and optimal position seen by tenting of 
the needle (arrows). C: Measuring puncture height from tenting to mitral annular plane on 4-chamber view. D: 3D 
view of wire (black arrows) across interatrial septum (yellow arrow). A: anterior, AoV: aortic valve, I: inferior, LA: left 
atrium, LV: left ventricle, MV: mitral valve P: posterior, RA: right atrium, S: superior.
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MitraClip® delivery system in the left atrium is limited to 5.0 cm and one should be 
aware that the clip needs to be advanced distally from the leaflet tips into the left 
ventricle to allow for proper leaflet grasping. Severe tenting in functional mitral 
regurgitation might lead to choose a slightly lower puncture site. Likewise, organic 
mitral regurgitation caused by prolapse or flail might benefit from a slightly higher 
puncture site. The puncture is guided on bi-plane interatrial septal view and sub-
sequent advancement of the wire into the left atrium and secured into the left 
upper pulmonary vein can be visualized with 3D full volume views (Figure 12).
Steering the guiding catheter in left atrium.
Over the wire across the interatrial septum, a septal dilator is inserted. After dilata-
tion, the guiding catheter is advanced into the left atrium, guided by alternating 
1-beat 3D full volume and bi-plane imaging to accurately follow the advancement 
and avoiding perforation of the posterior atrial wall, aortic puncture and impinge-
ment of the left atrial appendage (Figure 13. Subsequently the clip is introduced 









Steering guiding catheter in left atrium. A: Large 1-beat 3D full volume views of interatrial septum and mitral valve 
showing consecutive steps of introducing the guiding catheter into the left atrium and bending towards the mitral 
valve. This anatomic overview is used for orientation and to make sure no anatomic structures are damaged during 
manipulation. B: straddling position: sleeve markers (white arrows) are paired on the guide marker (black dashed 










manipulation avoiding any damage to left atrial structures or aorta, particularly 
since the clip system must be introduced further until straddling position is ob-
tained (Figure 13). Following straddling, using 1-beat 3D full volume or bi-plane 
views, the clip is bended medially and inferiorly towards the mitral valve, avoiding 
damage of the pulmonary vein ridge.
Positioning and aligning MitraClip® to target lesion.
The clip system is manipulated into mediolateral and anteroposterior direction 
to obtain a position on top of the target lesion. Color Doppler and bi-plane views 
at the bicommissural level and 1-beat 3D full volume acquisitions are the most 
frequently used views to guide this step (Figures 3, 4 and 14). It is important to 
notice that when the target regurgitant lesion on the color Doppler bi-plane view 
is identified, the system should be steered to appear in this view without further 
adjustments of the image.
Once the clip is at the target region, slight advancing and retracting of the system 
towards and away from the mitral leaflets and left ventricle is repeatedly tested 
in order to verify the system follows the correct path and angle, remaining at the 
target lesion site. Then the clip is opened and oriented perpendicular to the line 





pull back push forward
Figure 5.14
Device manipulations and resulting effects on bi-plane bicommissural view. Pulling back and pushing forward 
results in medial (M) and lateral (L) device orientation, respectively. Clockwise and anti-clockwise torque leads to 
posterior (P) and anterior (A) relocation, respectively.
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of coaptation of the mitral valve leaflets. This step is crucial as non-perpendicular 
clip attachment yields a significant risk of future clip detachment or leaflet lacera-
tion. Bi-plane bicommisural view is used to adapt the clip orientation until perpen-
dicularity is ascertained by absence of clip arm visualization on the bicommissural 
view, and symmetric appearance of both clip arms on the corresponding outflow 
tract view (Figure 15). Similarly, 1-beat 3D full volume acquisition allows for easy 
clip orientation (Figure 16). Once a satisfactory alignment is achieved, the clip is 
gently introduced into the left ventricle guided by bi-plane mode with simultane-
ous visualization of the bicommissural and long-axis views of the mitral valve, and 
maintenance of clip alignment should be vigorously checked as leaflet motion 
tends to affect clip arm alignment.
A                               B
Figure 5.15
Clip orientation and alignment on bi-plane imaging. A: The clip (grey) should be perpendicular to the line of co-
aptation. B: Perpendicularity is ascertained when on bicommisural bi-plane view (blue) no clip arms are seen and 
when both clip arms appear symmetrically on the corresponding left ventricular outflow tract view (orange).
A                             B
Figure 5.16
Clip orientation and alignment on 1-beat 3D full volume imaging. A: Perpendicularity to the line of coaptation is 
found when on the en face mitral view the clip points towards the center of the aortic valve. B: Left panel shows 
clip non-perpendicularity. After clockwise rotation of the clip, perpendicularity at central leaflet level is obtained, 










 In order to grasp both leaflets the clip system is pulled back gently with discrete 
manipulations by the interventionalist mainly in anteroposterior direction until 
both leaflets land on the clip arms, maintaining the perpendicular alignment and 
central position of the clip (Figure 17). Once both leaflets are on the clip arms, the 
grippers are lowered and the clip is closed (Figure 17). It is important to record this 
grasping procedure by a long cine run acquisition as a reference to re-evaluate in 
case of doubt about accurate grasping. Ideally both leaflets need to be in the clip 
for about 5 mm.
Evaluation of procedural effects
Mitral regurgitation reduction.
At first, reduction of mitral regurgitation should be evaluated. A double orifice 
mitral valve is created by MitraClip® therapy (Figure 19), often splitting the original 
jet into two small residual jets. Although qualitative interpretation of jet sever-
A                                        B
C                                        D
Figure 5.17
Leaflet grasping guided by bi-plane imaging. A: Clip in left ventricle with open arms, perpendicular orientation. B: 
Clip system is pulled back (arrows) with manipulations in anteroposterior direction to grasp both mitral leaflets. 
C: Grippers are lowered (arrows) when both mitral leaflets are on the clip arms. D: The clip is closed (arrows), ap-
proximating both the posterior and anterior mitral valve leaflet.
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ity reduction can easily be assessed by evaluation of reduction in jet width and 
jet area, these measures inherently are load dependent (Figure 18). No specific 
method for quantification of acute regurgitation reduction after MitraClip® therapy 
has been validated so far. As pointed out in Figure 10, 3D vena contracta area 
assessment of a single or multiple residual jets can be performed as a quantitative 
approach. A 3D vena contracta area reduction of >50 % has been suggested as 
the best quantitative parameter relating to subsequent reverse left ventricular 
remodeling after MitraClip® therapy.7 In addition semi-quantitative evaluation 
such as increased systolic forward pulmonary vein flow, increased left ventricular 
stroke volume and amelioration of pulmonary artery systolic pressures indirectly 
reflect adequate reduction of severity of mitral valve regurgitation (Figure 18). 
Acute procedural success is defined as reduction of mitral regurgitation ≤grade 2.
A                                     B
2.1 mmHg 4.2 mmHg
Figure 5.18
Acute procedural effect evaluation. A: Before MitraClip® therapy. B: After MitraClip® therapy. Significant reduction 
of mitral regurgitation based on reduced jet area and jet width is depicted. The blunted forward systolic pulmonary 
vein flow is significantly increased after the procedure (yellow arrows at left lower panels), indirectly reflecting 
adequate reduction of mitral regurgitation severity. No significant transmitral gradient developed after the inter-










Secondly, to avoid the risk of future clip detachment, it is essential to assure both 
leaflets are adequately captured and inserted between the grippers and both clip 
arms. Re-evaluation of the cine run of the grasping step can be particularly helpful. 
Anterior leaflet insertion is best seen on a 4-chamber mid-esophageal TOE view 
and the posterior leaflet insertion can adequately be visualized on the long-axis 
view. Both leaflets should be seen as going over the tip of both clip arms and at this 
point leaflet motion throughout the cardiac cycle needs to be restricted or absent 
to assure adequate leaflet insertion. The leaflet length inserted into the clip arms 
(ideally about 5 mm) can be assessed by subtracting the remaining mobile leaflet 
length from the preprocedual mobile leaflet length. At the bicommissural mitral 









Mitral leaflet insertion evaluation. A: Anterior mitral leaflet (arrow) evaluation on 4 chamber view. B: Angel’s view at 
bicommissural mitral valve level. C: Posterior mitral leaflet (arrow) evaluation at outflow tract view. D: Transgastric 
view showing dog-bone or figure eight pattern of double orifice (asterisks) mitral valve. E: 3D-zoom of double 
orifice (asterisks) mitral valve, indicating perpendicular clip alignment. See text for details.
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lets. On short-axis transgastric view the double orifice can be appreciated, similar 
to a 1-beat 3D full volume view, resembling a figure eight or dog-bone pattern. 
Additionally, the 1-beat 3D full volume view is essential to confirm perpendicular 
alignment of the clip arms to the mitral coaptation line.
Mitral valve area reduction.
Finally transmitral gradient and mitral valve area are evaluated to ascertain no 
functional mitral stenosis is created by the MitraClip® intervention. Continuous 
wave Doppler through one of the orifices created by the clip permits measure-
ment of the mean mitral valve gradient, which ideally remains below 5 mmHg 
(Figure 18). As the flow velocities across asymmetrical mitral orifices are equal, the 
choice of orifice for Doppler alignment is no issue.9 Less load and flow dependent 
quantification is provided by summing mitral areas of the orifices by planimetry 
at the tips of both leaflets during mid diastole, which can easily be obtained on 
3D-TOE post-processing on-line or off-line (Figure 8).
CONCLuSION
3D-TOE has become indispensable for optimal candidate selection and proce-
dural guidance in patients treated with MitraClip® therapy. Superior anatomic 
performance and comprehensive evaluation of regurgitant jet characteristics rep-
resent cornerstones for eligibility assessment. Standardized mitral valve display, 
alternating 1-beat 3D full volume and bi-plane acquisitions, improves procedural 
guidance. Intensive communication between a skilled imager and a well-trained 
interventionalist with each understanding of 3D-TOE from a technical and practi-
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Our aim was to evaluate the acute effects of transcatheter edge-to-edge mitral 
valve repair using the MitraClip device on mitral valve geometry in patients with 
functional mitral regurgitation (FMR).
Methods and Results
Forty-two patients (age 73 years [IQ range 66.1-78.0], 55% men, 62% ischaemic 
FMR) with moderate-to-severe and severe FMR treated with the MitraClip were 
included. Three-dimensional transoesophageal echocardiography was performed 
prior to and immediately after MitraClip implantation. Acute changes of mitral 
annular and leaflet geometry were assessed with dedicated mitral modelling 
software. FMR less than moderate grade was achieved in 36 (86%) patients. After 
MitraClip implantation, the mitral annulus became more elliptical (ellipticity from 
122±17% to 129±18%; p=0.04) with a non-significant reduction in anteropos-
terior diameter (33±6 to 32±5 mm, p=0.08). The coaptation area increased from 
350 mm2 (IQ range 289-493 mm2) to 434 mm2 (IQ range 328-523 mm2, p=0.008). 
In particular, a larger part of the anterior mitral leaflet was included in the coapta-
tion, leaving a smaller exposed anterior leaflet length of the A2 segment (from 
27±6 mm to 25±5 mm, p<0.05) while the exposed length of the posterior leaflet 
(P2 level) remained unchanged (12±4 mm pre- vs. 13±4 mm post-repair, p=0.15). 
There was no change in total leaflet area (1,811±582 mm2 pre- vs. 1,870±506 mm2 
post-repair, p=0.18). Annular height to intercommissural width ratio and tenting 
volume remained unchanged, suggesting no increase in leaflet stress.
Conclusions
The MitraClip device affects MV geometry in FMR patients by increasing mitral 









Functional mitral regurgitation (FMR) is common in heart failure patients and is as-
sociated with poor clinical outcomes.1-4 Surgical mitral valve repair has proven to 
be beneficial, providing significant improvement in symptoms and left ventricular 
(LV) function.5,6 However, many patients with significant FMR are not referred for or 
are denied surgical intervention due to a high operative risk, related to advanced 
age and the presence of associated comorbidities.7 Several minimally invasive and 
transcatheter based mitral valve repair techniques provide feasible alternative 
treatment options to conventional valve surgery for patients with a high operative 
risk. The transcatheter edge-to-edge mitral valve repair technique using the Mitra-
Clip system (Abbott Vascular-Structural Heart, Menlo Park, CA, USA) is designed to 
grasp the mitral valve leaflets at the middle scallops, creating a double orifice valve 
during diastole and maintaining closer apposition of the leaflets during systole to 
reduce the regurgitant volume. With more than 17,000 patients treated world-
wide, the MitraClip device has demonstrated to be a feasible and safe procedure, 
also in patients with FMR, and to improve symptoms.8,9 The effect of the MitraClip 
device on the geometry and function of the mitral valve, however, remains largely 
unexplored. Three-dimensional transesophageal (TEE) echocardiography allows 
for accurate measurements of mitral valve geometry.10 Accordingly, the present 
study aimed at evaluating the acute effects of transcatheter edge-to-edge repair 
on mitral annular geometry and leaflet coaptation zones of patients with FMR us-
ing 3-dimensional TEE.
METhODS
Patient population and data collection
A total of 59 patients were treated with the MitraClip device at the Leiden Uni-
versity Medical Centre between January 2012 and July 2014. Thorough clinical 
and echocardiographic evaluation was performed prior to the procedure by an 
interdisciplinary team of cardiac surgeons and cardiologists. Patients had symp-
tomatic moderate-to-severe or severe mitral regurgitation and were at high risk for 
conventional surgical mitral valve repair, defined by a logistic EuroSCORE>20% 
or the presence of specific risk factors associated with excessive morbidity and 
mortality. Evaluation of clinical symptoms included assessment of functional 
capacity according to the New York Heart Association (NYHA) functional class and 
the 6-minute walked distance test. Furthermore, a quality of life assessment was 
performed using the Minnesota Living With Heart Failure® questionnaire.11 Trans-
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thoracic echocardiographic (TTE) and TEE assessment were routinely performed 
before the intervention to assess left ventricular (LV) dimensions and function, 
mitral valve morphology and mitral regurgitation grade and evaluation of factors 
that may contraindicate the procedure.12 The procedure was guided with 3-dimen-
sional TEE allowing acquisition of 3-dimensional data of the mitral valve. In the 
current analysis only patients with FMR and sufficient quality of peri-procedural 
3-dimensional TEE data allowing for geometrical analysis of the mitral valve were 
included (n= 42).
Two-dimensional transthoracic echocardiographic evaluation
Pre-procedural TTE was performed using commercially available ultrasound sys-
tems (E9 or Vivid 7, GE Norway, Horten, Norway) equipped with an M5S transducer 
and 2-dimensional, M-mode and Doppler data were acquired with the patient in 
the left lateral decubitus position. LV dimensions and function were assessed ac-
cording to the recommendations of the American Society of Echocardiography and 
the European Association of Echocardiography.13 From the apical 4- and 2-chamber 
views the LV end-diastolic and end-systolic volumes and LV ejection fraction were 
measured according to the biplane Simpson’s method. LV diameters were assessed 
at end-diastole and end-systole from the parasternal long-axis view or M-mode 
recordings. From the apical 2-, 3- and 4-chamber views, colour and continuous 
wave Doppler data of the mitral valve were acquired and mitral regurgitation was 
quantitatively determined by the proximal isovelocity surface area method and by 
measuring the vena contracta according to current guidelines.14
Three-dimensional transesophageal echocardiographic data acquisition and 
evaluation
TEE was performed during the procedure using a commercially available ultra-
sound system (iE33, Philips Medical Systems, Andover, MA, USA) equipped with 
a fully sampled matrix-array TEE transducer (X7-2t Live 3D-TEE transducer, iE33, 
Philips Medical Systems, Andover, MA, USA) capable of acquiring both 2- and 
3-dimensional images to guide implantation of the MitraClip device and to assess 
acute procedural success. Three-dimensional images were acquired during the 
intervention before and directly after implantation of the MitraClip device, using 
multi-beat (7-14 beats) full-volume or 1-beat 3-dimensional-zoom acquisitions 
encompassing a pyramid volume. The multi-beat full-volume images were ac-
quired during respiratory breath-hold whenever possible to avoid stitch artefacts. 
In patients with atrial fibrillation, 1-beat 3-dimensional-zoom acquisitions with 
the sector adjusted to include the MV were performed. Furthermore, special care 








were digitally stored for off-line analysis with the MVQ software (QLAB Cardiac 3DQ 
v.10.0; Philips Medical Systems, Andover, MA, USA), which allows semi-automated 
3-dimensional quantification of the mitral valve geometry.10 From 3-dimensional 
full-volume or zoomed datasets of the mitral valve, the software displays three 
orthogonal multiplanar reformation planes of the mitral valve. The planes are 
manually aligned across the mitral annulus in a selected end-systolic frame to 
obtain bicommissural, outflow tract and short-axis views of the mitral valve. The 
bicommissural view was used to indicate the antero-lateral and postero-medial 
points of the mitral annulus, whereas the outflow tract view was used to define 
the anterior and posterior points of the mitral annulus, the aortic annulus and the 
mitral leaflet coaptation point. The mitral leaflet commissural points were set on 
the short-axis plane and the mitral leaflets and coaptation length were traced on 
multiple cross-sections (18-30) in the outflow-tract view, orthogonal to the inter-
commissural direction. The 3-dimensional rendered surgical en face view was used 
to correctly identify the coaptation point (Figure 1). Subsequently, the software 
automatically creates a 3-dimensional model of the mitral valve geometry and 
various measurements can be derived.
The measurements of the mitral valve performed with the MVQ software included 
anteroposterior and intercommissural annular diameters and area, and leaflet 
lengths, angles and areas. Mitral annular ellipsicity was calculated as the ratio 
between the anteroposterior annular diameter and the intercommisural diameter. 
Furthermore, to assess the effect of the MitraClip on mitral leaflet coaptation, the 
coaptation length at the middle scallops (A2P2) was measured and coaptation area 
was calculated by subtracting the exposed area of the anterior and posterior mitral 
leaflet (i.e. the area without the coapting part of the leaflets) from the total area of 
the anterior and posterior leaflet (i.e. the area including the coapting part of the 
leaflets). Moreover, the effect of the MitraClip on leaflet stress was analysed by as-
sessing the annular-height-to-intercommissural-width ratio and the non-planarity 
angle. The non-planarity angle was determined as the angle between the two vec-
tors from the anterior and posterior leaflet hinge points of the annulus to the centre 
of the intercommissural line. Additionally, tenting height at the A2P2 level, tenting 
volume and the angle between the mitral annulus and aortic annulus were mea-
sured. Three-dimensional TEE data were analysed by two experienced observers. 
An example of mitral geometry measurements performed before and after MitraClip 
implantation in a patient using MVQ software is displayed in Figure 2.
Procedural technique
The transcatheter edge-to-edge mitral valve intervention was performed as previ-
ously described using the MitraClip system and guided by fluoroscopy and 2- and 
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3-dimensional TEE.12,15 In brief, after transseptal punction, the clip delivery system 
was advanced into the left atrium and positioned above the mitral valve plane 
over the origin of the regurgitant jet. The device was oriented perpendicular to the 
line of coaptation and the system was advanced into the LV with the arms slightly 
opened. After ensuring good alignment of the device (just below the regurgitant 
orifice on the TEE bicommissural view of the mitral valve) and simultaneously visu-
Figure 6.1
Identification of 3-dimensional landmarks on multiplanar reformation planes using Mitral Valve Quantification 
(MVQ) software. Using the multiplanar reformation planes, the MVQ software identifies the landmark points of the 
mitral annulus. The anterior, posterior, anterolateral and posteromedial points of the mitral annulus are identified 
on the 2- and 3-chamber views. The en face view provides the cross-sectional area of the mitral annulus and si-
multaneously the 3-dimensional full volume of the mitral valve can be visualised. Left upper panel: identification 
of leaflet insertion points, right upper panel: tracing the mitral leaflets and marking the leaflet coaptation point, 
left lower panel: tracing the coaptation line, right lower panel: 3-dimensional surgical view of the mitral valve with 








alizing the arms of the device opened in the perpendicular TEE view (120-150°, or 
LV outflow tract view) the system was pulled-back to grasp the mitral leaflets in the 
arms of the clip and create a double-orifice valve. The grade of MR was assessed 
during the procedure using color and continuous wave Doppler echocardiography. 
Procedural success was defined as reduction of MR to grade ≤ 2. If needed, a sec-
ond clip was placed to ensure grade ≤ 2 MR without significant stenosis. The grade 
of residual MR was also evaluated at predischarge transthoracic echocardiogram 
using color flow Doppler and color flow jet area (MR jet area/ LA jet area).16
Statistical analysis
Distribution of the continuous data was tested by the Kolmogorov-Smirnov one-
sample test and the Shapiro-Wilk test. Normally distributed continuous variables 
are presented as mean ± standard deviation, whereas non-normally distributed 
variables are presented as median and interquartile range. Categorical variables 
PRE-CLIP POST-CLIP
1 12 2
3.0    
mm
9.2     
mm
207   
mm2
293   
mm2
3 3
α 31° α 48°
4 4
29.7 mm 24.6 mm
5 5
ß 55° ß 58°
6 6
16.6 % 15.3 %9.4    
mL
7.4    
mL
16.4 mm
7 8 7 8
18.2 mm
Figure 6.2
Example of changes in mitral valve geometry in a patient before and after MitraClip implantation with 3-dimen-
sional model. 1: 3-dimensional model of the mitral valve, 2: Coaptation length at the A2P2 level pre- and post-
MitraClip implantation, 3: Coaptation area pre- and post-MitraClip implantation, 4: Angle between anterior leaflet 
and mitral annulus aorta pre- and post-MitraClip implantation, 5: Length of the anterior (left) and posterior (right) 
leaflet at the A2 and P2 level respectively pre- and post-MitraClip implantation, 6: Angle between posterior leaflet 
and mitral annulus pre- and post-MitraClip implantation, 7: Ellipsicity pre- and post-MitraClip implantation, 8: 




Baseline demographic, clinical and echocardiographic patient characteristics.
n = 42
Male gender, n (%) 23 (55)
Age (years) 72.8 (IQ range 66.1-78.0)
Hypertension, n (%) 18 (43)
Hypercholesterolemia, n (%) 17 (42)
Positive family history of CVD, n (%) 8 (20)
(Ex-) smoker, n (%) 21 (50)
Diabetes Mellitus, n (%) 16 (38)
COPD, n (%) 6 (14)
Peripheral vascular disease, n (%) 11 (26)
Prior stroke, n (%) 5 (12)
Ischemic cardiomyopathy, n (%) 26 (62)
Prior myocardial infarction, n (%) 22 (52)
Location of myocardial infarction, n (%) 11 (50)
Anterior 6 (27) 
Inferior 2 (9) 
Anteroseptal 2 (9) 
Posterolateral 1 (5) 
Posterior 
NYHA class III-IV, n (%) 35 (83)
Logistic EuroSCORE (%) 17.7 (IQ range 10.9-27.4)
Glomerular filtration rate (ml/min/1.73m2) 49.3 (IQ range 26.4-75.0)
Sinus rhythm, n (%) 14 (33)
CRT, n (%) 16 (38)
Medication, n (%)
Betablockers 34 (81) 
ACE-/ Angiotensin receptor II inhibitors 28 (78) 
Diuretics 37 (88) 
Digoxin 11 (26) 
Statin 29 (69) 
Calcium antagonist 4 (10) 
Aspirin 13 (31) 
Anticoagulants 40 (95) 
LV end-diastolic diameter (mm) 63.2 ± 9.3
LV end-systolic diameter (mm) 52.7 ± 13.5
LV end-diastolic volume (ml) 176.5 (IQ range 133.8-243.8)
LV end-systolic volume (ml) 118.5 (IQ range 82.5-163.8)
LV ejection fraction (%) 33.7 ± 10.3
Mitral regurgitation
Grade 3 20 (48) 
Grade 4 22 (52) 
Number of clips implanted
1 clip 24 (57) 
2 clips 15 (36) 
3 clips 1 (2) 
4 clips 2 (5) 
ACE: Angiotensin Converting Enzyme, COPD: Chronic Obstructive Pulmonary Disease, CRT: Cardiac Resynchroniza-








are expressed as numbers and percentages. Comparisons of MV geometry pre- and 
post-procedure were performed using the paired Student T-test for normally dis-
tributed variables and the Wilcoxon signed-rank test for non-normally distributed 
variables. All statistical tests were 2-tailed and a p<0.05 was considered statisti-
cally significant. Statistical analysis was performed using SPSS 20.0.0 for windows 
(SPSS Inc., Chicago IL, USA).
RESuLTS
Baseline characteristics
Baseline demographic, clinical and echocardiographic characteristics of the 
patients are listed in Table 1. Moderate-to-severe FMR was observed in 48% of 
patients and severe FMR in 52%. Ischemic heart failure was the most frequent 
underlying etiology of heart failure (62%).
Changes in 3-dimensional mitral valve geometry after MitraClip
FMR reduction to ≤grade 2 was achieved in 36 (86%) patients (Figure 3). Changes 
in mitral valve geometry post-MitraClip implantation are presented in Table 2. After 
the procedure, the mitral annulus became more elliptical indicated by an increase 
in ellipsicity (from 122±17% to 129±17%, p<0.05), increase in both the anterior 
(from 27±7º to 34±8º, p<0.001) and posterior mitral leaflet angle (from 49±14º 
to 56±10º, p=0.02) and a decrease in the antero-posterior mitral annular diameter 
(from 33±6 mm to 32±5 mm, p=0.08). Furthermore, an increase in both coaptation 
length at the A2-P2 level (from 50±11 mm to 53±9 mm, p<0.001) and total coap-
tation area (from 215 mm2 (IQ range 164-264) to 281 mm2 (IQ range 238-386), 
p=0.005) were observed. In addition, the exposed length of the anterior mitral 
leaflet (i.e. excluding the coapting part of the leaflet) at the A2 level (from 27±6 mm 
to 25±5 mm, p=0.03) and the exposed anterior leaflet area (from 795±277 mm2 
to 730±222 mm2, p=0.04) decreased while the posterior leaflet length at the P2 
level and total leaflet area remained unchanged, indicating that the improvement 
in leaflet coaptation is due to a larger area of the anterior mitral leaflet involved 
in the coaptation (Figures 4 and 5). The annular height-to-intercommissural-width 
ratio, non-planarity angle and tenting volume remained unchanged after MitraClip 
therapy, suggesting no increase in leaflet stress.
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DISCuSSION
The results of this study demonstrate that the percutaneous edge-to-edge mitral 
valve repair procedure using the MitraClip device directly affects mitral valve ge-
ometry. By grasping the anterior and posterior leaflets, the coaptation length and 
area of the mitral leaflets significantly increase in end-systole. The contribution 
of the anterior mitral leaflet in the coaptation increases and the antero-posterior 
diameter of the mitral annulus is reduced leading to a more elliptical mitral an-
nular shape.
Few studies have assessed the effect of surgical annuloplasty on mitral valve 
anatomy using 3D-TEE. Greenhouse et al. used intraoperative 3-dimensional TEE 
to examine the regional effects of surgical mitral annuloplasty on annular geom-
etry and leaflet coaptation zones in patients with FMR.17 A significant increase in 
mitral leaflet coaptation length after band annuloplasty was observed, particularly 
at the middle scallops of the anterior mitral leaflet (2.9±2.6mm at baseline vs 
5.5±2.5mm post-surgery, p<0.01). The posterior annulus was displaced anteriorly 
leading to an increase of coaptation surface of the anterior leaflet and correction 
of the mitral regurgitation. Our findings are in agreement with this concept by 
showing that the exposed length and area of the anterior leaflet at the central scal-
lop (i.e. the anterior leaflet length and area without the coapting part) decreased. 
These changes were not accompanied by changes in the total mitral leaflet area, 
indicating inclusion of a larger proportion of the anterior leaflet into the area of 

















fect mitral coaptation geometry similarly to surgical mitral annuloplasty, however, 
through a different mechanism.
In patients with FMR treated with the Mitraclip device, Schmidt et al., reported 
significant reductions of the mitral annular area (mean difference 0.39±0.49cm2, 
p<0.001) and antero-posterior annular diameter (mean difference 0.28±0.32cm, 
p<0.001) as well as a significant reduction in tenting area (mean difference 
0.39±0.49cm2, p<0.001).18 The disparate results of the study by Schmidt et al and 
the present study may be explained by the different post-processing analysis. 
While Schmidt et al performed the measurements on the orthogonal multipla-
nar reformations of the 3-dimensional TEE volume set, in the present study the 
Table 6.2




Anteroposterior diameter (mm) 33.2 ± 6.2 32.1 ± 5.3 0.08
Intercommissural diameter (mm) 39.9 ± 6.4 41.1 ± 6.5 0.15
Ellipsicity (%) 121.8 ± 17.3 129.4 ± 18.4 0.04
Circumference (mm) 124.5 ± 19 124.8 ± 17.4 0.88
Annular area (mm2) 1178.0 ± 380.2 1170.7 ± 326.1 0.81
Annular height (mm) 5.5 ± 1.9 5.7 ± 1.9 0.62
Annular height to intercommissural width ratio (%) 20.2 ± 13.8 18.3 ± 6.3 0.41
Leaflets
Anterior leaflet length exposed A2 segment (mm)* 27.2 ± 5.5 25.4 ± 5.0 0.03
Posterior leaflet length exposed P2 segment (mm)* 11.6 ± 4.1 12.5 ± 4.3 0.15
Anterior leaflet exposed area (mm2)* 795.4 ± 277.0 729.8 ± 222.0 0.04
Posterior exposed leaflet area (mm2)* 636.9 ± 257.0 666.3 ± 227.5 0.32
Total leaflet area (mm2) 1811.2 ± 582.2 1870.3 ± 505.5 0.18
Anterior leaflet angle (º) 27.1 ± 7.4 33.6 ± 7.9 <0.001
Posterior leaflet angle (º) 49.0 ± 13.6 56.1 ± 10.3 0.02
Aortomitral angle (º) 134.8 ± 11.2 133.0 ± 11.3 0.39
Non-planarity angle (º) 122.6 ± 18.3 123.3 ± 18.4 0.82
Tenting height A2-P2 (mm) 8.1 ± 3.4 8.2 ± 3.0 0.65






Coaptation length A2P2 (mm) 5.0 ± 0.11 5.3 ± 0.87 <0.001







*The exposed length and area of the leaflets does not include the coapting part of the leaflet.
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measurements were performed on 3-dimensional models that permit better 
assessment of the saddle shape of the mitral annulus. The current analysis did 
however show a change in the shape of the mitral annulus with an increase in 












3-dimensional overview of acute effect of MitraClip 
therapy on mitral valve geometry showing an in-
crease in coaptation area. The long-axis view of the 
3-dimensional model is showed at baseline (upper 
panel) and after (bottom panel) MitraClip implanta-
tion with the arrow pointing the area of coaptation. 
A = anterior, AL = anterolateral, Ao = Aorta, P = pos-




















Schematic overview of acute effect of MitraClip device on mitral valve geometry. The MitraClip device leads to a 
decrease in exposed anterior leaflet length (AMVL) at the A2 level without change in overall mitral leaflet length 
and area, indicating a higher contribution of the AMVL into coaptation. Furthermore, the antero-posterior diameter 
tends to reduce with corresponding increases in the anterior and posterior mitral leaflet angle (α and β). AMVL = 








with previous reports.18-20 Recently, Schueler et al. showed that patients with 
FMR showed significant decreases in the anteroposterior diameter of the mitral 
annulus (from 4.0±0.6 cm to 3.6±0.6 cm, p<0.001), 3-dimensional mitral annulus 
area (from 14.4±3.9 cm2 to 12.9±3.4 cm2, p<0.001) and mitral valve sphericity 
index (from 0.9±0.1 to 0.8±0.1, p<0.001) whereas the intercommisural diameter 
remained unchanged.20 Interestingly, these changes were not observed in pa-
tients with degenerative mitral regurgitation. Furthermore, patients in whom the 
antero-posterior diameter acutely reduced ≥6.4% had superior clinical response 
to MitraClip therapy after 6 months of follow-up compared with patients showing 
less acute annulus diameter reduction. However, an acute reduction in the antero-
posterior diameter after MitraClip therapy would indicate significant traction on 
the mitral leaflets to reduce the distance between the anterior and posterior 
annulus. This high leaflet stress could affect the durability of the procedure. To 
assess leaflet stress, we analysed the annular-height to intercommissural-width 
ratio. In the present study, the annular-height to intercommissural-width ratio did 
not significantly reduce after MitraClip implantation, suggesting no acute increase 
in leaflet stress.21 Understanding the effects of the MitraClip on the geometry of 
the mitral valve will eventually help to identify patients that will benefit most from 
this procedure.
Clinical implications
Evaluating the effects of MitraClip on 3-dimensional mitral valve geometry is 
important to understand its therapeutic efficacy and durability. The present study 
showed that MitraClip increases the coaptation length and area due to a larger 
contribution of the anterior mitral leaflet into the coaptation. Furthermore, the 
anteroposterior diameter tends to reduce with corresponding increases in the 
anterior and posterior mitral leaflet angles. Subsequent iterations of the device 
or development of newer systems may consider these findings to improve the 
efficacy of the repair. Although the effects of these geometrical changes on long-
term durability were not evaluated in the present study, future investigations may 
shed light on this topic and help in the design of novel devices.
Limitations
There are several limitations inherent to this study. First, the study population 
was rather small. By recording both the pre- and postprocedural views during 
anaesthesia we aimed at creating a similar hemodynamic status for the pre- and 
postprocedural measurements of mitral annular geometry. However, the effects 
of the anaesthetics on patients’ hemodynamic status must be considered. Fur-
thermore, the clips caused shadowing artifacts and limited the evaluation of the 
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coaptation point. By tracing the coaptation point in the body of the MitraClip after 
the procedure, which is the point where the leaflets are grasped by the clip, we 
aimed at reducing the effect of the artifacts on the outcomes.
CONCLuSION
Percutaneous MitraClip therapy affects mitral valve geometry in FMR patients by 
increasing coaptation length and area mainly due to a larger contribution of the 
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QRS fragmentation (fQRS) and prolonged QTc interval on surface ECG are prognos-
tic in various cardiomyopathies, other than hypertrophic cardiomyopathy (HCM). 
The association between fQRS and prolonged QTc duration with occurrence of 
ventricular tachyarrhythmias or sudden cardiac death (VTA/SCD) in patients with 
HCM was explored.
Methods and Results
195 clinical HCM patients were studied. QTc duration was derived applying Bazett’s 
formula; fQRS was defined as presence of various RSR’ patterns, R or S notching 
and/or >1 additional R wave in any non-aVR lead in patients without pacing or (in)
complete bundle branch block. The endpoints comprised SCD, ECG documented 
sustained VTA (tachycardia or fibrillation) or appropriate implantable cardioverter 
defibrillator (ICD) therapies [anti-tachycardia pacing (ATP) or shock] for VTA in ICD 
recipients [n=58 (30%)]. QT prolonging drugs recipients were excluded. After a 
median follow-up of 5.7 years (IQR 2.7-9.1), 26 (13%) patients experienced VTA 
or SCD. Patients with fQRS in ≥3 territories (inferior, lateral, septal and/or anterior) 
(p=0.004) or QTc ≥460 ms (p=0.009) had worse cumulative survival free of VTA/
SCD than patients with fQRS in <3 territories or QTc <460 ms. fQRS in ≥3 territories 
(β 4.5, p=0.020, 95%CI 1.41-14.1) and QTc ≥460 ms (β 2.7, p=0.037, 95%CI 1.12-
6.33) were independently associated with VTA/SCD. Likelihood ratio test indicated 
assessment of fQRS and QTc on top of conventional SCD risk factors provides 
incremental predictive value for VTA/SCD (p=0.035).
Conclusions
Both fQRS in ≥3 territories and QTc duration are associated with VTA/SCD in HCM 










Hypertrophic cardiomyopathy (HCM) is characterized by cellular hypertrophy, 
interstitial fibrosis and myofiber disarray that increase the risk of (arrhythmic) 
sudden cardiac death (SCD).1 These ultra-structural alterations may account for 
abnormalities in left ventricular (LV) electrical activation, including depolarization 
and repolarization, reflected on surface electrocardiography (ECG).1, 2 Abnormal 
ECG findings, although non-specific, are found in between 75% and 95% of HCM 
patients.3 Recently the severity of ECG abnormalities in HCM patients were linked 
to the presence and extent of phenotypic expression as evaluated by cardiac mag-
netic resonance (CMR) imaging, including LV mass, hypertrophy and scarring (fibro-
sis).4 However, whether ECG abnormalities might relate to electrical instability and 
be useful for stratification of HCM patients at risk for ventricular tachyarrhythmia 
(VTA) or SCD remains poorly explored.
Fragmentation of the QRS complex (fQRS) on surface ECG (comprising various 
RSR` patterns of QRS morphology) represents a depolarization abnormality that 
has been related to presence of myocardial fibrosis.5-7 Moreover, the presence of 
fQRS is an independent predictor of VTA and/or mortality in patients with ischemic 
and non-ischemic cardiomyopathies, has been associated with reduced event-free 
survival in patients with Brugada syndrome and is a diagnostic marker in arrhyth-
mogenic right ventricular dysplasia.6, 8-10 Its potential clinical prognostic value in 
patients with HCM, however, is poorly studied.11 In addition, congenital or acquired 
QT prolongation on ECG is a well-known repolarization abnormality implying in-
creased risk of VTA and SCD.12, 13 Heart rate corrected QT (QTc) prolongation is not 
infrequent in HCM patients, but limited data exist on its clinical significance.14-20
Therefore the aim of this study was to explore the association of both fQRS and 
QTc duration with the occurrence of malignant VTA or SCD in HCM patients.
METhODS
Patient population 
Clinical HCM patients enrolled in an ongoing echocardiographic and clinical regis-
try at our department were included in this analysis if ECG was present within one 
year before or after the baseline echocardiographic exam and subjects were ≥18 
year-old (n=323). Clinical HCM was defined as a non-dilated LV with a maximal wall 
thickness of ≥15 mm on echocardiography in patients without systemic or alterna-
tive explanations for the magnitude of LV hypertrophy.21 Patients with ventricular 
pacing (n=20) or (in)complete bundle branch block (BBB) at baseline ECG were 
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excluded. In particular, RSR’ pattern in lead V1 and/or V2 with QRS duration ≥110 
or ≥120 ms and S wave of greater duration than R wave or greater than 40 ms in 
leads I and V6 was defined as incomplete right BBB (n=11) and complete right 
BBB (n=19), respectively.22 Left BBB (n= 12) was defined as a QRS duration ≥120 
ms with RSR’ pattern in leads I, aVL, V5 and V6.22 In addition, patients taking QTc 
prolonging medications were excluded (n=20). Finally, patients without clinical 
follow-up within the last 3 years (n=46) were also excluded from further analysis.
Extensive baseline evaluation including medical history, demographics, medi-
cations, ECG and echocardiography was performed in all patients and data were 
prospectively collected at the departmental Cardiology Information System 
(EPD-Vision®, Leiden University Medical Center, Leiden, the Netherlands) and 
retrospectively analyzed. According to guidelines, the SCD risk profile of the 
patients was determined based on the following clinical and echocardiographic 
parameters 21: secondary prevention implantable cardioverter defibrillator (ICD) 
indication, maximal LV wall thickness ≥30 mm, family history of SCD (≥ one 1st 
to 3th degree relative), unexplained syncope and, as additional risk factor, docu-
mented non-sustained ventricular tachycardia (≥3 beats at ≥120 bpm) prior to 
device implantation. Blood pressure response during exercise testing was not sys-
tematically available and therefore not included as a conventional SCD risk factor.
Patients were followed-up at the out-patient clinic or through contact with the 
general practitioners in order to evaluate the occurrence of cardiac events. The 
Ethical Committee of the Leiden University Medical Center approved this retro-
spective study and waived the need for written informed consent.
ECg analysis
Routine 12-lead ECG (settings: 0.05-300 Hz filter range, AC filter 50 Hz, paper 
speed 25 mm/s and voltage 10 mm/mV) was performed and stored digitally for 
off-line analysis, using a dedicated software (Siemens/Dräger Mega Care ECG Man-
agement System). QT interval and heart rate were automatically provided by the 
software. Heart rate corrected QT (QTc) duration was calculated applying Bazett’s 
formula [QTc=QT/√(60/heart rate)]. Detection of fQRS was performed manually. As 
shown in Figure 1, QRS fragmentation comprises presence of various RSR’ patterns, 
notching in the R or S wave or presence of >1 additional R in ≥2 beats of a non-aVR 
lead. fQRS was allocated to a territory when present in ≥2 contiguous leads of the 
inferior (II, III, aVF), lateral (I, aVL, V6), septal (V1,V2) or anterior (V3,V4,V5) regions.5 











Standard 2-dimensional transthoracic echocardiography was performed with the 
patient in left lateral decubitus position using commercially available ultrasound 
machines (System-5, Vivid-7 and E9, GE-Vingmed, Milwaukee, WI) equipped with 
a 3.5 MHz transducer. ECG-triggered standard 2-dimensional gray-scale and color-
Doppler images were acquired in cine-loop format and transferred to a workstation 
for off-line analysis (EchoPAC version 112, GE Medical Systems, Horten, Norway). 
Cardiac chamber quantification was performed in accordance with current recom-
mendations.23 Maximal LV wall thickness was assessed at end-diastole on the 
basal, mid or apical short-axis LV view. Simpson`s biplane method was applied to 
assess LV volumes that were indexed to body surface area and additionally used to 
calculate LV ejection fraction. Systolic anterior mitral leaflet motion was evaluated 
on M-mode acquisition in parasternal long-axis LV view. Mitral regurgitation was 
A
RsR` RSr` RSR` R notching S notching fragmentationfrag entation
B
QTc 487 ms                                              
resuscitation for VF after 2.4 years
C
QRS fragmentation (     ) in 3 territories, QTc 527 ms                                  
ATP for sustained VT after 1.1 years
Figure 7.1
Baseline electrocardiographic abnormalities: QRS fragmentation and QTc prolongation. Panel A: QRS fragmenta-
tion includes various RSR` patterns, notched R wave, notched S wave or presence of >1 additional R wave (frag-
mentation) in ≥2 beats per lead. (In)complete bundle branch block patients are excluded (see text for details). 
Panel B: Hypertrophic cardiomyopathy (HCM) patient with QTc prolongation. Of note, QRS fragmentation is also 
present in lead III (S notching). Panel C: QTc prolongation and extensive QRS fragmentation in the inferior (II,III,aVF), 
lateral (I,V6,aVL) and anterior (V3,V4,V5) territories in a HCM patient. ATP: antitachycardia pacing, QTc: heart rate 
corrected QT duration, VF: ventricular fibrillation, VT: ventricular tachycardia.
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semi-quantitatively graded as trivial (grade 1), mild (grade 2), moderate (grade 3) 
or severe (grade 4), according to current recommendations.24 Finally, presence of 
intraventricular or LV outflow tract gradient at rest was evaluated by pulsed-wave 
Doppler on the apical long-axis view and peak gradient was measured on continu-
ous wave Doppler recordings.
ICD implantation and settings
Transvenous approach was used for implantation of all defibrillator devices (Bos-
ton Scientific [Natick, MA, USA, formerly CPI, Guidant (St Paul, MN, USA)], Biotronik 
(Berlin, Germany), St Jude Medical/Ventritex (St Paul, MN, USA) and Medtronic 
(Minneapolis, MN, USA). The antitachycardia modus was set in all devices using 3 
consecutive zones with slightly varying limits per manufacturer: a monitor zone 
(150-155 to 185-190 bpm), an antitachycardia pacing (ATP) shock zone (185-190 
to 205-210 bpm), and an initial shock zone (≥205-210 bpm). In the monitor zone 
no therapy was programmed, unless during follow-up VTA was detected. An ini-
tial attempt to terminate arrhythmias by two ATP bursts was programmed in the 
ATP-shock zone, however, defibrillator shocks were fired if arrhythmia persisted. 
Shocks were the initial therapy for VTA with higher rate than the ATP shock zone. 
ICD device interrogation was regularly performed every 3 to 6 months after im-
plantation.
Study endpoint
The primary endpoint of the study included occurrence of malignant VTA or SCD, 
whichever occurred first. VTA was defined as sustained ventricular tachycardia or 
fibrillation documented on ECG or by appropriate ICD therapies (shock/ATP) for 
VTA in patients with an ICD. SCD was defined as (unexpected) death of a HCM 
patient inside or outside a hospital due to any cardiac cause within 1 hour of 
onset of symptoms (if documented).25 Deaths and cause of death were assessed 
by evaluating the official Dutch National Survival Registry, patients` clinical files 
and by direct communication with general practitioners.
Statistical analysis
According to distribution, continuous data were expressed as mean ± standard 
deviation or median ± interquartile range and compared between groups by 
Student-T test and Mann-Whitney U test, respectively. Categorical data were 
presented as percentages and compared with χ2 or Fisher-exact test, as appropri-
ate. A receiver operating curve (ROC) was constructed to derive a cut-off value 
for QTc with cut-point maximizing sum of sensitivity and specificity for prediction 









with Kaplan-Meier curve analysis. Patients were dichotomized according to the 
QTc duration cut-off and presence of fQRS in <3 vs ≥3 territories, and compared 
by log-rank test. Sensitivity, specificity, positive and negative predictive value for 
the study endpoint of these dichotomized ECG criteria were calculated. Among the 
various clinical, ECG and echocardiographic variables, the independent correlates 
of VTA/SCD were evaluated with multivariate Cox proportional hazard ratios. Vari-
ables showing a p-value <0.05 in univariate analysis were entered in multivariate 
Cox regression analysis. Finally, the likelihood ratio test was applied to explore 
the incremental value of QTc duration and fQRS on top of conventional SCD risk 
factors to predict the occurrence of VTA/SCD. Statistical analysis was performed 
using SPSS version 20.0. (SPSS Inc., Chicago, Illinois). All tests were two-sided and 
a p-value of <0.05 was considered statistically significant.
RESuLTS
Patient population
A total of 195 HCM patients (mean age 52 ± 13 years, 61% male) were included. 
Baseline clinical, echocardiograhic characteristics and SCD risk profile are summa-
rized in Table 1. The overall HCM population had a median LV wall thickness of 21 
mm (IQR: 18-24 mm), small ventricular cavity and preserved LV ejection fraction. 
Only a minority of patients (n=58, 30%) had an ICD at baseline, of which 13 (22%) 
were for secondary prevention reasons (survived sustained VTA).
Primary prevention ICD implantation was performed, in accordance to cur-
rent guidelines, if ≥1 conventional SCD risk factor(s) was present (n=43).21 ICD 
implantation in patients without SCD risk factors was performed in one patient 
with total atrio-ventricular conduction block and in one patient due to induction 
of ventricular fibrillation during electrophysiological study. Few patients (n=16) 
had prior septal alcohol ablation for symptomatic drug refractory LV obstruction.
Study endpoint
A total of 26 out of 195 patients (13.3%) experienced VTA/SCD after a median 
follow-up of 5.7 years (IQR 2.7-9.1). In particular 10 out of 137 patients without 
ICD (7%) reached the endpoint, consisting of sustained ventricular tachycardia 
(n=4), ventricular fibrillation (n=2) and SCD (n=4). Of note, at that time point these 
patients did not fulfill criteria for primary prevention ICD implantation. Additionally 
in 16 out of 58 baseline ICD recipients (28%) appropriate ICD therapy occurred 
with a total of 9 ATP and 7 shocks.
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QTc and fQRS 
Data on fQRS and for QTc duration on ECG are listed in Table 2. Mean QTc duration 
in the overall study population was 427 ± 28 ms. QTc duration ≥460 ms comprised 
highest sum of sensitivity (31%) and specificity (89%) for prediction of the study 
endpoint (area under curve 0.61 on ROC analysis). Significant QTc prolongation 
≥460 ms was noted in a total of 26 out of 195 HCM patients (13%). The vast 
majority of HCM patients (n=181, 93%) displayed a fQRS in at least one ECG 
Table 7.1







(n 26) p value*
Clinical 
Age, years 52 ± 13 52 ± 13 50 ± 10 0.51
BSA, m2 2.02 ± 0.2 2.02 ± 0.2 2.01 ± 0.2 0.91
Male, n (%) 119 (61) 99 (59) 20 (77) 0.07
Sinus rhythm, n (%) 171 (88) 147 (87) 24 (92) 0.44
Heart rate, bpm 69 ± 14 69 ± 14 72 ± 14 0.32
Arterial hypertension, n (%) 69 (35) 63 (37) 6 (23) 0.09
β-blocker use, n (%) 69 (35) 59 (35) 10 (38) 0.91
Previous MI, n (%) 8 (5) 7 (4) 1 (4) 1.00
Echocardiography
Max wall thickness, mm 21 (18-24) 21 (18-24) 23 (20-26) 0.15
LVEDVI, ml/m2 50 (41-59) 49 (39-59) 53 (44-65) 0.28
LVESVI, ml/m2 16 (11-20) 16 (11-20) 19 (14-25) 0.28
LVEF, % 69 (63-73) 69 (63-73) 66 (55-71) 0.05
SAM of mitral valve, n (%) 75 (38) 66 (39) 9 (35) 0.63
MR grade, (0-4/4) 1.11 ± 0.7 1.07 ± 0.8 1.15 ± 0.7 0.74
IVPG rest ≥30 mmHg, n (%) 37 (19) 33 (20) 4 (15) 1.00
HCM risk profile
Max wall thickness ≥ 30 mm, n (%) 20 (10) 19 (11) 1 (4) 0.48
Family Hx SCD, n (%/175) 91 (52) 78 (51) 13 (59) 0.48
Non-sustained VT, n (%/189) 52 (28) 39 (24) 13 (50) 0.006
Unexplained syncope, n (%/193) 17 (9) 9 (5) 8 (31) <0.001
ICD at baseline, n (%) 58 (30) 42 (25) 16 (62) <0.001
Secondary prevention ICD, n (%/58) 13 (22) 10 (24) 3 (19) 1.00
Prior septal alcohol ablation, n (%) 16 (8) 14 (8) 2 (8) 1.00
BSA: body surface area (Mosteller formula), EDVI, end-diastolic volume indexed to BSA, EF: ejection fraction, ESVI: 
end-systolic volume indexed to BSA, Hx: history, ICD: implantable cardioverter defibrillator, IVPG: intra ventricular 
pressure gradient, LV: left ventricular, Max: maximal, MI: myocardial infarction, SAM: systolic anterior movement, 
SCD: sudden cardiac death, VT: ventricular tachycardia, VTA: ventricular tachyarrhythmia, *: for comparison of VTA/









lead with a median of 4 leads affected per patient. A total of 145 patients (75%) 
exhibited a fQRS in ≥1 ECG territory. Leads III, aVF and aVL were the most affected 
in 69%, 62% and 52% of cases, respectively. Leads V4, V3 and V1 were the least 
affected in only 13%, 16% and 21% of patients, respectively. fQRS was most 
commonly observed in the inferior territory (61%), followed by the lateral (31%), 
anterior (13%) and septal territories (11%). Presence of fQRS in ≥3 territories was 
noted in 15 out of 195 (8%) of patients.
Table 7.2








(n 26) p value*
Duration, ms 97 ± 12 97 ± 12 99 ± 13 0.30
Fragmentation, n (%)
≥ 1 lead 181 (93) 156 (92) 25 (96) 0.70
Inferior territory 118 (61) 101 (60) 17 (65) 0.56
Lead II 85 (44) 73 (43) 12 (46) 0.78
Lead III 135 (69) 114 (67) 21 (81) 0.17
Lead aVF 121 (62) 105 (62) 16 (62) 0.95
Lateral territory 60 (31) 48 (28) 12 (46) 0.07
Lead I 50 (26) 40 (24) 10 (38) 0.11
Lead aVL 102 (52) 86 (51) 16 (62) 0.31
Lead V6 55 (28) 47 (28) 8 (31) 0.76
Septal territory 22 (11) 17 (10) 5 (19) 0.17
Lead V1 41 (21) 85 (21) 6 (23) 0.78
Lead V2 42 (25) 36 (21) 6 (23) 0.84
Anterior territory 22 (13) 16 (9) 6 (23) 0.04
Lead V3 32 (16) 28 (17) 4 (15) 1.00
Lead V4 26 (13) 21 (12) 5 (19) 0.34
Lead V5 42 (25) 33 (20) 9 (35) 0.08
Number of leads 4 (2-5) 4 (2-5) 4 (3-6) 0.53
≥ 3 territories 15 (8) 10 (6) 5 (19) 0.02
QTc 
Duration, ms 427 ± 28 425 ± 25 440 ± 34 0.01
≥460 ms, n (%) 26 (13) 18 (11) 8 (31) 0.01
QTc: heart rate corrected QT duration, SCD: sudden cardiac death, VTA: ventricular tachyarrhythmia, * p value for 
comparison of no VTA/SCD versus VTA/SCD group.
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hCM patients with versus without study endpoint
The patient population was dichotomized based on the occurrence (n=26, 13.3%) 
or absence (n=169, 86.7%) of the study endpoint (VTA/SCD). These 2 groups 
showed similar clinical and conventional echocardiographic characteristics, as 
summarized in Table 1. Patients with VTA/SCD, however, showed higher baseline 
HCM SCD risk profile, evidenced by higher prevalence of non-sustained ventricu-
lar tachycardia (50% versus 24%, p=0.006) and prior unexplained syncope (31% 
versus 5%, p<0.001).
Concerning baseline ECG characteristics (Table 2), mean QTc duration was longer 
in patients with VTA/SCD versus patients without (440 ± 34 ms versus 425 ± 25 
ms, p=0.01) and a higher percentage of patients with VTA/SCD showed a QTc dura-
tion ≥460 ms as compared to their counterparts (31% versus 11%, p=0.01; Figure 
2). No significant difference between patients with versus without VTA/SCD was 
observed for the presence of fQRS in any individual lead, the median number of 
leads with fQRS, nor the territory affected by fQRS, except for the anterior territory 
(23% versus 9%, p=0.04). Interestingly, the prevalence of fQRS in ≥3 territories 
was higher in subjects with VTA/SCD (19% versus 6%, p=0.03; Figure 2).
QTc duration, fQRS and the study endpoint
The cumulative survival free of VTA/SCD was worse in patients with a QTc duration 
≥460 vs <460 ms (p=0.009) or fQRS in ≥3 vs <3 territories (p=0.004). (Figure 3). 
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Prevalence of novel electrocardiographic criteria in relation to the study endpoint. HCM: hypertrophic cardiomy-
opathy, fQRS: presence of QRS fragmentation, QTc: heart rate corrected QT duration, SCD: sudden cardiac death, 









occurrence of VTA/SCD of 31%, comparable to 33% if presence of fQRS ≥3 ter-
ritories. When both ECG criteria co-exist in one patient, a high positive predictive 
value of 75% is noted, yielding low sensitivity, however. As shown in Table 4, QTc 
duration ≥460 ms, fQRS in ≥3 territories, non-sustained ventricular tachycardia 
and unexplained syncope were univariate correlates of VTA/SCD. Of note, other 
conventional SCD risk factors, secondary prevention ICD indication and prior sep-
tal alcohol ablation were not significantly associated with the study endpoint. In 
the multivariate analysis, both QTc duration ≥460 ms and fQRS in ≥3 territories 
remained independently related to VTA/SCD, in addition to non-sustained ven-
tricular tachycardia and unexplained syncope (Table 4).
Moreover, excluding secondary prevention ICD recipients (n=13), likelihood 
ratio test indicated that assessment of both ECG parameters, QTc duration ≥460 
ms and fQRS in ≥3 territories, provided incremental value over conventional SCD 
risk factors to predict occurrence of VTA/SCD (p=0.035; Figure 4).
Log rank p 0.009
QTc ≥ 460 ms














   
   
   
   
   
   
   
   
   
   

























QTc < 460 ms           169           133            95            74             48             36               
QTc ≥ 460 ms            26             20             16            12             10              5
Log rank p 0.004
fQRS ≥ 3 territories













   
   
   
   
   
   
   
   
   
   



























fQRS < 3 territories  180          140           101           81             57             40              
fQRS ≥ 3 territories   15            13             10             5               1               1
Figure 7.3
Cumulative survival free of ventricular tachyarrhythmia or sudden cardiac death according to novel electrocardio-
graphic criteria. fQRS: presence of QRS fragmentation, QTc: heart rate corrected QT duration.
Table 7.3
Sensitivity, specificity, positive and negative predictive value of novel ECG criteria for prediction of ventricular 









QTc ≥460 ms 31 89 89 31
fQRS ≥3 territories 19 94 88 33
QTc ≥460 ms AND fQRS ≥3 territories 12 99 80 75
fQRS: presence of QRS fragmentation, NPV: negative predictive value, PPV: positive predictive value
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DISCuSSION
The main findings of this study are 1) fQRS in ≥3 territories and QTc prolongation 
≥460 ms are easily identifiable surface ECG markers which are prevalent in 8% and 














* QTc ≥ 440 ms or fQRS ≥ 3 territories
Figure 7.4
Likelihood ratio test to predict occurence of ventricular tachyarrhythmia or sudden cardiac death. Excluding sec-
ondary prevention ICD recipients (n=13), assessment of the novel electrocardiographic (ECG) criteria on top of 
conventional sudden cardiac death (SCD) risk factors (see main text for details) in the remaining HCM patients 
yields incremental value to predict occurrence of ventricular tachyarrhythmia or sudden cardiac death. fQRS: QRS 
fragmentation, QTc: heart rate corrected QT duration.
Table 7.4
Univariate and multivariate Cox regression analysis for the study endpoint.
univariate multivariate
HR p value 95% CI HR p value 95% CI
Age, years 1.0 0.638 0.98-1.04
Male gender 2.0 0.140 0.80-4.96
β-blocker use 1.1 0.807 0.49-2.50
LVEF, per % 0.96 0.081 0.93-1.01
Max wall thickness ≥ 30 mm 3.6 0.209 0.49-26.6
Family Hx SCD 1.4 0.397 0.62-3.40
Non-sustained VT 2.5 0.019 1.16-5.45 3.3 0.005 1.42-7.48
Unexplained syncope 5.6 <0.001 2.41-13.5 4.7 0.002 1.95-11.7
Secondary prevention ICD 1.7 0.217 0.73-4.00
fQRS ≥3 territories 4.0 0.008 1.44-10.9 4.5 0.020 1.41-14.1
QTc ≥460 ms 2.9 0.013 1.25-6.62 2.7 0.037 1.12-6.33










block and 2) both parameters are independently associated with VTA and SCD in 
this HCM population (with almost 50% at relatively low-risk), showing incremental 
predictive value over conventional SCD risk factors for primary prevention.
Most HCM patients have a benign course reflected by a 1% annual risk of pre-
sumed arrhythmic SCD in non-selected cases.1 Identification of the subset of HCM 
patients at high-risk for SCD, however, remains a clinical challenge. Various SCD 
risk factors, including personal history of cardiac arrest, massive LV hypertrophy, 
family history of SCD, presence of non-sustained ventricular tachycardia and un-
explained syncope have been identified.21 Although ICD therapy in HCM patients 
at high risk for SCD based on these risk factors undoubtly remains a treatment 
cornerstone, the robustness of evidence supporting these risk factors is variable 
and in particular risk factors for primary prevention are limited by low positive 
predictive value (between 10% and 20%).21, 26 Therefore improvement of risk 
prediction in HCM remains an unmet clinical need.27 Although the vast majority of 
HCM patients show abnormal ECG findings, no specific ECG abnormality has been 
validated for risk stratification so far.3, 28, 29 This study indicated that the presence 
of fQRS in ≥3 territories or QTc ≥460 ms on baseline ECG were independently 
associated with VTA or SCD.
fQRS in hCM
In ischemic and non-ischemic dilated cardiomyopathy patients, fQRS has been 
related to fibrosis and represents a strong prognostic marker for VTA and/or mor-
tality.6-8, 30 
Th e origin of fQRS on ECG in HCM patients is poorly studied. Recently, in a study 
including 82 HCM patients, detection of fQRS was reported to predict presence of 
fibrosis identified on DE-CMR, yielding a positive and negative predictive value of 
86% and 68% respectively.31 In addition, the ECG lead territory displaying fQRS 
correlated with the myocardial region where fibrosis was detected. In this study 
75% of HCM patients displayed fQRS in ≥1 ECG territory, with the inferior territory 
most often affected. These findings are in line with previous reports, indicating 
presence of fibrosis on DE-CMR in up to 80% of HCM patients, with small amounts 
of fibrosis often detected in the inferior region at the conjunction with the right 
ventricle.32, 33 However, apart from local fibrosis (scar), it should be considered that 
fQRS in HCM may also stem from tissue heterogeneity such as myofiber disarray, 
interstitial (diffuse) fibrosis or functional rather than structural (scar) modulation of 
conduction, as suggested in other channelopathies (such as Brugada syndrome).9 
Therefore fQRS in HCM patients may not necessarily relate focal fibrosis, as as-
sessed by DE-CMR imaging.
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The potential clinical value of fQRS on ECG in HCM to predict malignant VTA or 
SCD was suggested previously.34 Recently, a study involving 179 HCM subjects 
showed that presence of paced ventricular ECG fractionation during electrophysi-
ologic testing was predictive of SCD.35 Only one study so far by Kang et al., com-
prising 167 relatively low-risk HCM patients without BBB (no ICD recipients, but 
presence of ≥1 conventional SCD risk factors in 42%), reported that presence of 
fQRS (in particular in the inferior leads) on surface ECG independently of conven-
tional SCD risk factors related to occurrence of VTA/SCD during follow-up.11 The 
present study demonstrated that fQRS in ≥3 territories in HCM was independently 
associated with a nearly 5-fold increased risk for VTA or SCD, suggesting that the 
extent of fibrosis rather than its presence is related to adverse cardiac outcome, 
in line with previous reports in HCM patients using delayed-enhancement CMR 
(DE-CMR) to identify fibrosis.33, 36 The fact that presence of ≥3 territories was 
required to relate to VTA/SCD in our study compared to ≥1 territory (in particular 
the inferior territory) in the report of Kang et al., might also be attributed to the 
use of more sensitive ECG settings by default in our centre, which allows for more 
sensitive detection of fQRS (0.05-300 Hz vs. 0.15-100 Hz filter range).11 Similar to 
our report, Kang et al. also pointed out higher predictive value for VTA/SCD when 
adding fQRS to conventional SCD risk factors.11
fQRS in HCM patients, likely representing (local or diffuse) fibrosis and/or tissue 
heterogeneity, may reflect the vulnerable structural substrate that is a prerequisite 
for occurrence of re-entry VTA that occurs if appropriate triggers coincide.
QTc in hCM
The QT interval, comprising the interval between QRS onset and end of the T 
wave, mainly reflects myocardial repolarization. QTc prolongation in HCM patients 
is consistently reported.14, 15, 19, 20 In our large cohort of 195 HCM subjects, QTc 
prolongation defined as a duration ≥460 ms had a prevalence of 13%. In HCM 
patients QTc prolongation has been, although weakly, related to extent of LV maxi-
mal wall thickness, LV outflow tract obstruction, underlying causative mutation 
(potentially affecting sodium or potassium ion channels related to depolarization 
and repolarization) and even sympathetic tone differences.4, 14, 15, 20, 37 Furthermore, 
the presence of fibrosis, myofiber disarray and/or (microvascular) ischemia might 
be other determinants of QTc in this patient population.
QTc duration has prognostic value in predicting occurrence of VTA or SCD in pa-
tients with congenital or acquired long QT.12, 13 In the present study a QTc duration 
≥460 ms was significantly associated with a nearly 3-fold increased risk for VTA 
or SCD. QTc duration ≥460 ms was independently associated with VTA/SCD and 









Recently Gray et al., in a group of 164 high-risk HCM patients, all ICD recipients, 
showed that QTc duration ≥439 ms independently of presence of conventional 
risk factors predicts appropriate ICD therapies, yielding a more than 3-fold risk 
increase.20 QTc prolongation, comparable to numbers reported in our lower risk 
profile HCM patients, was 2 times more frequent in patients that received versus 
did not experience appropriate ICD therapy, up to 79% versus 40% respectively.20 
Longer QTc duration in patients with history of SCD or SCD during follow-up was 
also noted in a study by Baranowski et al., including a group of 26 HCM subjects.18 
Sherrid et al. in a study involving 330 HCM ICD recipients did not find a signifi-
cant difference in QTc duration between subjects with appropriate versus no ICD 
discharge.29 However, this study did not exclude QTc duration confounders such 
as intake of QTc prolonging drugs or bundle branch block, had shorter follow-up 
time compared to our study and to that of Gray et al., and focused on high-risk 
HCM patients with ICD only.20 A QTc duration ≥480 ms in a subgroup analysis of 90 
out of 479 HCM patients was not able to discriminate between subjects with and 
without appropriate ICD discharge, but again involved exclusively high-risk HCM 
patients without excluding patients with BBB.14 
The exact mechanism of VTA or SCD in HCM patients with prolonged QTc remains 
speculative, but may involve early after depolarizations due to prolonged ven-
tricular repolarization which can lead to re-entry and provoke torsades de pointes. 
Another potential mechanism is depolarization abnormality, including fQRS, offer-
ing a substrate for maintaining the re-entry circuit after initiation of torsades de 
pointes.38 
Clinical implications
The current study suggests that surface ECG may be of clinical value for man-
agement and decision-making in selected HCM patients. Conventional SCD risk 
factors have only moderate PPV about 10 to 20%, particularly when applied for 
primary prevention.39 We indicated that PPV of both novel ECG criteria for VTA/
SCD is above 30% and is of incremental predictive value when applied in primary 
prevention HCM patients. Therefore presence of fQRS or QTc prolongation in fact 
might serve as an easy to obtain additional SCD risk marker on top of conventional 
risk parameters and help to optimize selection of candidates for prophylactic ICD 
implantation. Nevertheless, appropriate ICD therapy does not entirely correspond 
to SCD events and thus further prospective validation in larger HCM patient 
cohorts is needed to confirm these findings. In addition, given the prognostic 
impact of QTc duration in HCM patients, the current study underlines the clinical 
importance of measuring QTc duration in HCM patients and suggests a restrictive 
approach when considering administration of drugs that may prolong QTc duration 
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or careful monitoring of QTc duration if drug initiation is deemed to be necessary 
in this population.
Limitations 
Some limitations to this study need consideration. First, high ECG filter settings 
allow high sensitivity to detect ECG abnormalities but imply a risk of over-diag-
nosing fQRS which cannot be excluded in the current study. Second, although a 
potential mechanistic link between fQRS and myocardial fibrosis (as assessed by 
DE-CMR) has been previously suggested in HCM patients, this evaluation was not 
performed in this study cohort due to absence of systematic CMR data at the time 
of ECG. Although validation of equating true fractionation with a local conduction 
abnormality such as r-prime is lacking, the definition of QRS fragmentation applied 
in present analysis is similar to the study of Das et al, demonstrating the link be-
tween scar due to myocardial infarction and fQRS in patients with coronary artery 
disease.5 Third, our findings were observed in a relatively low-risk HCM population 
(only 30% ICD recipients and 48% without family history of SCD) in the absence 
of BBB or QTc prolonging drugs and therefore can-not be extrapolated to other 
subsets of HCM patients. Four, appropriate ICD therapy should not be regarded 
as a full surrogate of SCD as it tends to overestimate historical mortality in HCM. 
Fifth, the absolute number of events was typically low despite a moderately sized 
HCM study cohort. Finally, as ICD recipients have continued rhythm monitoring, 
the occurrence of VTA events is potentially biased in favor of these patients. Due 
to these limitations, this study should be regarded as hypothesis generating.
CONCLuSION
Extensive QRS fragmentation and QTc prolongation in clinical HCM patients are 
independently associated with VTA and/or SCD in this cohort of HCM patients 
(48% at relatively low-risk). Both parameters are incremental to conventional SCD 
risk factors. These findings suggest that baseline ECG, widely available at low cost, 










 1. Maron BJ, Maron MS. Hypertrophic cardiomyopathy. Lancet. 2012;381:242-255.
 2. Dumont CA, Monserrat L, Soler R et al. Interpretation of electrocardiographic abnormali-
ties in hypertrophic cardiomyopathy with cardiac magnetic resonance. Eur Heart J. 2006; 
27:1725-1731.
 3. Maron BJ. Hypertrophic cardiomyopathy: a systematic review. JAMA. 2002; 287:1308-1320.
 4. Delcre SD, Di Donna P, Leuzzi S et al. Relationship of ECG findings to phenotypic expression 
in patients with hypertrophic cardiomyopathy: a cardiac magnetic resonance study. Int J 
Cardiol. 2013; 167:1038-1045.
 5. Das MK, Khan B, Jacob S et al. Significance of a fragmented QRS complex versus a Q wave 
in patients with coronary artery disease. Circulation. 2006; 113:2495-2501.
 6. Das MK, Suradi H, Maskoun W et al. Fragmented wide QRS on a 12-lead ECG: a sign of 
myocardial scar and poor prognosis. Circ Arrhythm Electrophysiol. 2008; 1:258-268.
 7. Basaran Y, Tigen K, Karaahmet T et al. Fragmented QRS complexes are associated with car-
diac fibrosis and significant intraventricular systolic dyssynchrony in nonischemic dilated 
cardiomyopathy patients with a narrow QRS interval. Echocardiography. 2011; 28:62-68.
 8. Das MK, Maskoun W, Shen C et al. Fragmented QRS on twelve-lead electrocardiogram 
predicts arrhythmic events in patients with ischemic and nonischemic cardiomyopathy. 
Heart Rhythm. 2010; 7:74-80.
 9. Morita H, Kusano KF, Miura D et al. Fragmented QRS as a marker of conduction abnormality 
and a predictor of prognosis of Brugada syndrome. Circulation. 2008; 118:1697-1704.
 10. Peters S, Trummel M, Koehler B. QRS fragmentation in standard ECG as a diagnostic 
marker of arrhythmogenic right ventricular dysplasia-cardiomyopathy. Heart Rhythm. 2008; 
5:1417-1421.
 11. Kang KW, Janardhan AH, Jung KT et al. Fragmented QRS as a candidate marker for high-risk 
assessment in hypertrophic cardiomyopathy. Heart Rhythm. 2014 Aug 11(8): 1433-1440.
 12. Goldenberg I, Moss AJ. Long QT syndrome. J Am Coll Cardiol. 2008; 51:2291-2300.
 13. Straus SM, Kors JA, De Bruin ML et al. Prolonged QTc interval and risk of sudden cardiac 
death in a population of older adults. J Am Coll Cardiol. 2006; 47:362-367.
 14. Johnson JN, Grifoni C, Bos JM et al. Prevalence and clinical correlates of QT prolongation in 
patients with hypertrophic cardiomyopathy. Eur Heart J. 2011; 32:1114-1120.
 15. Jouven X, Hagege A, Charron P et al. Relation between QT duration and maximal wall thick-
ness in familial hypertrophic cardiomyopathy. Heart. 2002; 88:153-157.
 16. Martin AB, Garson A, Jr., Perry JC. Prolonged QT interval in hypertrophic and dilated cardio-
myopathy in children. Am Heart J. 1994; 127:64-70.
 17. Yetman AT, Hamilton RM, Benson LN et al. Long-term outcome and prognostic determinants 
in children with hypertrophic cardiomyopathy. J Am Coll Cardiol. 1998; 32:1943-1950.
 18. Baranowski R, Chojnowska L, Michalak E et al. Analysis of the corrected QT before the onset 
of nonsustained ventricular tachycardia in patients with hypertrophic cardiomyopathy. 
Pacing Clin Electrophysiol. 2003; 26:387-389.
 19. Yi G, Elliott P, McKenna WJ, Prasad K et al. QT dispersion and risk factors for sudden cardiac 
death in patients with hypertrophic cardiomyopathy. Am J Cardiol. 1998; 82:1514-1519.
 20. Gray B, Ingles J, Medi C, Semsarian C. Prolongation of the QTc Interval Predicts Appropriate 
Implantable Cardioverter-Defibrillator Therapies in Hypertrophic Cardiomyopathy. JACC 
Heart Fail. 2013; 1:149-155.
– 142 –
 21. Gersh BJ, Maron BJ, Bonow RO et al. 2011 ACCF/AHA Guideline for the Diagnosis and 
Treatment of Hypertrophic Cardiomyopathy: a report of the American College of Cardiol-
ogy Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll 
Cardiol. 2011; 58:e212-260.
 22. Surawicz B, Childers R, Deal BJ et al. AHA/ACCF/HRS recommendations for the standard-
ization and interpretation of the electrocardiogram: part III: intraventricular conduction 
disturbances: a scientific statement from the American Heart Association Electrocardiog-
raphy and Arrhythmias Committee, Council on Clinical Cardiology; the American College 
of Cardiology Foundation; and the Heart Rhythm Society. Endorsed by the International 
Society for Computerized Electrocardiology. J Am Coll Cardiol. 2009; 53:976-981.
 23. Lang RM, Bierig M, Devereux RB et al. Chamber Quantification Writing Group, American 
Society of Echocardiography’s Guidelines, Standards Committee, European Association of 
Echocardiography. Recommendations for chamber quantification: a report from the Ameri-
can Society of Echocardiography’s Guidelines and Standards Committee and the Chamber 
Quantification Writing Group, developed in conjunction with the European Association of 
Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 
2005; 18:1440-1463.
 24. Zoghbi WA, Enriquez-Sarano M, Foster E et al. American Society of Echocardiography. 
Recommendations for evaluation of the severity of native valvular regurgitation with two-
dimensional and Doppler echocardiography. J Am Soc Echocardiogr. 2003; 16:777-802.
 25. Goldberger JJ, Cain ME, Hohnloser SH et al. AHA/ACCF/HRS scientific statement on non-
invasive risk stratification techniques for identifying patients at risk for sudden cardiac 
death: a scientific statement from the American Heart Association Council on Clinical Car-
diology Committee on Electrocardiography and Arrhythmias and Council on Epidemiology 
and Prevention. Circulation. 2008; 118:1497-1518.
 26. Maron BJ, Spirito P, Shen WK et al. Implantable cardioverter-defibrillators and prevention of 
sudden cardiac death in hypertrophic cardiomyopathy. JAMA. 2007; 298:405-412.
 27. O’Mahony C, Jichi F, Pavlou M et al. A novel clinical risk prediction model for sudden cardiac 
death in hypertrophic cardiomyopathy (HCM Risk-SCD). Eur Heart J. 2014; 35:2010-2020.
 28. Bongioanni S, Bianchi F, Migliardi A et al. Relation of QRS duration to mortality in a commu-
nity-based cohort with hypertrophic cardiomyopathy. Am J Cardiol. 2007; 100:503-506.
 29. Sherrid MV, Cotiga D, Hart D et al. Relation of 12-lead electrocardiogram patterns to 
implanted defibrillator-terminated ventricular tachyarrhythmias in hypertrophic cardiomy-
opathy. Am J Cardiol. 2009; 104:1722-1726.
 30. Das MK, Saha C, El Masry H et al. Fragmented QRS on a 12-lead ECG: a predictor of mortality 
and cardiac events in patients with coronary artery disease. Heart Rhythm. 2007; 4:1385-
1392.
 31. Sheikh N, Papadakis M, Bastiaenen R et al. Fragmented QRS: a predictor of myocardial 
fibrosis in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2012; 59: E1584-E1584.
 32. Choudhury L, Mahrholdt H, Wagner A et al. Myocardial scarring in asymptomatic or mildly 
symptomatic patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2002; 40:2156-
2164.
 33. Moon JC, McKenna WJ, McCrohon JA et al. Toward clinical risk assessment in hypertrophic 










 34. Femenia F, Arce M, Arrieta M et al. Surface fragmented QRS in a patient with hypertrophic 
cardiomyopathy and malignant arrhythmias: Is there an association? J Cardiovasc Dis Res. 
2012; 3:32-35.
 35. Saumarez RC, Pytkowski M, Sterlinski M et al. Paced ventricular electrogram fractionation 
predicts sudden cardiac death in hypertrophic cardiomyopathy. Eur Heart J. 2008; 29:1653-
1661.
 36. O’Hanlon R, Grasso A, Roughton M et al. Prognostic significance of myocardial fibrosis in 
hypertrophic cardiomyopathy. J Am Coll Cardiol. 2010; 56:867-874.
 37. Yanagisawa-Miwa A, Inoue H, Sugimoto T. Diurnal change in QT intervals in dilated cardio-
myopathy and hypertrophic cardiomyopathy. Am J Cardiol. 1991; 67:1428-1430.
 38. Haraoka K, Morita H, Saito Y et al. Fragmented QRS is associated with torsades de pointes 
in patients with acquired long QT syndrome. Heart Rhythm. 2010; 7:1808-1814.
 39. Gersh BJ, Maron BJ, Bonow RO et al. 2011 ACCF/AHA guideline for the diagnosis and treat-
ment of hypertrophic cardiomyopathy: a report of the American College of Cardiology 




Potential role of fibrosis imaging in severe 
valvular heart disease 
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ABSTRACT
The increasing burden of valvular heart disease (predominantly aortic stenosis 
and mitral regurgitation) parallels the ageing of the population. Timing of surgery 
in asymptomatic patients is controversial, and is currently considered in the pres-
ence of variables (such as reduced left ventricular ejection fraction, left ventricular 
dilatation, pulmonary hypertension, reduced exercise capacity, increased plasma 
levels of biomarkers and arrhythmias) that occur relatively late in the disease 
progression, with suboptimal outcome after surgery. Accordingly, early markers 
to guide therapeutic management are needed. In both aortic stenosis and mitral 
regurgitation, left ventricular fibrosis can be detected in the early stage of the dis-
ease and the extent of LV fibrosis may provide an early marker for disease severity. 
Currently, new non-invasive imaging technology is being developed that may 
permit direct or indirect assessment of left ventricular fibrosis; indirect assess-
ment of left ventricular fibrosis refers mainly to sophisticated quantification of 
left ventricular function (which indirectly reflects left ventricular fibrosis extent). 
An overview of these non-invasive imaging techniques is provided in this article, 
and the potential role of early detection of left ventricular fibrosis in patients with 
aortic stenosis or mitral regurgitation is discussed.
kEy POINTS
1. In left-sided valvular heart disease, pressure overload (aortic stenosis) is more pro-fibrotic than 
volume overload (mitral regurgitation)
2. Fibrosis causes adverse left ventricular remodeling, functional impairment and is associated with 
poor clinical outcome
3. Non-invasive imaging techniques to assess direct left ventricular fibrosis include:
o Contrast-enhanced cardiac magnetic resonance:
 § Focal (replacement) fibrosis
o T1-weighted cardiac magnetic resonance:
 § Diffuse fibrosis: T1-mapping, extracellular volume (ECV)
o Echocardiographic calibrated integrated backscatter
o Molecular imaging: 
 § Collagen-targeted agents with cardiac magnetic resonance
 §  Radiolabelled angiotensin converting enzyme inhibitors and angiotensin receptors 
antagonists with single photon emission computed tomography or positron emission 
tomography
4. Non-invasive imaging techniques to assess indirect left ventricular fibrosis include:
o Strain and strain rate imaging:
 § Tissue Doppler imaging
 § Speckle tracking echocardiography
 § Tagged cardiac magnetic resonance










Currently, the most encountered valve diseases include aortic stenosis (AS) and 
mitral regurgitation (MR); data from population-based studies showed that ap-
proximately 9% of individuals aged 65 years or more have either MR or AS.1,w1 
While indications for surgery are well-defined in symptomatic patients, the op-
timal timing of surgery in asymptomatic severe AS or MR remains controversial. 
Currently, surgical intervention is considered in the presence of reduced left 
ventricular ejection fraction (LVEF), left ventricular (LV) dilatation, pulmonary 
hypertension, reduced exercise capacity, increased plasma levels of biomarkers 
(e.g. NT-proBNP) and arrhythmias (e.g. atrial fibrillation), since all these variables 
are associated with worse prognosis if treated medically.w2-w3 However, most of 
these variables are encountered only once AS or MR have progressed significantly, 
leading to suboptimal clinical outcomes after surgery.w2-w3
Accordingly, markers that could identify early structural and functional abnor-
malities of the LV are needed to potentially facilitate the decision for timing of 
surgery thereby improving clinical outcomes. In both AS and MR, ultra-structural 
changes of the LV with expansion of the extracellular matrix and fibrosis formation 
may occur due to pressure and volume overload, respectively.w4-w5 Fibrosis causes 
increased LV stiffness, leading to diastolic dysfunction and subtle worsening of 
systolic function, whereas overt LV systolic dysfunction (reduced LVEF) will occur 
later in the course of AS and MR.
Focal fibrosis reflects scar tissue formation by replacement of dead myocardial 
cells by collagen, which is observed after myocardial infarction, for example. In 
valvular heart disease however, pressure or volume overload predominantly cause 
diffuse interstitial fibrosis, a distinct type of fibrosis.w4-w6 This type of fibrosis in-
creases the interstitial collagen without notable cell loss and therefore it may be 
(partially) reversible.w6 
Recently, a rapid development in non-invasive imaging technology has occurred 
which may permit direct or indirect assessment of LV fibrosis. Particularly new car-
diac magnetic resonance (CMR) techniques (with or without contrast agents) permit 
direct assessment of LV fibrosis, whereas strain imaging with advanced echocar-
diographic techniques or CMR can be used to detect subtle systolic LV dysfunction 
(while LVEF is still normal), which provides an indirect reflection of LV fibrosis. This 
article provides an overview of these non-invasive imaging techniques and the 
potential role for early detection of structural and functional LV abnormalities in 
patients with AS or MR. In Table 1, a summary is provided of direct and indirect 
imaging techniques for quantitative or qualitative fibrosis evaluation.2 In the para-






































































































































































































































































































































































































































































































































































IMAgINg TEChNIQuES FOR DIRECT ASSESSMENT OF LV FIBROSIS
1. Delayed contrast-enhanced cardiac magnetic resonance
Delayed contrast-enhanced cardiac magnetic resonance (CMR) has become the 
gold standard imaging technique to assess and quantify focal fibrosis in the 
left ventricle. Gadolinium chelates are extracellular contrast media that do not 
penetrate intact cell membranes and accumulate in the myocardial extracellular 
space. Several minutes after intravenous administration, the contrast agent is 
trapped into the expanded extracellular space and (after nullifying the signal of 
the myocardium), is visualized as increased signal intensity (white) compared to 
normal myocardium (black) (Figure 1).3 However, detection of diffuse LV fibrosis 
with delayed contrast-enhanced CMR standard techniques may be difficult since 
this technique relies on relative signal differences between normal myocardium 
and interstitial collagen.
Figure 8.1
Delayed contrast-enhanced cardiac magnetic resonance patterns that can be observed in patients with severe aor-
tic stenosis (AS). A. Absence of delayed enhancement. B. Anterior and septal sub-endocardial contrast-enhance-
ment, similar to that noted in infarcted myocardium. C. Focal spots of contrast-enhancement in the lateral midwall 
(arrows). D. Linear septal midwall contrast-enhancement. E and F: Midwall contrast-enhancement of the lateral wall 
( arrows). With permission from Dweck et al. J Am Coll Cardiol 2011;58:1271-9.
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2. T1 weighted cardiac magnetic resonance
For assessment of diffuse LV fibrosis, where there is no clear differentiation be-
tween normal and diseased myocardium, T1 weighted CMR imaging techniques are 
increasingly applied. T1 weighted techniques are based on the energy released by 
the tissue (protons) after applying radiofrequency pulses. This relaxation process 
follows an exponential formula that includes a time constant, the so-called T1 
time. The shorter the T1 time constant is, the faster the relaxation process. T1 time 
can be assessed prior to (native T1) or after (post-contrast T1) contrast administra-
tion using a variety of possible techniques with multiple or single breath-holds 
(Figures 2 and 3).4 
Normal native T1 values range between 900 and 1100 ms and increase in 
circumstances of increased density of protons (water content or edema).4 The 
Figure 8.2
T1 relaxation time assessment by cardiac magnetic resonance. A. Sequential images at the same cardiac phase 
of different heartbeats are acquired after an inversion pulse, thereby obtaining a multitude of different inversion 
times. T1 recovers secondary to longitudinal magnetization paralleled by inversion time increment. B. T1 relax-
ation curves are constructed after data sorting by inversion time. Post-contrast shorter T1 relaxation time is seen 
in areas of myocardium with increased interstitium (fibrosis, inflammation) (red curve) versus normal myocardium 
(green curve). C. Epicardial inflammation is seen on the T1 map (red region and yellow arrows). D. By inverting the 
pixel values, an R1 map (1/T1) can be generated providing visualization of regions of fibrosis similar to conven-









measurement of native T1 time is also highly dependent on the magnetic field 
strength and acquisition techniques.5,w7
Post-contrast T1 weighted techniques have been used more frequently to as-
sess diffuse LV fibrosis. After continuous or bolus gadolinium contrast administra-
tion, the volume distribution of contrast media is higher within the interstitium 
or fibrotic myocardium than in normal myocardium, resulting in a shortened T1 
time.4,w7 The relative shortening in T1 time is related to the extent of myocardial 
fibrosis. Renal clearance, acquisition protocol, contrast dose, body composition 
and hematocrit may significantly affect the absolute post-contrast T1 value.5 To 
partially overcome these limitations, quantification of extracellular volume (ECV) 
has been developed.4,w7 The ECV is estimated by calculating the volume distribu-
tion of gadolinium in the extracellular myocardial space relative to the blood in 
a dynamic steady state. In the myocardial tissue, the contrast exchange rate with 
the blood is higher than the net clearance of the contrast from the blood, which 
defines the dynamic steady state. This dynamic steady state can be achieved with 
continuous intravenous infusion of gadolinium (until the T1 in the myocardium 
and blood pool are constant) or following an intravenous bolus of gadolinium 
(assuming equilibrium between the concentration of contrast in blood pool and 
Figure 8.3
Native T1 relaxation mapping in aortic stenosis. Mid-ventricular short-axis color-coded T1 maps (upper row) and 
corresponding delayed contrast-enhanced cardiac magnetic resonance images. Examples (from left to right) of a 
normal individual (T1=944 ms), a patient with moderate AS and moderate left ventricular hypertrophy (T1=951 
ms), and a patients with severe AS and severe hypertrophy (T1=1020 ms). With permission from Bull et al. Heart 
2013;99:932-7.
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myocardium at each time point after the bolus).4, 5 The T1 time is then calculated 
according to the formula: (1-Hematocrit) x (post 1/T1myocardium - pre 1/T1myocardium) / 
(post 1/T1blood - pre 1/T1blood) where the factor (1-Hematocrit) represents the volume 
distribution of gadolinium in blood pool.5 Normal ECV values range between 24% 
and 28% of the myocardium.4 Both myocardial T1 and ECV can be visually repre-
sented by color-coded maps of the left ventricle. ECV represents a very promising 
biomarker of diffuse myocardial fibrosis closely correlated with collagen extent. 
However, its assessment is technically challenging and needs further standardiza-
tion to allow accurate and reproducible measurements during single-breath-hold 
without confounding effects of heart-rate and through-plane motion.4 To optimize 
T1 scan planning and acquisition, and to standardize analysis, a recent expert 
consensus document has been produced.6
3. Calibrated integrated backscatter with echocardiography
Collagen and water content affect myocardial tissue reflectivity of ultrasound 
waves. Dedicated off-line cardiac ultrasound software permits evaluation of tis-
sue reflectivity amplitudes, sampled at the pericardium and the LV myocardium 
at different locations. Subsequently, calibrated integrated backscatter (IBS) is cal-
culated by subtraction of mean backscatter intensity of the pericardium from the 
LV myocardium (Figure 4).2 Higher IBS values (less negative) suggest larger diffuse 
fibrosis burden, as validated by in vivo biopsy specimens.w8 Echocardiographic IBS 
offers relatively easy and fast assessment of LV fibrosis, but the main limitations 
include reduced inter- and intra-observer reproducibility due to noise, confound-
ing effects of the location of the sample volume, artefacts and dependence on the 
settings of the ultrasound systems.7
Figure 8.4
Calibrated integrated backscatter (IBS) in aortic stenosis. A. Normal subject: with values of calibrated IBS of the 
septum and posterior wall of -26.9 dB and -29.3 dB, respectively (after subtracting the value of the pericardium, 
in red). B. Patient with severe aortic stenosis shows increased calibrated IBS (less negative) of the septum (-7.5 dB) 










Molecular imaging of fibrosis comprises direct visualization and quantification 
of radionuclide tracers that bind to specific molecular or cellular compounds 
involved in the pathogenesis of myocardial fibrosis. Integrins, matrix metal-
loproteinases, angiotensin converting enzyme (ACE) inhibitors, angiotensin II 
receptor antagonist, factor XIII and collagen constitute the main targeted agents 
for molecular imaging of fibrosis.w6 So far, the studies evaluating the role of mo-
lecular imaging to assess fibrosis have focused on animal models of myocardial 
infarction and ischemic heart failure and there are no data on fibrosis associated 
to valvular heart disease.w6,w9 The use of integrins, matrix metalloproteinases and 
factor XIII as targeted agents permits assessment of early inflammatory response 
and wound healing process of the infarcted tissue and therefore may predict LV 
remodeling. In contrast, collagen-targeted CMR contrast agents or radiolabeled 
ACE-inhibitors or angiotensin receptor antagonists have been developed to char-
acterize postinfarction myocardial fibrosis and LV remodeling. In mouse models 
of chronic myocardial infarction, the use of gadolinium-based collagen-targeted 
contrast agent (EP-3533) for in vivo CMR imaging of myocardial fibrosis has shown 
feasible.w10 On dynamic T1-weighted CMR data, the washout time constants of 
the targeted agent (EP-3533) was significantly longer than those for gadolinium 
alone in the regions of scar (194.8±116.8 min vs 25.5±4.2 min and 45.4±16.7 
min vs 25.1±9.7 min, respectively, p<0.05 for both) which suggest improvement in 
visualization and characterization of scar.w10 The cardiac renin-angiotensin system 
is enhanced in cardiac hypertrophy and fibrosis and the development of targeted 
radiolabeled agents have permitted in vivo imaging of angiotensin converting 
enzyme activity in the myocardium with positron emission tomography (PET) and 
single photon emission computed tomography (SPECT).8 By using a high-affinity 
analog of lisinopril radiolabelled with 99mTechnetium, the tissue upregulation of 
angiotensin converting enzyme in heart failure may be visualized with SPECT-CT. 
This molecular imaging may help to identify the patients at high risk to develop 
overt heart failure in whom a more aggressive therapeutic strategy may be needed 
to improve the prognosis. However, molecular imaging of fibrosis is currently 
restricted to research and further histological validation is needed.
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IMAgINg TEChNIQuES FOR INDIRECT ASSESSMENT OF LV FIBROSIS
1. Strain and strain rate imaging with echocardiography and cardiac 
magnetic resonance
Deformation imaging comprises quantitative assessment of the magnitude of 
myocardial fiber contraction and relaxation (myocardial mechanics).9 Strain refers 
to the relative change of myocardial fiber length over time and is expressed as a 
percentage with positive and negative values reflecting myocardial shortening or 
thickening and lengthening or thinning, respectively. Strain rate refers to change 
of strain per unit of time. Deformation imaging is highly sensitive to detect subtle 
changes in systolic LV function, even before LVEF becomes reduced (Figure 5) or 
LV dilatation occurs.10 ,11 
Early loss of longitudinal deformation is observed in the majority of cardiac 
disorders and is inversely associated to the presence and extent of fibrosis (re-
duced elasticity) in both ischemic and non-ischemic cardiomyopathies. Intrinsic 
contractility, loading conditions as well as chamber geometry influence myocar-
dial deformation.12 Accordingly, deformation imaging represents an indirect and 
non-specific measure of fibrosis.2 
Quantitative deformation analysis can be performed with echocardiographic 
imaging techniques such as tissue Doppler imaging (TDI) or 2-dimensional speckle 
tracking echocardiography (STE), but also with CMR using tissue tagging. TDI as-
sesses myocardial tissue velocities to calculate strain (rate). However (as with any 
Doppler technique), TDI-derived strain is dependent on the insonation angle and 
Figure 8.5
Differences in left ventricular strain in patients with normal ejection fraction. A. Normal subject with normal global 
longitudinal strain (GLS, -21.5%) and left ventricular ejection fraction (LVEF 65%). B. Patient with severe aortic 
stenosis, LV hypertrophy and subclinical LV dysfunction shown by reduced GLS (-11.3%) despite preserved LVEF 
(62%). C. Impaired GLS (-18.6%) in a patient with LV dilatation, due to severe organic mitral regurgitation, despite 









strain can only be assessed accurately in those LV segments which are properly 
aligned along the ultrasound beam.7 STE, developed more recently, assesses myo-
cardial displacement to calculate deformation, based on 2-dimensional (or even 
3-dimensional) spatial tracking of ‘speckles’ (natural acoustic markers present in 
bimodal echocardiographic images) throughout the cardiac cycle. This technique 
operates at lower frame rates and is angle-independent. Therefore comprehensive 
function analysis including longitudinal, circumferential and radial function as 
well as rotational mechanics can be studied for all myocardial segments. Recent 
advances also allow differentiation between epicardial and endocardial layers. 
High quality grey-scale images are required for proper tracking and definition of 
the region of interest confined to the LV myocardium. Absolute values might differ 
between software vendors due to different speckle tracking algorithms.7, 9 
CMR tissue tagging is a complex technique of spatial modulation of cardiac tissue 
magnetization. Specific magnetic field gradients and time series of radiofrequency 
pulses ‘taggs’ the myocardium, creating a dark line grid that can be followed dur-
ing subsequent acquisitions throughout the cardiac cycle. This permits assessment 
of LV displacement and strain (rate) calculation. Similar to STE, it allows compre-
hensive analysis of longitudinal, circumferential and rotational mechanics of the 
LV myocardium.w11 The technique is not widely available, requires expertise and is 
currently restricted for research.
2. Perfusable tissue fraction and index with positron emission tomography
Focal or diffuse myocardial fibrosis can be also detected with PET using 15O-labeled 
water and carbon monoxide (C15O) as radiotracers and quantifying the perfusable 
tissue fraction and index of the LV. The perfusable tissue fraction is defined as 
the fraction of tissue capable to exchange 15O-labeled water within a region of 
interest while the perfusable tissue index is the proportion of 15O-labeled water-
perfusable tissue within the anatomic tissue derived from the transmission scan. 
Increased myocardial fibrosis diminishes exchangeability of water leading to a 
low perfusable tissue index.2 A reduction in the perfusable tissue index has been 
correlated with increasing extent of LV fibrosis after myocardial infarction.w12 In 
addition, compared with healthy volunteers, patients with hypertrophic cardiomy-
opathy show a decreased perfusable tissue index in the non-hypertrophied lateral 
wall suggesting the presence of diffuse fibrosis.w13 In light of these observations, 
it would be expected that patients with severe AS and LV hypertrophy for example 
could also show reduced perfusable tissue index, although currently no such data 
are available.
– 156 –
RELEVANCE OF FIBROSIS IMAgINg IN AORTIC STENOSIS
In AS, the increased wall stress due to pressure overload is initially compensated 
by concentric LV hypertrophy to maintain normal cardiac output. This structural 
remodeling often coincides with development of predominantly reactive (diffuse 
interstitial) and later replacement (focal) fibrosis as a result of a complex interplay, 
mainly determined by up-regulation of the renin-angiotensin-aldosterone system, 
transforming growth-factor β and tissue inhibitors of matrix metalloproteinases.
w4,w14-w15 Interestingly, the fibrotic response (similar to the extent of LV hypertro-
phy) may vary substantially between patients despite similar AS severity, indicat-
ing multi-factorial pathophysiology.3 While calcification is established as the main 
determinant of progressive valve narrowing, fibrosis initiates transition from com-
pensating LV hypertrophy towards adverse LV remodeling, functional impairment 
and poor outcome in patients with severe AS (Table 2).w4,w14-w15 The pathophysi-
ological mechanism relating myocardial fibrosis to adverse prognosis in patients 
with AS is debated but probably involves deterioration of diastolic and systolic LV 
function as well as substrate formation for atrial/ventricular tachy-arrhythmias.
w14 Hence, fibrosis could be a strong biomarker of early cardiac dysfunction in 
severe AS implying increased mortality risk and may prove useful to select optimal 
timing for aortic valve replacement. Currently symptomatic status or LVEF<50% 
is considered a class I indication for valve replacement in patients with severe 
AS.w3 However, most patients are asymptomatic and have normal LVEF. Moreover, 
few non-randomized studies demonstrated significant survival benefit with earlier 
intervention.w16-w17 These findings point out the clinical need for additional mark-
ers in patients with severe AS to optimize timing of intervention. A non-invasive 
imaging technique that detects and quantifies fibrosis, and correlates to outcome 
may be of use.
Experience with fibrosis imaging in aortic stenosis
Focal fibrosis is detected in 30% to 60% of patients with severe AS using de-
layed contrast-enhanced CMR and comprises between 3% and 7% of the LV 
myocardium, depending on the population.3,13,14,15,w18-w19 Often, the distribution 
of fibrosis is patchy, multifocal and restricted to (often basal) subendocardial or 
mid-wall myocardial layers (Figure 1).3,13,w18 Excessive activation of the cardiac 
renin-angiotensin system, direct mechanical forces and ischemia due to an imbal-
ance between the increased myocardial mass and the relatively reduced capillary 
flow reserve are proposed pathophysiological mechanisms for this replacement 
fibrosis. 3,13,w18 A positive correlation between fibrosis degree on the one hand, and 









higher fibrotic burden in the LV demonstrated in low-gradient severe AS patients, 
irrespective of LVEF.w20 More extensive fibrosis on delayed contrast-enhanced CMR 
in AS patients is associated with heart failure symptoms and increased NT-proBNP 
levels.15 In 58 patients with symptomatic severe AS, Weidemann et al. observed 
that patients without fibrosis significantly improved in New York Heart Association 
(NYHA) functional class, LVEF and showed LV reverse remodeling after surgical 
valve replacement, contrary to patients who showed focal fibrosis in ≥2 LV seg-
ments.15 Focal fibrosis remained unchanged for all patient groups postoperatively, 
indicating irreversible myocardial damage (macroscopic scar formation).15 A more 
recent study (including 28 symptomatic AS patients) extended these results 
showing that the degree of fibrosis was independently associated with survival 
(irrespective of age), LVEF and symptomatic status.w18 This independent relation 
was confirmed by Dweck et al. in 143 patients with moderate (40%) and severe 
(60%) AS.3 Those patients with mid-wall hyperenhancement had 5-fold increased 
Table 8.2
Correlations between the extent and severity of left ventricular fibrosis on non-invasive imaging and clinically 
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tion, TDI: Tissue Doppler Imaging
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all-cause mortality (HR 5.35; 95% CI 1.16-24.56). Patients with mid-wall enhance-
ment who underwent aortic valve surgery had better survival than those treated 
conservatively but worse compared to surgically treated patients without fibrosis. 
Interestingly, almost half of the deaths occurred in patients with only moderate 
AS and mid-wall fibrosis, underscoring the prognostic relevance of focal fibrosis.3
Focal fibrosis, however, occurs at later disease stages, while diffuse fibrosis is 
the predominant pattern in AS patients. Higher septal IBS values, correlating with 
diffuse fibrosis histology, were shown in 35 severe AS patients (Figure 4).w21 The 
presence of significant LV fibrosis, defined as a value of end-diastolic IBS of the 
septum indexed to the pericardial IBS >56.6%, permitted identification of patients 
with LV dysfunction. In addition, significant LV fibrosis assessed with calibrated IBS 
was associated with lack of LVEF improvement after valve replacement.w21 A reduc-
tion of IBS values after surgical replacement suggests at least partial reversibility 
of diffuse fibrosis (or reduced water content due to cell volume reduction) in AS 
patients and could predict LV reverse remodeling.w22 Recent development of T1 
mapping techniques has renewed interest on diffuse fibrosis imaging in this group 
of patients. Various studies have correlated several parameters derived from na-
tive and post-contrast T1 mapping CMR techniques. In 18 patients with severe 
AS the correlation between contrast-enhanced T1 weighted CMR derived ECV and 
histological quantification of myocardial fibrosis was assessed.w23 ECV showed 
a strong linear correlation with histological collagen volume fraction (r2 = 0.86), 
suggesting the potential of T1 weighted CMR for fibrosis assessment.w23 However, 
using native T1 mapping, Bull et al. showed a modest correlation between native 
T1 values and histological collagen volume fraction in 19 patients with severe AS 
undergoing aortic valve replacement (Figure 3).16 These findings suggest a signifi-
cant variability among the different methodologies to assess diffuse myocardial 
fibrosis (Table 3).16,17,w18,w21,w23 Independently of the T1 mapping CMR technique 
used, all studies showed that patients with AS have increased diffuse myocardial 
fibrosis.16,w23 Bull et al. reported higher native T1 values in symptomatic (1014±38 
ms) versus asymptomatic (972±33 ms) AS patients.16 In addition, Flett et al. 
showed higher ECV (18.1±8.1 versus 13.4±6.5 %, p<0.05) in 63 patients with AS 
as compared to 30 control patients and this parameter was an important predictor 
of 6-minute walking distance.14 After valve surgery ECV (as a measure of diffuse 
fibrosis) remained unchanged and 80% of patients who died within the first 6 
months were within the upper ECV tertile.14 However, the considerable overlap of 
the T1 mapping results between the patients with AS versus control individuals as 
well as reproducibility issues may currently limit the use of this technique for indi-
vidual patients.14 In addition to direct fibrosis assessment, reduction in LV function 









is inversely correlated to extensive histological fibrosis (r = -0.57).w15 However, the 
vast majority of patients with AS have preserved LVEF, since LVEF mainly reflects 
radial function, which is preserved in hypertrophied hearts until end-stage of the 
disease.w24-w25
In patients with AS however, fibrosis mainly affects subendocardial to mid-wall 
layers of the myocardium that determine longitudinal LV function. Weidemann et 
al. showed an inverse relationship between the extent of fibrosis and LV longi-
tudinal strain (rate) in patients with severe AS.15 Many patients with severe AS 
and preserved LVEF present with impaired longitudinal deformation.11 In more 
advanced disease stages, impaired LV radial and circumferential strain, corre-
sponding to more transmural myocardial fibrosis, have been reported.11 The main 
determinants of global LV longitudinal strain in AS patients are stenosis valve 
severity, global afterload (valvulo-arterial impedance), LV mass, fibrosis and con
tractility.11,12,15,w20,w26-w27 Since all these determinants show a significant relation 
with outcome in patients with AS, detection of subtle LV dysfunction by strain 
imaging may improve risk stratification (and therapeutic decision making). Indeed, 
reduced LV longitudinal function relates to exercise intolerance and was the single 
independent predictor of mortality or heart failure hospitalization after valve 
replacement in symptomatic patients with severe AS.w27-w28 Importantly, LV lon-
gitudinal deformation was an independent predictor of death or symptom-driven 
valve replacement in asymptomatic patients with severe AS and preserved LVEF. In 
particular, a global LV longitudinal strain value >-15% indicated worse event-free 
survival.w29
RELEVANCE OF FIBROSIS IMAgINg IN MITRAL REguRgITATION
Assessment of myocardial fibrosis in patients with organic MR is of interest since 
early detection of associated LV and left atrial (LA) structural changes may help to 
Table 8.3
Correlations of non-invasive imaging versus histology based fibrosis assessment in valvular heart disease patients 
(all p<0.05).
Study Imaging technique Nr patients, type of valve disease Correlation
Di Bello et alw21 Calibrated integrated backscatter 35, AS r = 0.74
Camelli et al17 Longitudinal left atrial strain 46, MR r = - 0.82*
Azevedo et alw18 Delayed contrast-enhancement 28, AS r = 0.69
Bull et al16 Native T1 relaxation time 19, AS r = 0.66
Flett et alw23 T1 based extracellular volume 18, AS r2 = 0.86
* Correlated to left atrial biopsy.
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identify patients who may benefit from surgical valve repair while still asymptom-
atic. In contrast, in functional (ischemic) MR, there is often extensive focal fibrosis 
with severe structural LV changes due to scar formation after previous infarction, 
and therefore detection of diffuse fibrosis may not help in the timing of surgery.
Organic MR comprises primary abnormalities of the mitral valve morphology and 
causes volume overload of both the LV and the LA, leading to chamber dilata-
tion and eccentric LV hypertrophy. In contrast to concentric pressure overload LV 
hypertrophy (as noted with AS), the eccentric LV hypertrophy caused by chronic 
volume overload associated with organic MR is less pro-fibrotic.w30 A recent study 
involving rat surgical models of pressure and volume overload attempted to 
explain this phenomenon.w31 Compared with pressure overload models, volume 
overload models showed less myocardial ischemia and replacement fibrosis.w31 
In addition, proteolytic activity in large animal models of MR, has been related 
to reduced support and content of extracellular matrix in eccentric hypertrophy, 
thereby facilitating LV dilatation.w31-w32 Although MR is less pro-fibrotic than AS, 
increased interstitial tissue in the LV on biopsies obtained in patients undergoing 
mitral valve repair/replacement is suggested to contribute to development of car-
diac failure.w33 Moreover, histology revealed a larger content of subendocardial dif-
fuse LV interstitial fibrosis in patients with MR as compared to patients without MR 
(18% versus 4%, p<0.05).w34 Similar to AS, compelling evidence points out that LV 
fibrosis in MR relates to LV dilatation, functional impairment and adverse outcome. 
These findings may impact on timing of surgery in patients with severe organic MR. 
Development of symptoms or LV dysfunction (LVEF ≤60% or LV end-systolic di-
ameter ≥40-45 mm) are class I indications for mitral valve surgery in patients with 
severe organic MR.w3 However, these indications should probably not be awaited 
for, as surgical outcome seems better in absence of these characteristics.18,w35-w36 
Additional risk stratification is therefore warranted and (indirect) fibrosis imaging 
may be of importance.
Experience with fibrosis imaging in organic mitral regurgitation
In organic MR, indirect myocardial fibrosis assessment has been obtained using 
strain imaging. In contrast, CMR, IBS or molecular imaging studies in patients with 
MR are scarce. Similar to patients with AS, most MR patients have preserved LVEF. Of 
note, in significant MR supra-normal LVEF values defines normal systolic function 
due to coincidence of increased preload and reduced afterload during the initial 
compensated phase. Subclinical LV dysfunction despite preserved LVEF, assessed 
by impaired LV longitudinal strain, however, is often encountered in asymptomatic 
patients with severe MR (Figure 5).10 More advanced disease stages are associ-









of LV longitudinal strain in MR are regurgitant volume, LV geometry (dilatation) 
and intrinsic contractility, related to myocardial fibrosis.10,w38-w39 Reduced strain in 
MR patients may therefore parallel LV geometric changes (dilatation) rather than 
contractility impairment, and therefore, some authors have advocated to correct 
the LV strain values for LV dimensions.10,12 
In a large series of 233 patients with moderate-severe MR and overall preserved 
LVEF, Witkowski et al. showed that impaired longitudinal LV strain together with LV 
end-systolic dimension predict postoperative LV dysfunction (LVEF <50%), inde-
pendently of baseline LVEF ≤60%, symptoms and atrial fibrillation.19 In particular, 
a global LV longitudinal strain value ≥-19.9% predicted long-term LV dysfunction 
after mitral valve repair with a sensitivity and specificity of 90% and 79%, respec-
tively.19 Additionally, impaired recruitment of longitudinal contractility by strain 
imaging during exercise was also associated with post-operative LV dysfunction in 
patients with preserved LVEF undergoing surgery for severe MR.w40 Pre-operative 
high-normal LVEF may be misleading and mask latent LV dysfunction that is only 
observed post-operatively when acute preload reduction leads to LVEF decrease 
below normal values.19,w41 Whether impaired LV longitudinal strain also predicts 
worse survival after valve intervention remains to be demonstrated.
Not only the LV, but also the LA has been the subject of research. Recently, a 
close inverse correlation between left atrial global (reservoir) strain and histologi-
cal interstitial fibrosis in patients with severe organic MR (r = -0.82) was shown 
(Figure 6).17 The potential clinical relevance of such findings was explored in 
another study involving 121 patients with severe MR.20 Impaired global LA longitu-
dinal (reservoir) strain was related to long-term mortality after mitral valve surgery, 
incremental to guideline based indications for mitral surgery and LA size.20, w3 LA 
strain could potentially predict post-operative survival in patients with severe MR, 
without guidelines-based risk factors (Figure 7).20 Apart from myocardial deforma-
tion, both delayed contrast-enhancement CMR and, more recently, T1 weighted 
imaging of the LA have shown correlation to LA fibrosis.w42-w43 However, no data 
exist on assessment of LA fibrosis with CMR techniques in patients with severe MR.
uNRESOLVED ISSuES 
Based on these experimental and clinical studies, the question remains whether 
fibrosis may help in the decision when to intervene in asymptomatic AS patients 
with preserved LVEF. Various other issues need further study to define the pre-
cise role of LV fibrosis for risk stratification and decision-making strategies. For 
example, is fibrosis independent from and superior to other risk factors currently 
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Figure 8.6
Relation between extent of left atrial fibrosis and left atrial reservoir strain in patients with severe mitral regurgita-
tion. Four patients operated on for severe mitral regurgitation with (from left to right) progressive left atrial dilata-
tion corresponding to more impaired left atrial function (reservoir strain, decreasing from 45% to 9%) and larger 
extent of fibrosis on histology of the left atrial free wall (hematoxylin-eosin and Masson’s trichrome staining). With 











   
   
   
   
   
   
   
   
   
   
   
   














Follow up (years) Follow up (years) Follow up (years)
All patients                                                             
x
(n = 117)
Asymptomatic patients                          
x
(n = 83)
Patients without conventional 
guidelines-based surgical criteria            
(n = 44)
Patients at risk
LA strain > 24 %     49            49            41            21            12                   39            39           32            16            10                   32             32             25            13              9                
LA strain ≤ 24 %     68            62            55            22            13                   44            43           39        26            16                   12              12            11             9               4   
Log rank p=0.036Log rank p=0.024 Log rank p=0.060
LA-strain > 24% LA-strain > 24% LA-strain > 24%
LA-strain ≤ 24% LA-strain ≤ 24%
LA-strain ≤ 24%
Figure 8.7
Prognostic value of LA strain in patients undergoing mitral valve surgery for severe organic mitral regurgitation. 
Dichotomizing the population based on a cut-off value of LA strain of 24%, patients with an LA strain >24% 
had better cumulative survival compared with patients with an LA strain ≤24%, independently of symptoms or 










used, such as NT-proBNP? In addition, for risk estimation, should LV fibrosis be 
considered as a continuum or should a threshold be applied (if more than a certain 
percentage fibrosis is present in the LV, then surgical intervention should be con-
sidered)? which fibrosis needs to be detected: focal or diffuse fibrosis? And which 
non-invasive imaging technique is optimal for assessment and quantification of LV 
fibrosis? And what will be the precise role of indirect fibrosis assessment using LV 
strain? Moreover, it is not clear whether a potential relation between fibrosis and 
outcome can be extrapolated to patients with different AS severity. And finally, 
does infarct related LV fibrosis alter predictive value in AS patients? 
Similarly, for asymptomatic patients with severe organic MR, the key issue is 
whether strain imaging is specific enough for risk stratification of individual pa-
tients and to justify early intervention in asymptomatic patients with preserved 
LVEF. In addition, would LV or LA strain provide the optimal risk stratification 
and therapy guidance in these patients? And will strain imaging be independent 
and superior to other risk factors, including NT-proBNP? And, if considered for 
risk stratification and therapy guidance, will a threshold of LV and/or LA strain be 
used or a continuum? Moreover, the value of imaging techniques such as contrast-
enhanced CMR or T1 mapping in MR should be explored both for the LV and the LA.
Importantly, apart from fibrosis (extracellular matrix alterations), other factors 
such as cell death, impaired excitation-contraction coupling due to altered calcium 
homeostasis and mismatch between cardiomyocyte and vascular growth contrib-
ute to transition of compensated hypertrophy towards heart failure.w31 Molecular 
imaging of specific signaling pathways involved in these factors may therefore 
provide novel insights and ultimately contribute to risk stratification in patients 
with valvular heart disease.
CONCLuSION
If successfully performed prior to complications arise, surgical correction of AS 
or MR may reverse patients to normal life expectancy. Timing of surgery in as-
ymptomatic patients is currently considered in the presence of reduced LVEF, LV 
dilatation, pulmonary hypertension, reduced exercise capacity, increased plasma 
levels of biomarkers or atrial fibrillation. These markers however, occur relatively 
late in the disease progression, and outcome after surgery is suboptimal. LV fi-
brosis occurs earlier, and may be a future marker to improve therapeutic decision 
making. Novel non-invasive imaging techniques have been developed to detect 
fibrosis directly or to assess subtle changes in LV systolic dysfunction (while LVEF 
is still preserved), secondary to LV fibrosis. Future research is needed to determine 
– 164 –
whether LV fibrosis assessment with these imaging techniques may further refine 
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Left atrial (LA) mechanics in patients with severe mitral regurgitation (MR) remain 
largely unexplored. The present evaluation assessed the effect of severe mitral re-
gurgitation (MR) on left atrial (LA) function, its potential relation with conventional 
surgery indications and long-term postoperative survival.
Methods and Results
2D-speckle tracking strain and volumetric indices of LA reservoir, conduit and 
contractile function were assessed in 121 severe MR patients and 70 controls. 
Patients were divided according to presence (n=46) or absence (n=75) of ≥1 
guidelines-based criteria for mitral surgery (symptoms, left ventricular (LV) ejec-
tion fraction ≤60%, LV end-systolic diameter ≥40mm, atrial fibrillation or systolic 
pulmonary arterial pressure >50mmHg).
In patients with severe MR, as compared to controls, significant LA reservoir and 
contractile dysfunction was observed, which was more pronounced in patients 
with mitral surgery indication (all p<0.05 for strain and volumetric indices). Of all 
LA function indices, LA reservoir strain was an independent predictor (OR=0.88, 
95%CI 0.82-0.94, p<0.001) and had the highest accuracy to identify patients with 
indication for mitral surgery (area under ROC curve=0.8, 95%CI 0.72-0.87). A total 
of 117 patients underwent mitral valve surgery. Patients with LA reservoir strain 
≤24% showed worse survival at a median of 6.4 years (4.7-8.7 years) after mitral 
surgery (p=0.02), regardless the symptomatic status prior to surgery. LA reservoir 
strain, on top of mitral surgery indications, provided incremental predictive value 
for postoperative survival.
Conclusion
Impaired LA reservoir strain in patients with severe organic MR relates to long-term 
survival after mitral valve surgery, independently of and incremental to current 










Severe chronic mitral regurgitation (MR) causes a significant left atrial (LA) volume 
overload, leading to LA dilatation as compensatory mechanism to maintain LA pres-
sure homeostasis and prevent pulmonary congestion.1 Measures of LA remodeling, 
such as LA diameter and LA volume index, have been shown to predict outcome in 
patients with severe organic MR, and are helpful for risk stratification and clinical 
decision-making in these patients.2-4 However, chronic MR may induce significant 
LA ultra-structural changes, potentially affecting LA myocardial contractility and 
relaxation before LA dilatation occurs.3,5-8 Therefore, assessment of LA function, 
rather than dimension, might be of significant value to guide therapy in patients 
with severe MR. However, data on the effect of severe MR on LA function are scarce 
and the potential incremental value of LA function assessment to predict timing 
for surgery is unexplored.9-12 
Different LA functions can be evaluated, including reservoir (storage of pulmo-
nary venous inflow during ventricular systole), conduit (passive emptying during 
early diastole) and contractile (active emptying at late diastole) functions. These 
sequential LA functions play a crucial role in cardiac performance by optimizing left 
ventricular (LV) filling,13,14 and can be measured with conventional 2-dimensional 
(2D) echocardiography by detecting the phasic changes of LA volume during the 
cardiac cycle. More recently, 2D speckle tracking longitudinal deformation (strain 
and strain rate) imaging also showed accurate characterization of all phases of LA 
function.14-18
Therefore, the aim of this study was 1) to characterize LA reservoir, conduit and 
contractile function using 2D-speckle tracking deformation imaging in patients 
with chronic severe organic MR, 2) to determine its clinical relation to the presence 
of guidelines-based conventional indications for mitral surgery and 3) to explore 
its association with long-term survival after mitral valve surgery.2,19
METhODS
Patient population
The patient population consisted of patients presenting with chronic severe 
organic MR, who were referred to our centre within the last decade. Clinical and 
echocardiographic data were prospectively collected in the departmental Cardiol-
ogy Information System (EPD-Vision®, Leiden University Medical Center, Leiden, 
and the Netherlands) and retrospectively analyzed.
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Clinical assessment included demographics, medications, identification of co-
morbidities and symptoms according to the New York Heart Association (NYHA) 
functional class. Echocardiographic evaluation included conventional measure-
ments and speckle tracking analysis for LA deformation analysis. Patients with prior 
cardiac surgery or myocardial infarction, congenital heart disease, concomitant 
mitral stenosis exceeding mild severity (mean gradient ≥5 mmHg) or significant 
aortic valve disease were excluded. In addition, in order to avoid confounders for 
increased pulmonary pressure, patients with significant pulmonary disease were 
excluded.
Patients were further dichotomized based on the presence of ≥1 conventional 
criterion for mitral surgery indication, according to current guidelines: NYHA class 
3 to 4 symptoms, LV ejection fraction (EF) ≤60 %, LV end-systolic diameter ≥40 
mm, atrial fibrillation or systolic pulmonary arterial pressure at rest >50 mmHg.2 
Accordingly, phasic LA functions were evaluated in both patient groups.
In addition, 70 individuals with similar age, body surface area and gender dis-
tribution served as a control group. These subjects underwent clinically indicated 
echocardiography for evaluation of potential cardiac symptoms, murmur or in-
creased cardiovascular risk profile, but all showed absence of significant structural 
or functional abnormalities.
A total of 117 (97%) patients underwent mitral valve surgery at a mean of 85 
± 19 days after the baseline echocardiographic exam. This practice is in line with 
current guidelines, advocating that early mitral valve surgery may be performed in 
experienced valve centers with high repair rate for patients presenting with severe 
organic mitral regurgitation, despite absence of symptoms or LV dysfunction.2 
All-cause mortality was assessed in all operated patients by reviewing patients’ 
medical files and by evaluation of the official Dutch National Survival Registry for 
patients that were followed by the referring center postoperatively.
Echocardiography
Transthoracic 2D-echocardiography was performed in left lateral decubitus posi-
tion using commercially available ultrasound systems (System-5, Vivid-7 and E9, 
GE-Vingmed, Milwaukee, WI) equipped with a 3.5 MHz transducer. ECG-triggered 
standard 2D gray-scale and color-Doppler images were acquired in cine-loop 
format and transferred to a workstation for off-line analysis (EchoPAC 110.0.0, 
GE Medical Systems, Horten, Norway). Chamber quantification was performed 
conform to current recommendations.20 Left atrial anteroposterior linear diameter 
was measured on 2D left parasternal long axis view. LV and LA volumes were as-
sessed using Simpson biplane method and were indexed to body surface area.20 









guidelines, a multi-parametric integrative approach was used to assess MR sever-
ity (additional transesophageal images were used when available).21 In particular, 
an effective regurgitant orifice area ≥40 mm² or regurgitant volume ≥60 ml, using 
the proximal isovelocity surface area method (PISA), as well as the presence of flail 
mitral leaflet or ruptured papillary muscle defined severe mitral regurgitation. If 
none of these factors were present or PISA was not feasible (due to excentricity of 
regurgitant jet), presence of vena contracta width ≥7 mm in combination with ≥1 
qualitative (large central jet, severe coanda effect, large flow convergence radius, 
dense mitral envelope at continuous wave Doppler) and/or semi-quantitative 
(pulmonary Doppler systolic venous flow reversal, E wave dominance ≥1.5 m/s) 
variable(s) defined severe mitral regurgitation.21 MR etiology was categorized as 
flail (free mitral leaflet edge reversing into the LA), prolapse (mitral leaflet coapta-
tion line behind annular plane without edge reversing into LA) or degenerative 
(degenerative mitral valve abnormalities without flail or prolapse).20 All Doppler 
measurements represented the average of 3 beats and 5 beats if atrial fibrillation 
was present. Mitral inflow was analyzed to assess early flow (E wave), deceleration 
time and mitral valve pressure gradient.22 Early diastolic peak velocity (E`) was 
derived from the lateral wall on the apical four-chamber view color tissue Dop-
pler acquisition. Systolic pulmonary arterial pressure at rest was calculated using 
the maximal tricuspid regurgitant jet velocity and right atrial pressure estimation, 
based on diameter and respiratory variation of the inferior caval vein.20
Left atrial function: volumetric indices
LA volumes were assessed just before mitral valve opening (maximal LA volume, 
Volmax), at mitral valve closure (minimal LA volume, Volmin) and at P-wave onset 
on ECG just before atrial contraction, if sinus rhythm (pre-A LA volume, VolP). As 
previously reported, LA reservoir function was calculated as LA expansion index 
(Volmax - Volmin / Volmin x 100), LA conduit function as LA passive emptying fraction 
(Volmax - VolP / Volmax x 100) and LA contractile function as LA active emptying frac-
tion (VolP - Volmin / VolP x 100).14,17 In patients with atrial fibrillation, LA contractile 
function could not be calculated.
Left atrial function: deformation indices 
LA longitudinal strain and strain rate was assessed with 2D-speckle tracking analy-
sis with QRS onset as the reference point, applying a commercially available LV 
strain software package on the LA (EchoPAC 110.0.0).23 In summary, the region of 
interest was adjusted to include the LA myocardium in both the four-chamber and 
two-chamber apical views that included both the LA and LV. Manual correction was 
performed to optimize tracking results if needed. The values of LA strain and strain 
– 176 –
rate were calculated as the average value of the four-chamber and two-chamber 
view, as described in Figure 1. As previously reported, LA reservoir function was 
calculated as peak systolic LA strain (LA reservoir strain), while LA contractile func-
tion was measured as the LA strain value at P-wave onset on ECG, if sinus rhythm 
(LA contractile strain). Finally, LA conduit function was assessed as the difference 
between LA reservoir and contractile strain (LA conduit strain).15 In addition, LA 
reservoir strain rate was measured as peak systolic positive value, LA conduit 
strain rate as the early diastolic negative peak and LA contractile strain rate as the 
late diastolic negative peak (if in sinus rhythm) (Figure 1). In patients with atrial 
fibrillation, LA contractile strain (rate) could not be calculated.
Fifteen subjects were randomly selected to perform a blinded inter- and 







Assessment of left atrial phasic function by 2D-speckle tracking echocardiography in a control subject. Panel A: 
four-chamber longitudinal strain, panel B: two-chamber longitudinal strain, panel C: four-chamber longitudinal 
strain rate, panel D: two-chamber longitudinal strain rate. The white dotted line represents the mean value of 
the tracked left atrial segments. Reservoir, conduit and contractile phase are represented by color-coded arrows 
(yellow, pink and blue respectively). Measurements are averaged over the four-chamber and two-chamber views. 
In this subject, reservoir, conduit, and contractile strain and strain rate were 38.6%, -22.1%, -16.5% and 1.75 s-1, 









For simplicity reasons, the absolute deformation values were reported as posi-
tive numbers.
Statistical analysis
Continuous variables were presented as mean ± standard deviation and compared 
with independent Student-t test and Mann-Whitney or Kruskal-Wallis tests if not 
normally distributed. Percentages were used for categorical values and compared 
by χ2-test. Multiple group comparisons were performed with one-way ANOVA test 
with post hoc Bonferroni test. Receiver-operating characteristic (ROC) analysis was 
performed to assess the accuracy of various deformation and volumetric indices 
of LA function to predict presence of conventional indications for mitral surgery. 
The optimal cut-off value was obtained by maximizing the sum of sensitivity and 
specificity. Subsequently, multiple logistic regression analysis identified indepen-
dent predictors of the presence of mitral surgery indications. Covariates with a 
significance p<0.05 at univariate level were included in the multivariate logistic 
regression analysis, which was performed using a backward elimination approach. 
In addition, Cox regression analysis including conventional guidelines-based 
criteria for mitral surgery and LA reservoir strain was performed to identify the 
independent determinants of long-term mortality after mitral surgery. To maximize 
the possibility to detect any relationship of this clinical model with post-operative 
mortality, covariates with univariate significance of p<0.10 were introduced in the 
multivariate analysis. Kaplan-Meier curves were constructed to explore differences 
in long-term survival after mitral valve surgery in different patient subgroups that 
were stratified according to LA reservoir strain, using the previously mentioned 
ROC curve-based cut-off value and compared by log-rank test. The incremental 
value of successive conventional guidelines-based criteria for mitral surgery and 
LA reservoir strain to predict postoperative mortality was assessed with the likeli-
hood ratio test: the model containing the covariate of interest was tested against 
the nested model not containing the covariate. Finally, linear regression analysis 
was performed to explore the correlation between LA reservoir strain, LA diameter 
and LA volume indexed to body surface area (LAVI) respectively. Statistical analysis 
was performed using SPSS version 17.0. (SPSS Inc., Chicago, Illinois) and STATA ver-
sion 12.1 (STATA Corp., College Station, Texas) software. All tests were two-sided 




A total of 160 patients with chronic severe organic MR who underwent complete 
clinical and echocardiographic examination were included. Thirty-nine patients 
(24%) with poor acoustic window were excluded. Mean frame rate for echocardio-
graphic exams performed within the first half of the last decade did not significantly 
differ from those performed during the most recent half (56.4 frames/s versus 59.4 
frames/s, respectively, p=0.31). Clinical and echocardiographic characteristics of 
the remaining 121 patients (mean age 63 ± 13 years, 77% men) are summarized in 
Table 1. Overall, a preserved LV systolic function was observed, with mild LV dilata-
tion and severe LA dilatation. Severe mitral regurgitation was documented with a 
mean mitral vena contracta width of 8 ± 0.9 mm, E wave 1.3 ± 0.2 m/s and PISA 
radius of 11 ± 2 mm. Forty-six patients did not have any conventional criterion 
for mitral surgery indication whereas 75 patients had ≥1 criterion. In particular, 
symptoms were present in 34 (28%) patients, LVEF ≤60 % in 19 (16%) patients, 
LV end-systolic diameter ≥40 mm in 27 (22%) patients, atrial fibrillation in 26 
(21%) patients and systolic pulmonary arterial pressure at rest >50 mmHg in 29 
(24%) patients. Of note, no patients presented with LVEF ≤30 %. By definition, 
presence of atrial fibrillation, NYHA class III and IV, LV end-systolic diameter, LVEF 
and pulmonary arterial pressure significantly differed between patients with con-
ventional criteria for mitral surgery versus patients without (Table 1). In addition, 
age, use of β-blockers, use of diuretics, LAVI, MR vena contracta width, E wave and 
deceleration time were significantly different between both groups (all p<0.05).
Left atrial function in severe mitral regurgitation
Patients with severe organic MR showed significantly impaired LA reservoir func-
tion as compared to control subjects, assessed both by volumetric expansion 
index or strain and strain rate (all p<0.001), as indicated in Table 2. In addition, 
LA conduit function assessed with volumetric passive emptying fraction (p=0.20) 
or LA strain rate (p=0.57) did not differ significantly between patients with se-
vere organic MR and controls, whereas LA strain was significantly impaired only 
in patients with severe organic MR (p=0.01). In 95 (79%) patients who were in 
sinus rhythm during echocardiography, LA contractile function was reduced when 











Baseline characteristics of controls and the overall study population with dichotomization according to presence 











( n=75 ) p *
Clinical characteristics
Age, years 63 ± 12 63 ± 13 59 ± 14 66 ± 11 0.008
Men, n (%) 47 (67) 77 (64) 32 (70) 45 (60) 0.30
BSA, kg/m² 1.9 ± 0.21 1.9 ± 0.20 1.9 ± 0.21 1.9 ± 0.20 0.80
AF, n (%) 0 (0) 26 (21) 0 (0) 26 (35) < 0.001
NYHA class, n (%) < 0.001
I 70 (100) 38 (32) 20 (43) 18 (24) 
II 0 (0) 49 (40) 26 (57) 23 (31) 
III 0 (0) 30 (25) 0 (0) 30 (40) 
IV 0 (0) 4 (3) 0 (0) 4 (5) 
Hypertension, n (%) 31 (45) 11 (10) 4 (10) 7 (11) 1.00
Hypercholesterolemia, n (%) 20 (29) 11 (10) 4 (10) 7 (11) 1.00
Diabetes, n (%) 9 (13) 4 (3) 0 (0) 4 (5) 0.30
Smoking history, n (%) 25 (43) 21 (21) 7 (18) 14 (23) 0.20
Medication use, n (%)
β-Blocker 8 (12) 41 (34) 8 (17) 33 (44) 0.003
Diuretic 9 (13) 36 (30) 7 (15) 29 (39) 0.006
ACE-I/ARB 22 (32) 54 (45) 17 (37) 37 (49) 0.20
Statin 21 (31) 20 (17) 5 (11) 15 (20) 0.20
MR etiology 0.13
Degenerative - 7 (6) 1 (2) 6 (8) 
Flail - 40 (33) 12 (26) 28 (37) 
Prolapse - 74 (61) 33 (72) 41 (55) 
Echocardiographic data 
LVESD, mm 25.2 ± 4.1 34.8 ± 6.4 31.9 ± 4.5 36.6 ± 6.7 < 0.001
LVEDVI, mL/m² 55 ± 11 85 ± 21 84 ± 18 87 ± 23 0.70
LVESVI, mL/m² 20 ± 6 28 ± 11 25 ± 7 30 ± 13 0.20
LVEF, % 64 ± 6 68 ± 8 70 ± 5 66 ± 9 0.047
LA diameter, mm 35 ± 4 49 ± 8 46 ± 6 50 ± 8 0.001
LAVI, mL/m² 31 ± 8 76 ± 33 64 ± 23 83 ± 36 0.002
Vena contracta, mm 1.7 ± 1.25 8.0 ± 0.92 7.6 ± 0.81 8.2 ± 0.91 <0.001
E wave, m/s 0.6 ± 0.2 1.3 ± 0.2 1.2 ± 0.2 1.4 ± 0.2 <0.001
E’ 7.3 ± 2.0 8.5 ± 2.1 8.5 ± 1.6 8.6 ± 2.4 0.9
DT, ms 218 ± 49 180 ± 43 189 ± 34 174 ± 47 0.01
PAPsys at rest, mmHg 26 ± 5 43 ± 16 32 ± 8 49 ± 17 <0.001
ACE-I/ARB: angiotensin-converting enzyme / angiotensin receptor blocker, AF: atrial fibrillation, BSA: body surface 
area, DT: deceleration time, EDVI: end-diastolic volume indexed to BSA, EF: ejection fraction, ESD: end-systolic 
diameter, ESVI: end-systolic volume indexed to BSA, LAVI: left atrial volume indexed to BSA, LV: left ventricle, MR: 
mitral regurgitation, NYHA: New York Heart Association, PAPsys: systolic pulmonary artery pressure, *: for compari-
son between patient group with versus without mitral surgery indication
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Left atrial function to predict surgical indication
As summarized in Table 2, LA dysfunction was more pronounced in patients with 
mitral surgery indications versus patients without and all phases of LA function 
(reservoir, conduit and contractile) were affected, either assessed by volumetric or 
deformation parameters. Patients without mitral surgery indications showed im-
pairment of LA reservoir and contractile function but preserved conduit function.
Subsequently, ROC analysis was performed to determine the value of all differ-
ent deformation and volumetric indices of phasic LA function to predict the pres-
ence of guidelines-based mitral surgery indications (Table 3). This analysis showed 
that LA reservoir strain had the highest predictive value among all LA function 
indices, evidenced by an area under the curve of 0.80 (CI 95% 0.72-0.87, Figure 
2A). In particular, a value of LA reservoir strain ≤24 % predicted the presence 
of mitral surgery indications with a sensitivity and specificity of 76% and 72%, 
respectively (Figure 2B).
LA reservoir strain was therefore implemented into further analysis to explore 
the independent predictive value of LA function for the presence of mitral surgery 
indications in patients with severe organic MR. Univariate logistic regression analy-
sis showed that age (OR 1.04, 95% CI 1.01-1.07, p=0.01), use of β-blockers (OR 
3.7, 95% CI 1.5-9.1, p=0.004), use of diuretics (OR 3.5, 95% CI 1.4-8.9, p=0.008), 
Table 9.2
Phasic left atrial function indices of controls and the overall study population with dichotomization according to 
presence or absence of mitral surgery indication.










( n=75 ) p *
Reservoir function
Strain (%)† 31 ± 6.1† 22 ± 8.4 † 27 ± 6.6 † 19 ± 7.7 † <0.001† 
Strain rate (s-1) † 1.25 ± 0.28† 0.95 ± 0.32 † 1.12 ± 0.27 0.85 ± 0.31 † <0.001† 
Expansion index (%)† 191 ± 61† 111 ± 64 † 150 ± 70 † 87 ± 46 † <0.001† 
Conduit function
Strain (%)† 17 ± 5.1† 15 ± 5.0 † 17 ± 4.7† 13 ± 4.7 † <0.001† 
Strain rate (s-1) † 1.08 ± 0.38† 1.0 ± 0.32† 1.14 ± 0.34† 0.98 ± 0.32 † 0.04† 
Passive emptying fraction (%)† 35 ± 9.9† 34 ± 9.6† 37 ± 9.9† 33 ± 9.1 † <0.001† 
Contractile function ‡
Strain (%)† 14 ± 3.0† 9.2 ± 3.5 † 10 ± 3.5 † 8 ± 3.4 † 0.03† 
Strain rate (s-1) † 1.65 ± 0.55† 1.04 ± 0.39 † 1.15 ± 0.4 † 0.94 ± 0.35 † 0.06† 
Active emptying fraction (%)† 44 ± 9.4† 28 ± 11 † 32 ± 12 † 24 ± 10 † 0.001† 
All deformation indices are presented as positive absolute numbers. *: p-value for comparison between patient 










LAVI (OR 1.02, 95% CI 1.01-1.04, p=0.003), MR vena contracta width (OR 2.29, 
95% CI 1.43-3.66, p=0.001) and LA reservoir strain (OR 0.86 95% CI 0.81-0.92, 
p<0.001) were significantly related to the presence of mitral surgery indications 
in patients with severe MR. Multivariate logistic regression analysis subsequently 
identified LA reservoir strain as an independent predictor of the presence of mitral 
surgery indication (OR 0.88, 95% CI 0.82-0.94, p<0.001), together with MR vena 
contracta width (OR 2.04, 95% CI 1.21-3.47, p=0.008) and use of β-blocker (OR 
3.2, 95% CI 1.2-8.7, p=0.03). Each 1% decrease in LA reservoir strain increased 
the risk of having an indication for mitral surgery by 12%.
Left atrial strain and long-term survival after mitral valve surgery
After a median follow-up of 6.4 years (interquartile range 4.7-8.7 years) after 
mitral valve surgery, all-cause mortality occurred in 20 out of the 117 operated 
patients (17%). Cox regression analysis, restricted to LA function (reservoir strain) 
and remodeling parameters (LA diameter and LAVI), together with conventional 
criteria for mitral surgery, indicated that LA reservoir strain, using the ≤24 % 
cut off value (HR 3.8, p=0.04, CI 1.10-12.93), and symptoms (HR 2.3, p=0.07, CI 
0.94-5.71) were related to long-term mortality after mitral valve surgery. In addi-
tion, LA diameter ≥55 m or LAVI ≥60 mL/m2 did not show significant relation with 
postoperative mortality.3,4 At multivariate level, only LA reservoir strain (HR 3.5, 
p=0.045, CI 1.03-12.20) showed to be independently related to mortality (Table 
Table 9.3
Receiver operating characteristic analysis to assess predictive value for presence of conventional guidelines-
based mitral surgical indication(s).
Parameter ROC AUC 95% CI
Reservoir function
Strain (%) 0.80 0.72-0.87 
Strain rate (s-1) 0.75 0.66-0.84 
Expansion index (%) 0.79 0.71-0.87 
Conduit function   
Strain (%) 0.73 0.64-0.82 
Strain rate (s-1) 0.66 0.56-0.76 
Passive emptying fraction (%) 0.60 0.49-0.71 
Contractile function*   
Strain (%) 0.65 0.54-0.76 
Strain rate (s-1) 0.66 0.55-0.77 
Active emptying fraction (%) 0.70 0.59-0.81 
Positive absolute numbers for all deformation indices were used. AUC: area under curve, CI: confidence interval, 
ROC: receiver operating characteristic, *: measured only in 95 out of 121 patients in sinus rhythm.
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4). In addition, likelihood ratio test indicated that assessment of LA reservoir strain, 
using the cut-off value, on top of assessment of conventional guidelines-based 
indications for mitral surgery provides significant incremental value to predict 
long-term postoperative mortality (p=0.03). (Figure 3)
Figure 9.2
Left atrial reservoir strain to predict the presence of mitral surgery indication in patients with severe mitral re-
gurgitation. Panel A: receiver operating characteristic curve. Panel B: sensitivity-specificity curve with vertical line 
indicating a reservoir strain cut-off value of ≤24 % to predict presence of surgical indication with sensitivity of 76 









Kaplan Meier survival analysis showed that patients with baseline LA reservoir 
strain values ≤24 % had worse long-term survival compared with patients with LA 
reservoir strain >24 % (log rank p=0.02) (Figure 3). This association was observed 
also among asymptomatic patients before mitral surgery (n= 83/117, log rank 
p=0.04) (Figure 3). Interestingly, a significant trend towards worse survival was 

































Likelihood ratio test for prediction of long-term mortality after mitral valve surgery. Left atrial reservoir strain 
shows incremental value to predict long-term postoperative mortality in severe organic mitral regurgitation when 
assessed on top of conventional guidelines-based indications for surgery. AF: atrial fibrillation, LVEF: left ventricu-
lar ejection fraction, LVESD: left ventricular end-systolic diameter, NYHA: New York Heart Association, PAP: systolic 
pulmonary artery pressure at rest.
Table 9.4
Cox regression analysis for postoperative all-cause mortality. The relation of currently recommended clinical and 
echocardiographic variables for decision-making in severe organic mitral regurgitation with long-term postopera-
tive mortality is explored.
Variables
Univariate Multivariate
HR (95% CI) p HR (95% CI) p
Symptoms (NYHA 3 or 4) 2.3 0.94-5.71 0.07 2.1 0.86-5.26 0.10
LVEF ≤60 % 1.1 0.31-3.63 0.93
LVESD ≥40 mm 2.0 0.77-4.96 0.16
Atrial fibrillation 1.8 0.70-4.87 0.21
PAPsys at rest >50 mmhg 1.2 0.46-3.20 0.67
LA diameter ≥55 mm 2.5 0.57-10.8 0.23
LA volume index ≥60 mL/m2 1.8 0.58-5.35 0.32
LA reservoir strain ≤24 % 3.8 1.10-12.93 0.04 3.5 1.03-12.20 0.045
CI: confidence interval, HR: hazard ratio, LA: left atrial, LVEF: left ventricular ejection fraction, LVESD: left ventricu-
lar end-systolic diameter, NYHA: New York Heart Association, PAPsys: systolic arterial pulmonary artery pressure.
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underwent early mitral valve surgery despite absence of any conventional surgical 
indication compared to patients with LA reservoir strain >24 % (log rank p=0.06) 
(Figure 4).
Left atrial reservoir strain versus diameter and volume
LA reservoir strain showed significant linear correlation with LA diameter (R -0.57, 
R2 0.33, p<0.001, 95% CI -0.79 to -0.46) and LAVI (R -0.57, R2 0.32, p<0.001, 95% 
CI -0.18 to -0.11) (Figure 5). However, 47 out of 98 patients (48%) with LA diameter 
<55 mm and 15 out of 44 patients (34%) with LAVI <60 mL/m2 had LA reservoir 
strain ≤24 % (Figure 5).
Observer variability
Bland-Altman analysis showed an intra-observer bias of 1.1% (95% CI -4.2 to 
6.4%), -0.02% (95% CI -5,1 to 5.0%) and -1.1% (95% CI -4.5 to 2.3%) for LA 
reservoir, conduit and contractile strain assessment, respectively. Similarly, re-
spective inter-observer biases of -1.3% (95% CI -6.6 to 3.9%), 1.2% (95% CI -2.8 
to 5.1%) and 0.1% (95% CI -4.1 to 4.3%) were noted.
DISCuSSION
The main findings of current study can be summarized as follows: 1) patients 











   
   
   
   
   
   
   
   
   
   
   
   














Follow up (years) Follow up (years) Follow up (years)
All patients                                                             
x
(n = 117)
Asymptomatic patients                          
x
(n = 83)
Patients without conventional 
guidelines-based surgical criteria            
(n = 44)
Patients at risk
LA strain > 24 %     49            49            41            21            12                   39            39           32            16            10                   32             32             25            13              9                
LA strain ≤ 24 %     68            62            55            22            13                   44            43           39        26            16                   12              12            11             9               4   
Log rank p=0.036Log rank p=0.024 Log rank p=0.060
LA-strain > 24% LA-strain > 24% LA-strain > 24%
LA-strain ≤ 24% LA-strain ≤ 24%
LA-strain ≤ 24%
Figure 9.4
Kaplan-Meier survival after mitral valve surgery according to left atrial reservoir strain. Conventional surgical cri-
teria: symptoms, left ventricular (LV) ejection fraction ≤60 %, LV end-systolic diameter ≤40 mm, atrial fibrillation 









voir, conduit and contractile function, 2) LA reservoir strain is an accurate and 
independent predictor of the presence of conventional guidelines-based mitral 
surgery indications and 3) LA reservoir strain relates to long-term survival after 
mitral valve surgery, independently of and incremental to current conventional 
guidelines-based mitral surgery indications.
Phasic LA function in severe MR 
LA reservoir function
During LV systole, pulmonary venous inflow distends the LA, which acts as a 
reservoir by storing energy under the form of pressure.14 LA reservoir function 
is mainly determined by LA compliance (stiffness) and LV systolic function (sys-
tolic apical motion of the LV base, facilitating LA filling), and to a lesser extent 
by right ventricular systole (pulmonary venous inflow). 13,14,24 While increased LA 
reservoir function has been reported in mild MR, due to an initial increase in LA 
compliance,1,9,10 decreased LA reservoir function has been described in patients 
with severe MR, as assessed with several imaging techniques. 9,10,12 Similarly, the 
current study showed that severe MR is associated with a significant reduction in 
LA reservoir function.
Reduced LV systolic function may lead to impaired LA reservoir function as 
previously demonstrated.24 However, in the present study LV ejection fraction was 
preserved in the majority of the patients and therefore this factor may not explain 
per se the impairment of LA reservoir function.
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Figure 9.5
Correlation between left atrial reservoir strain, diameter and indexed volume. LA reservoir strain ≤24 % (associ-
ated with worse survival after mitral valve surgery) is present in 48% and 34% of patients despite LA diameter 
<55 mm and LAVI <60 mL/m2, respectively (purple squares).
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Furthermore, significant ultra-structural changes of the LA myocardium, includ-
ing presence of interstitial fibrosis, myocyte hypertrophy, chronic inflammatory 
changes and decreased capillary density have been reported in patients with se-
vere MR and might cause the reduction in LA reservoir function.5-7,25 In particular, a 
recent study on 46 severe MR patients that underwent mitral valve surgery showed 
a strong negative correlation between histological LA fibrosis and LA reservoir 
strain.26 Ultra-structural changes are due to the chronic volume overload and in-
creased LV filling pressures and significantly affect LA myocardial wall properties, 
such as relaxation and compliance (stiffness), ultimately leading to the observed 
reduction in LA reservoir function.3 
LA conduit function
Following the reservoir phase, the LA functions as a conduit during early diastole, 
allowing for a passive transfer of blood from the pulmonary veins towards the LV. 
LA conduit function is mainly determined by LA elasticity (recoil) and afterload 
(LV relaxation and early LV filling pressure).13,14 In the current study, reduced LA 
conduit function was observed in patients with severe MR and mitral surgery 
indication. Increased early diastolic LV filling pressures have been reported in 
subjects with MR, due to increased atrio-ventricular pressure gradient, increased 
LV stiffness and decreased LA recoil, and might therefore be an explanation of 
impaired LA conduit function in these patients.9,25,27 In addition, ultra-structural 
changes of the LA wall may cause impaired LA elasticity, reducing LA recoil and 
affecting LA conduit function.3,12 
LA contractile function
In patients in sinus rhythm, active LA contraction finalizes LV filling during late 
diastole and depends on LA afterload (LV compliance and end-diastolic filling 
pressure) and LA intrinsic contractility, following Starling’s law.13,14,28 Improved 
LA contractile function has been reported in patients with mild MR and may be 
explained by the fact that LA myocardial wall operates higher on the Frank-Starling 
curve (larger LA volumes leads to higher contractility).9,10,28 In the current study, 
including severe organic MR patients, impaired LA contractile function assessed 
with speckle tracking echocardiography was observed. This finding may be related 
to the presence of a decreased LA contractility, due to exhaustion of the Frank-
Starling mechanism by severe volume overload and to ultra-structural alterations 
of the atrial myocardium. Moreover, increased LA afterload may have also contrib-
uted to the impairment of LA contractile function, since increased LV end-diastolic 









LA reservoir strain and mitral surgical indication 
Optimal timing of surgical treatment of severe organic MR is crucial, particularly 
in asymptomatic patients.2 Current guidelines recommend mitral valve surgery 
based on the presence of symptoms, LV systolic dysfunction, atrial fibrillation 
or pulmonary hypertension, which reflect MR severity and its impact on cardiac 
performance and symptomatic status.2,19 However, severe MR primarily affects the 
LA causing significant LA dysfunction and remodeling, which implies that LA char-
acteristics may indicate the hemodynamic implications of severe MR at an earlier 
stage than conventional criteria for surgical indication.30 The predictive value of 
LA reservoir strain observed in the present evaluation might be explained by the 
fact that reduced LA compliance, and therefore impaired LA reservoir function, is 
directly related to the duration and severity of MR and represents an important 
substrate for the occurrence of symptoms, atrial fibrillation or the development 
of pulmonary hypertension. In fact, decreased atrial compliance due to increased 
LA stiffness may cause inadequate LA pressure homeostasis. Therefore small in-
creases in LA volume may lead to significant increases of LA and pulmonary artery 
pressures, which can be associated with the development of pulmonary hyperten-
sion and symptoms during exercise.13 This has been demonstrated in other clini-
cal conditions, for example in patients with diastolic heart failure.29 Reduced LA 
reservoir strain, and not LA volume, was shown to be associated with the presence 
of symptoms and was directly related to atrial stiffness.29 In addition, LA reservoir 
strain was demonstrated to be inversely related to LA wall fibrosis (affecting atrial 
compliance), and to be associated to a higher burden of atrial fibrillation14. Finally, 
at more advanced stages, severe MR may cause LV systolic dysfunction which can 
decrease LA reservoir function by reduced systolic apical motion of the LV base.24 
LA reservoir strain and mortality after mitral valve surgery 
The present evaluation showed that LA reservoir strain is related to long-term sur-
vival in patients operated for severe organic MR, independently of conventional 
indications for mitral surgery, including symptoms, LV dysfunction, atrial fibrilla-
tion and significant pulmonary hypertension. In particular, LA reservoir strain ≤24 
% was associated with increased risk for postoperative mortality. In addition to 
conventional mitral surgery indications, LA diameter ≥55 mm or LAVI ≥ 60 mL/m² 
have been recently proposed as additional criteria for indication to mitral surgery 
as they yield increased mortality under conservative management, but not after 
mitral valve surgery. We indicated, however, that LA reservoir might be a more 
sensitive approach than LA diameter or LAVI to detect the impact of MR on cardiac 
performance, as previously shown in diabetic and hypertensive patients.8 A sig-
nificant proportion of patients in fact showed LA reservoir strain <24 %, implying 
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increased mortality risk after mitral valve surgery, despite LA diameter <55 mm or 
LAVI <60 mL/m².
Limitations 
Some limitations to the current study should be acknowledged: 1) no invasive 
assessment of LA mechanical properties or afterload was performed to prove the 
determinants of reduced LA function, which must be the focus of further specific 
studies; 2) Limited impairment of LA function in the control group of current study 
can not be excluded, due to a fairly high proportion of subjects with cardiovas-
cular risk factors such as diabetes and hypertension. This population, however, 
represents a real-life population without presence of overt structural or functional 
disease and more stringent selection of patients without any risk factors most 
likely would have only amplified significance of differences in LA function found 
between controls and severe MR patients. 3) To firmly establish the predictive 
value of LA reservoir strain independent of conventional indications for mitral 
surgery, our findings need validation in larger patient cohorts.
CONCLuSION
Severe MR is associated with significant LA dysfunction that strongly relates to 
presence of conventional indications for mitral surgery and, more important, is 
associated with long-term postoperative survival. LA dysfunction, measured as 
reservoir strain, may be a valuable clinical marker for follow-up and decision-
making in patients with severe organic MR, irrespective of conventional mitral 
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Accurate predictors of appropriate implantable cardioverter defibrillator (ICD) 
therapy in hypertrophic cardiomyopathy (HCM) patients are lacking. Both left atrial 
volume index (LAVI) and global longitudinal strain (GLS) have been proposed as 
prognostic markers in HCM patients. The specific value of LAVI and GLS to predict 
appropriate ICD therapy in high-risk HCM patients was studied.
Methods and Results
LAVI and 2-dimensional speckle tracking-derived GLS were assessed in 92 HCM 
patients undergoing ICD implantation (69% men, mean age 50±14 years). During 
long-term follow-up, appropriate ICD therapies, defined as antitachycardia pacing 
and/or shock for ventricular arrhythmia, were recorded.
Appropriate ICD therapy occurred in 21 patients (23%) during a median follow-
up of 4.7 (2.2-8.2) years. Multivariate analysis revealed LAVI (p=0.03) and GLS 
(p=0.04) to be independent predictors of appropriate ICD therapy. Both LAVI 
and GLS showed higher accuracy to predict appropriate ICD therapy compared 
to presence of ≥1 conventional sudden cardiac death (SCD) risk factor(s) [area 
under the curve 0.76 (95%CI:0.65-0.87) and 0.65 (95%CI:0.54-0.77) versus 0.52 
(95%CI:0.43-0.58) respectively, p<0.001]. No patient with both LAVI <34mL/m2 
and GLS<-14% experienced appropriate ICD therapy. Assessment of both LAVI 
and GLS on top of conventional SCD risk factors provided incremental clinical 
predictive value for appropriate ICD therapy, as shown by likelihood ratio test 
(p<0.001) and integrated discrimination improvement index (0.17, p<0.001).
Conclusion
LAVI and GLS provide high negative predictive value for appropriate ICD therapy 
in high-risk HCM patients. Additionally to conventional SCD risk factors, both 










Implantable cardioverter defibrillator (ICD) is currently recommended in patients 
with hypertrophic cardiomyopathy (HCM) at high risk for sudden cardiac death.1 In 
particular, ICD implantation is a class I indication for secondary prevention in HCM 
patients who survive cardiac arrest or present with sustained ventricular tachy-
cardia. In addition, the presence of one or more sudden cardiac death (SCD) risk 
factors, including family history of SCD, left ventricular (LV) hypertrophy ≥30 mm, 
non-sustained ventricular tachycardia (nsVT), recent unexplained syncope and/or 
abnormal blood pressure response during exercise testing qualifies patients for 
ICD implantation as primary prevention.2 Although appropriate ICD therapy in this 
high-risk population occurs at a yearly rate of 3.3%, inappropriate ICD therapy 
or other device-related complications are seen in 4.8% and 3.4% of patients per 
year, respectively.3 Hence, weighting risk-benefit of ICD implantation in HCM pa-
tients is of paramount importance and has created a currently unmet clinical need 
for accurate predictors of appropriate ICD therapy that may optimize candidate 
selection and timing criteria for ICD implantation.2, 4 
Impaired myocardial mechanics are commonly observed in HCM patients, de-
spite normal LV ejection fraction.5, 6 Global longitudinal strain (GLS), which reflects 
the active deformation of all LV myocardial segments, has been proposed as a 
sensitive marker of LV systolic function and can be currently quantified by speckle 
tracking echocardiography.7 In addition, HCM patients are often characterized 
by abnormal myocardial relaxation and significant LV diastolic dysfunction, ulti-
mately resulting in increased left atrial volume index (LAVI).8 Both GLS and LAVI, 
as a sensitive marker of LV systolic function and a specific marker of LV diastolic 
function respectively, have therefore been identified as prognostic factors in HCM 
patients.9-14 However, their potential role to predict appropriate ICD therapy is 
unexplored. Therefore, the aim of our study was 1) to evaluate the value of SCD 
risk factors, GLS and LAVI to predict appropriate ICD therapy in high-risk HCM 
patients and 2) to explore whether LAVI and GLS assessment provide incremental 
prognostic value over SCD risk factors.
METhODS
Patient population 
HCM patients who underwent ICD implantation for primary or secondary preven-
tion in our centre during the last decade were evaluated. HCM was defined as 
presence of a non-dilated and hypertrophic LV with wall thickness ≥15 mm in 
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the absence of any other cardiac or systemic disease that could account for the 
magnitude of LV hypertrophy.2 All patients underwent extensive clinical, electro-
cardiographic and echocardiographic evaluation before implantation and patients’ 
data were prospectively collected in the departmental Cardiology Information 
System (EPD-Vision®, Leiden University Medical Center, Leiden, the Netherlands) 
and retrospectively analyzed. Patients were excluded from the analysis if 2-di-
mensional (2D) echocardiography was not available prior to ICD implantation. 
Patients with severe mitral regurgitation or prior extensive myocardial infarction 
were also excluded.
Clinical data included demographics, medications and identification of co-
morbidities. Echocardiographic evaluation consisted of conventional measure-
ments and included 2D-speckle tracking echocardiography for LV deformation 
analysis. The SCD risk profile of HCM patients was determined based on clinical 
and echocardiographic parameters, according to current guidelines.2 In particular, 
conventional SCD risk factors were defined as secondary prevention ICD indica-
tion, family history of SCD (≥ one 1st or 2nd degree relative), maximal LV wall 
thickness ≥30 mm, unexplained syncope or documented nsVT (≥3 beats at ≥120 
bpm) prior to ICD implantation. Blood pressure response during exercise testing 
was not included as it was not part of clinical routine in the early years of our study 
period. In addition LV resting gradient ≥30 mmHg was determined.
The patient population was dichotomized based on occurrence or absence of 
appropriate ICD therapy at follow-up and the incremental prognostic value of LAVI 
and GLS was evaluated over conventional SCD risk factors.
ICD implantation and settings 
All defibrillator systems used were implanted via transvenous approach. During 
the implant procedure, sensing and pacing threshold was determined and defibril-
lation threshold testing was performed. Used systems were manufactured by Bio-
tronik (Berlin, Germany), Boston Scientific [Natick, MA, USA, formerly CPI, Guidant 
(St Paul, MN, USA)], Medtronic (Minneapolis, MN, USA), and St Jude Medical/Ventri-
tex (St Paul, MN, USA). The antitachycardia settings in all devices were programmed 
with three consecutive zones with limits varying slightly per manufacturer: a moni-
tor zone (lower limit between 150-155 bpm; upper limit between 185-190 bpm), 
an antitachycardia pacing (ATP) shock zone (lower limit between 185-190 bpm; 
upper limit between 205-210 bpm), and an initial shock zone (≥205-210 bpm). 
In the monitor zone, no therapy was programmed unless ventricular arrhythmia 
was detected during follow-up. In the ATP-shock zone, two bursts of ATP were 








of ventricular arrhythmia faster than the ATP shock zone, device shocks were the 
initial therapy. Therapy settings were adapted only when clinically indicated.
Echocardiography 
Transthoracic 2D-echocardiography was performed with the patient in left lateral 
decubitus position using commercially available ultrasound machines (Vivid-5, 
Vivid-7 and E9, GE-Vingmed, Milwaukee, WI) equipped with a 3.5 MHz transducer. 
ECG-triggered standard 2D gray-scale and color-Doppler images were acquired in 
cine-loop format and transferred to a workstation for off-line analysis (EchoPAC 
110.0.0, GE Medical Systems, Horten, Norway). Chamber quantification was 
performed conform to current recommendations.15 Maximal LV end diastolic wall 
thickness was assessed by LV evaluation in short axis view at basal, mid and apical 
level. LV volumes were assessed by Simpson biplane method, indexed to body 
surface area and used to calculate LV ejection fraction.
Assessment of LV GLS was performed as previously described.16 In summary, a 
region of interest covering the LV myocardium in a two-, four- and apical long-axis 
view was selected to perform automated frame-by-frame 2D-speckle tracking 
throughout the cardiac cycle. Manual correction was performed to optimize track-
ing results when appropriate. GLS was calculated as the average peak longitudinal 
strain value of the two-, four- and apical long-axis view (Figure 1). Mean frame rate 
for deformation analysis was 61 frames/s.
In addition, end-systolic LA volume was measured using Simpson biplane meth-
od and indexed to body surface area. LV diastolic function was analyzed assessing 
mitral inflow peak E (early diastolic) velocity, peak A (late diastolic) velocity, E/A 
ratio and deceleration time.17 In addition, E prime was derived from the lateral 
wall on a four-chamber color tissue-Doppler acquisition. The presence of a systolic 
anterior movement of the mitral valve was also evaluated by M-mode imaging at 
the level of the mitral leaflets in a parasternal long-axis view. Mitral regurgitation 
severity was semi-quantitatively assessed, based on conventional spectral and 
color-Doppler echocardiography as recommended.18 Screening for presence of an 
intraventricular or LV outflow tract gradient at rest was systematically performed 
using pulsed wave Doppler and peak gradient was measured by continuous wave 
Doppler.
Endpoints 
Occurrence of appropriate ICD therapy, defined as ATP and/or shock for ventricular 
tachycardia and/or ventricular fibrillation, was the main endpoint of this study. 
Inappropriate ICD therapy was noted when ATP and/or shock occurred despite 
absence of ventricular tachycardia and/or ventricular fibrillation. ICD device in-
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no ICD therapy after 8.2 years
Figure 10.1
Assessment of 2D-speckle tracking global longitudinal strain. Left ventricular (LV) global longitudinal strain (GLS) is 
calculated as the average of the peak longitudinal strain values obtained in the 3 apical echocardiographic views. 
The bull’s eye view is a color-coded representation of longitudinal strain values of all tracked LV segments (deep 
red reflects normal strain, light red and blue reduced and severely reduced strain, respectively). Panel A: Impaired 
GLS in a patient with hypertrophic cardiomyopathy that experienced appropriate implantable cardioverter defi-








terrogation was scheduled every 3-6 months after implantation and data were 
included until occurrence of the study end point or until last date of ICD check-up 
during the last year (between February 2011 and March 2012) for patients that did 
not experience the study endpoint.
Statistics 
Continuous variables are presented as mean ± standard deviation when normal 
and as median with inter-quartile ranges when not normally distributed. Categori-
cal variables are given as absolute numbers and percentages. Baseline character-
istics between groups with and without appropriate ICD therapy were evaluated 
by Student-t test, Kruskall-Wallis or χ2-test, when appropriate. In order to evaluate 
the association between SCD risk factors and appropriate ICD therapy, only pa-
tients with primary prevention indication were considered, for which incidence 
rates of appropriate ICD therapy were calculated and expressed per 100-patient 
years. Difference in incidence rates according to the number of SCD risk factors 
were tested by Poisson regression, and expressed as incidence rate ratios.
In order to identify parameters potentially associated with appropriate ICD 
therapy, assessment of independent predictors of appropriate ICD therapy was 
initially performed using a staged multivariable Cox proportional-hazards regres-
sion analysis to avoid model over-fit, given the relatively low incidence of the end 
point. Significant univariable predictors at a threshold p<0.2 were entered in a 
first multivariable analysis that used a backward elimination approach to identify 
predictors of appropriate ICD therapy. Variables with p<0.05 in the first multivari-
able model were entered in a second multivariable model, now containing the 
variables of interest, LAVI and GLS. Second, the predictive value of LAVI and GLS 
and conventional SCD risk factors was evaluated by receiver operating character-
istic (ROC) analysis and comparison of respective areas under the curve (AUC).19 To 
define cut-offs from ROC analysis, a high sensitivity (>85%) was stipulated to en-
sure identification of patients who would experience the endpoint. These cut-offs 
were used for subsequent analysis. Sensitivity, specificity, negative and positive 
predictive values for appropriate ICD therapy were calculated for LAVI and GLS, as 
well as conventional SCD risk factors, assuming a realistic 20% 5-year incidence 
of appropriate ICD therapy. Kaplan-Meier curves were constructed for LAVI and 
GLS for survival free of appropriate ICD therapy, and compared by log-rank test. 
Additionally, the potential incremental value of LAVI and GLS over SCD risk factors 
to predict appropriate ICD therapy was evaluated by likelihood ratio testing and 
assessment of integrated discrimination improvement index (IDI). Absolute IDI is 
a reclassification statistic that studies a new model`s discriminatory improvement 
to predict the outcome variable (appropriate ICD therapy), calculated by summing 
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the IDI components (net true predictive probabilities) of cases (patients experi-
encing appropriate ICD therapy) and controls (patients without appropriate ICD 
therapy).20 Finally, a similar explorative analysis was performed to test the relation 
of both LAVI and GLS with occurrence of inappropriate ICD therapy.
Statistical analysis was performed using SPSS version 17.0. (SPSS Inc., Chicago, Il-
linois) and STATA version 12 (STATA Corp., College Station, Texas) software. All tests 
were two-sided and a p-value of <0.05 was considered statistically significant.
RESuLTS
Patient population 
A total of 92 HCM patients (69% men, mean age 50 ± 14 years) who underwent 
ICD implantation were included. Baseline characteristics of the study population 
are summarized in Table 1. Peri-procedural echocardiography was performed at a 
median of 11 days before ICD implantation and all patients were in sinus rhythm 
at the time of echocardiographic evaluation. Despite normal LV volumes and pre-
served LV ejection fraction, mean GLS was impaired in the HCM patients (-13.3 ± 
3.5%). In addition, an enlarged LA volume (LAVI) was observed in these patients 
[39 (31-49) mL/m2]. A total of 22 patients (24%) that survived prior cardiac arrest, 
sustained ventricular tachycardia or ventricular fibrillation received an ICD for 
secondary prevention. The remaining 70 patients (76%) had a primary prevention 
indication for ICD implantation, based on the presence of ≥1 conventional SCD 
risk factors (n=63), or on additional factors such as complete heart block (n=1), 
LV systolic dysfunction (n=1), inducibility of ventricular fibrillation during electro-
physiological study (n=3) or abnormal blood pressure response during exercise 
testing (n=2).
Long-term ICD end points 
A total of 21 patients (23%) experienced an appropriate ICD therapy during a 
median follow-up of 4.7 (2.2-8.2) years (shock only n=6, shock after unsuccessful 
ATP n=3, ATP only n=12). According to ICD interrogation, appropriate ICD therapy 
was given for ventricular fibrillation (n=5), fast ventricular tachycardia in the 
programmed ventricular fibrillation zone (n=12) or ventricular tachycardia in the 
programmed ventricular tachycardia zone (n=4).
As shown in Table 1, patients presenting with versus without appropriate ICD 
therapy were more likely to be men (p=0.02) and were characterized by more 
impaired GLS (p=0.03) and increased LAVI (p<0.001). The overall HCM risk profile 















(n = 21) p value*
Clinical characteristics
Age, years 50 ± 14 49 ± 14 53 ± 12 0.2 
Men, n (%) 63 (69) 44 (62) 19 (91) 0.02 
BSA kg/m2 2.0 ± 0.24 2.0 ± 0.25 2.1 ± 0.19 0.3 
Systolic BP, mmHg 133 ± 21 133 ± 20 133 ± 24 1.0 
Diastolic BP, mmHg 77 ± 11 77 ± 11 77 ± 10 0.9 
Medication use, n (%)
β-blockers 51 (59) 36 (55) 15 (71) 0.2 
Calcium-antagonists 23 (26) 17 (26) 6 (29) 0.8 
Diuretics 11 (13) 8 (12) 3 (14) 0.7 
Echocardiography
IVS, mm 22 (18-26) 22 (18-26) 22 (21-26) 0.3 
PW, mm 11 (10-13) 11 (10-13) 12 (11-14) 0.3 
LV EDD, mm 44 ± 7 44 ± 6 45 ± 7 0.3 
LV EDVI, mL/m2 48 (35-60) 47 (39-59) 59 (40-69) 0.1 
LV ESVI, mL/m2 14 (10-19) 14 (10-18) 15 (11-26) 0.1 
LV EF, % 70 (64-76) 71 (65-77) 68 (52-76) 0.3 
GLS, % -13.3 ± 3.5 -13.8 ± 3.6 -11.9 ± 2.5 0.03 
LAVI, mL/m2 39 (31-47) 36 (29-43) 47 (41-58) < 0.001 
E/A 1.0 (0.8-1.6) 0.96 (0.8-1.7) 1.2 (0.9-1.5) 0.66 
E/E` 11 (8-14) 11 (8-14) 12 (7-15) 0.9 
DT, ms 197 ± 53 192 ± 51 211 ± 56 0.14 
Systolic anterior movement, n (%) 32 (35) 25 (36) 7 (33) 0.8
MR ≥grade 3, n (%)  2 (2) 2 (2) 0 (0) 1.0 
HCM risk profile     
Primary prevention ICD, n (%) 70 (76) 54 (76) 16 (76) 1.0 
LVH, mm 24.1 ± 4.9 23.6 ± 5.3 25.9 ± 3.0 0.1 
LVH ≥30 mm, n (%) 10 (11) 9 (13) 1 (5) 0.5 
Family SCD, n (%) 47 (57) 38 (59) 9 (50) 0.4 
Family HCM, n (%)  54 (65) 44 (68) 10 (56) 0.3 
Unexplained syncope, n (%) 19 (21) 12 (18) 7 (33) 0.1 
nsVT, n (%) 34 (38) 23 (34) 11 (52) 0.1 
Resting gradient ≥30 mmHg, n (%) 17 (19) 13 (18) 4 (19) 0.9 
BP: blood pressure, BSA: body surface area, DT: deceleration time, EDD: end diastolic diameter, EDVI: end diastolic 
volume indexed to BSA, EF: ejection fraction, ESVI: end systolic volume indexed to BSA, GLS: global longitudinal 
strain, ICD: implantable cardioverter defibrillator, IVS: interventricular septum, HCM: hypertrophic cardiomyopathy, 
LAVI: left atrial volume indexed to BSA, LV: left ventricle, LVH: left ventricular hypertrophy, MR: mitral regurgitation, 
nsVT: non-sustained ventricular tachycardia, PW: posterior wall, SCD: sudden cardiac death. *: p value for compari-
son of group of patients with versus without appropriate ICD therapy
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trend towards higher maximal LV wall thickness and increased prevalence of nsVT 
and syncope prior to ICD implantation in the group of patients with appropriate 
ICD therapy. Of note, incidence of appropriate ICD therapy did not differ between 
primary and secondary ICD indication patients (p=1.0), nor was it significantly 
related to the number of conventional SCD risk factors in primary prevention ICD 
recipients. In particular, compared with primary prevention ICD recipients with 1 
SCD risk factor, patients with 2 SCD risk factors had an incidence rate ratio of ap-
propriate ICD therapy of 1.5 (95%CI 0.93-2.6) and patients with 3 SCD risk factors 
had an incidence rate ratio of 2.0 (95%CI 0.60-6.4, p for trend=0.06) (Figure 2).
Predictors of appropriate ICD therapy 
Univariable Cox proportional-hazards regression analysis revealed LAVI, GLS, male 
gender, presence of nsVT and unexplained syncope prior to ICD implantation as 
predictors of appropriate ICD therapy (all p<0.2) (Table 2). Staged multivariable 
analysis showed that LAVI and GLS, and not any SCD risk factors, were indepen-
dent predictors of appropriate ICD therapy (all p<0.05). A resting LV gradient of 
≥30 mmHg was not related to appropriate ICD therapy in this patient cohort.
ROC curve analysis indicated that the presence of ≥1 SCD risk factors had limited 
value to predict appropriate ICD therapy when compared to both LAVI and GLS 
[AUC 0.52, 95% confidence interval (CI): 0.43-0.58 versus AUC 0.76, 95% CI 0.65-
0.87 and AUC 0.65, 95% CI: 0.54-0.77, respectively] (p<0.001). LAVI ≥34 mL/m² 
and GLS ≥-14% provided high sensitivity of 95% and 86% respectively to predict 
appropriate ICD therapy, reaching up to 100% if at least one of both was present 


















   
   
   
   
   
   
   
   
















Appropriate ICD therapy in primary prevention patients according to number of sudden cardiac death risk factors 









Uni- and multivariable cox proportional-hazards regression analysis to identify predictors of appropriate implant-
able cardioverter defibrillator therapy.
Parameter
Univariable Multivariable
HR (95% CI) p-value HR (95% CI) p-value
Male gender 4.4 (1.0-19) 0.046 4.2 (0.99-18) 0.05
GLS, % 1.16 (1.02-1.31) 0.02 1.15 (1.02-1.30) 0.03 
LAVI, mL/m2 1.02 (1.01-1.03) 0.004 1.01 (1.00-1.03) 0.02 
E/E’ 0.98 (0.92-1.1) 0.7
MR grade 1.1 (0.57-2.0) 0.9
Secondary prevention ICD indication 1.1 (0.41-3.0) 0.8
LVH ≥30 mm 0.36 (0.047-2.6) 0.3   
Family SCD 0.86 (0.34-2.2) 0.7   
Unexplained syncope 2.2 (0.88-5.6) 0.09 2.6 (0.99-6.7) 0.05 
nsVT 2.36 (0.999-5.59) 0.05 2.38 (0.976-5.78) 0.06 
Resting gradient ≥30 mmHg 1.3 (0.44-4.0) 0.6
CI: confidence interval, GLS: global longitudinal strain, HR: hazard ratio, ICD: implantable cardioverter defibrilla-
tor, LAVI: left atrial volume indexed to body surface area, LVH: left ventricular hypertrophy, nsVT: non-sustained 
ventricular tachycardia, SCD: SCD.
Table 10.3















LAVI, ml/m² 0.76 0.65 - 0.87 - - - - 
LAVI ≥34 ml/ m² - - 95 45 97 30
GLS, % 0.65 0.54 - 0.77 - - - -
GLS ≥-14% - - 86 45 93 28
GLS ≥-14% or LAVI ≥34 ml/m² - - 100 24 100 24 
SCD risk factors
Secondary prevention ICD indication 0.52 0.41-0.63 24 76 80 20 
Primary prevention ICD indication:       
LVH ≥30 mm† 0.48 0.42 - 0.55 5 87 79 9 
Family history of SCD† 0.45 0.32 - 0.59 50 41 77 17 
Prior nsVT† 0.58 0.45 - 0.71 52 66 85 28 
Prior unexplained syncope† 0.58 0.46 - 0.70 33 82 83 32
AUC: area under the curve, CI: confidence interval, FHSCD: family history of SCD, GLS: global longitudinal strain, HR: 
hazard ratio, ICD: implantable cardiac defibrillator, LAVI: left atrial volume indexed to body surface area, LVH: left 
ventricular hypertrophy, NPV: negative predictive value, nsVT: non-sustained ventricular tachycardia, PPV: positive 
predictive value, ROC: receiver operating characteristic analysis, SCD: SCD, SCD risk factors: SCD risk factor, sens: 
sensitivity, spec: specificity, *: calculation based on 20% prevalence of appropriate ICD therapy, †: one of SCD 
risk factors
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of 24%. More importantly, the combined presence of LAVI <34 mL/m2 and GLS 
<-14% adequately ruled out likelihood of appropriate ICD therapy, reflected by a 
negative predictive value of 100%.
Finally, the Kaplan-Meier survival curves for LAVI and GLS revealed a significant 
difference in time to survival free of appropriate ICD therapy for both LAVI ≥34 mL/ 
m2 versus <34 mL/ m2 (p<0.001) and GLS ≥-14% versus <-14% (p=0.003) (Figure 
3). In particular, after a median follow-up of 1, 3 and 5 years a respective 12%, 
24% and 32% of patients with LAVI ≥34 mL/m2 reached the endpoint, whereas 
their counterparts showed significantly lower cumulative event rates (0%, 4% and 
4%, respectively). HCM patients with GLS ≥-14% experienced appropriate ICD 
therapy in 9%, 23% and 32% after 1,3 and 5 years, respectively, while patients 
with GLS <-14% showed lower cumulative event rates of 6%, 9% and 9%.
Incremental value of LAVI and gLS to predict appropriate ICD therapy
The addition LAVI ≥34 mL/m² to a baseline model which included the presence 
of ≥1 SCD risk factor(s) provided incremental value to predict appropriate ICD 
therapy as indicated by the likelihood ratio test (p<0.001) and an IDI of 0.13 
(p<0.001) (Figure 4). Sequential addition of GLS further improved prediction of 
appropriate ICD therapy (likelihood ratio test p=0.02 and IDI 0.04 with p=0.02). 
Therefore, adding both LAVI and GLS on top of presence of ≥1 SCD risk factors 
provided the best calibration for appropriate ICD therapy prediction, reflected by 
the likelihood ratio test p<0.001 and IDI 0.17 with p<0.001. Importantly, the same 
results were observed (IDI 0.19, p<0.001) when only considering IDI in primary 
prevention indication ICD recipients (n=70), which is of particular clinical interest 
as ICD implantation is unlikely to be withheld in secondary prevention indication 
HCM patients. Importantly, assessing both LAVI and GLS on top of conventional 
SCD risk factors in primary prevention patients results in reclassification of about 
1 out of 5 primary prevention ICD recipients into a very low-risk group, who expe-
rienced no appropriate ICD therapy during follow-up [12/70 pts (17%) have both 
LAVI and GLS below the pre-specified cut-off values with presence of 0, 1 and 2 
SCD risk factors in 3 (25%), 6 (50%) and 3 (25%) patients respectively].
LAVI, gLS and inappropriate ICD therapy
During the median follow-up of 4.7 (2.2-8.2) years 19 patients (21%) experienced 
at least one inappropriate ICD therapy event. Patients with versus without inap-
propriate ICD therapy had similar LAVI [37.4 (33.8-45.1) versus 39.3 (31.0-48.8) 
ml/m², p=0.806] and GLS (-13.8±3.23 versus -13.2±3.56 %, p=0.579) at baseline, 
respectively. In addition, at univariable Cox regression analysis LAVI did not relate 








nor did GLS [HR 0.99 (0.88-1.13), p=0.970]. Survival free of inappropriate ICD 




Kaplan-Meier analysis to evaluate survival free of appropriate ICD therapy in 92 HCM patients. Panel A: left atrial 
volume indexed to body surface area (LAVI). Panel B: left ventricular global longitudinal strain (GLS). ICD: implant-
able cardioverter defibrillator.
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LAVI ≥34 versus <34 ml/m² (log rank p=0.330) as well as for patients with baseline 
GLS ≥-14 versus <-14 % (log rank p=0.670).
DISCuSSION
The main findings of the current study can be summarized as follows: 1) the value 
of conventional SCD risk factors to predict appropriate ICD therapy in high-risk 
HCM patients was limited, however, 2) LAVI and GLS were shown to be independent 
predictors of appropriate ICD therapy in this population and 3) assessment of both 
parameters provided significant incremental predictive value over conventional 
SCD risk factors, particularly to identify patients at very low risk of appropriate ICD 
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Figure 10.4
Likelihood ratio test bar graph. This test shows incremental value of sequential assessment of left atrial volume 
indexed to body surface area (LAVI) and left ventricular global longitudinal strain (GLS) over conventional sudden 









SCD risk factors and appropriate ICD therapy 
Although conventional SCD risk factors are established criteria to recommend ICD 
implantation in HCM patients, no strong evidence is currently available that these 
factors can also accurately predict the occurrence of appropriate ICD therapy.2 
The largest multi-center HCM registry so far, which included 506 unrelated HCM 
patients who underwent ICD implantation, observed in fact that no single con-
ventional SCD risk factor, nor the number of SCD risk factors, was associated with 
appropriate ICD therapy.1 A recent observational study in 1606 HCM patients (of 
which 19% with an ICD) also suggested that no single SCD risk factor could in-
crease the risk of SCD or appropriate ICD shock, although aggregation of multiple 
SCD risk factors did increase this risk, however, with limited power to discriminate 
high versus low risk subjects.21 Similar findings were also observed in smaller 
single-center series.22-24 Only one study, evaluating 104 HCM patients, identified 
the presence of nsVT as an independent predictor of appropriate ICD therapy, 
although with wide confidence limits [HR 10.3 (95%CI 1.13-92.99)] and modest 
positive predictive value (22%).25 Although the independent predictive value of 
secondary prevention indication for appropriate ICD therapy has not been shown 
unequivocally, appropriate ICD therapy is highly prevalent amongst secondary 
prevention ICD recipients and recently showed a significant association to appro-
priate ICD therapy on a univariable level.1, 23, 26 
The results of the current evaluation are in line with previous studies, indicating 
rather limited predictive value of conventional SCD risk factors for appropriate ICD 
therapy.1 Although conventional SCD risk factors remain mainstay to refer HCM 
patients for ICD implantation, additional markers are clinically needed to optimize 
candidate selection and allow accurate risk-benefit weighting of ICD implantation 
in these patients.
gLS and LAVI in hCM 
HCM is a cardiomyopathy characterized by LV hypertrophy, myocardial fiber disar-
ray and interstitial fibrosis.4, 28, 29 These structural alterations are responsible for 
significant LV systolic dysfunction, which is often difficult to detect with conven-
tional echocardiographic measures such as LV ejection fraction. Echocardiographic 
speckle tracking deformation imaging has been proposed as a highly sensitive 
technique which is able to accurately measure myocardial strain in a specific seg-
ment or in the overall LV.7 With the use of this technique, a significant impairment 
of GLS was demonstrated in HCM patients, despite the presence of preserved LV 
ejection fraction.5, 9, 10 In addition, impaired GLS in HCM patients has also been 
associated with occurrence of nsVT and adverse cardiac outcome.10 
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The above-mentioned HCM structural alterations are also responsible for a 
significant LV diastolic dysfunction, due to impaired myocardial relaxation, and 
increased LV filling pressures. In addition to these factors, intra-ventricular gradi-
ents and mitral regurgitation severity are main determinants of increased LA size, 
a characteristic finding in many HCM patients.13, 30 Increased LA size is therefore 
considered a marker of HCM disease severity and showed to be an independent 
predictor of adverse outcome in this population.11, 13 Increased LA diameter has 
shown to be a strong mortality predictor in a study including 1491 HCM patients.31 
Most recently, O’Mahony et al reported on a large series of 3675 relatively low-risk 
HCM patients (only 41 had baseline ICD, 1%), showing LA diameter independently 
related to SCD or appropriate ICD shock.32 Asymmetric LA remodeling, however, 
may occur and therefore LAVI is currently recommended as the preferred param-
eter of LA size, as large variation in LA volume may coincide with little variation in 
LA diameter.11, 15, 33 
Studies in HCM patients evaluating ICD recordings prior to appropriate ICD 
discharge have shown that the vast majority of patients suffered from sustained 
monomorphic ventricular tachycardia or ventricular fibrillation, often preceded by 
increased heart rate due to sinus tachycardia and atrial fibrillation or late-coupled 
premature ventricular complexes, respectively.34, 35 These findings indicate that 
coincidence of arrhythmogenic substrate (allowing for uni-directional conduction 
block and re-entry) as well as adequate modulators (including electrolyte distur-
bances, maladaptive autonomic responses affecting heart rate, intra-ventricular 
gradients or ischemia) are prerequisites for ventricular tachyarrhytmias in these 
patients.34, 35 We hypothesize that both GLS and LAVI may indirectly reflect the 
underlying arrhythmogenic substrate, if not modulators, in HCM patients, includ-
ing fibrosis and fiber disarray. These findings may contribute to the rationale for 
the independent and incremental value of both LAVI and GLS over SCD risk factors 
to predict appropriate ICD therapy in this population, as shown in current study.
Clinical implications 
The present findings suggest that assessment of both LAVI and GLS on top of 
conventional SCD risk factors may optimize referral criteria and timing of ICD im-
plantation in HCM patients at increased risk for SCD. All patients that experienced 
appropriate ICD therapy were identified by presence of LAVI or GLS above the 
cut-off value of ≥34 mL/m2 or ≥-14% respectively (sensitivity 100%). This strat-
egy, however, showed a rather modest positive predictive value of 24%, indicating 
that, although patients who may benefit from ICD are identified applying this ap-
proach, still a large number of ICD’s would be implanted in patients who will not 








More importantly, when both LAVI and GLS were below the pre-specified cut-
off values, a low-risk patient for appropriate ICD therapy was identified with a 
negative predictive value of 100%. When applying this strategy, no single patient 
experienced appropriate ICD therapy during a median period of approximately 
5 years. In particular, about 1 out of 5 patients (19%) could be re-classified ac-
cording to this approach as at low-risk and therefore eventually reassured that 
appropriate ICD therapy will not occur. These findings might therefore suggest 
considering the use of these parameters to delay ICD implantation in some HCM 
patients, with careful follow-up. This option might prevent these patients from 
exposure to potential adverse ICD-related events such as inappropriate therapy or 
device-related complications that might significantly impact on the quality of life 
or outcome of the ICD recipients.
Limitations 
Several limitations to this study should be mentioned. The present evaluation most 
likely was underpowered to prove the absence of relationship between number of 
SCD risk factors and occurrence of appropriate ICD therapy, although our findings 
are in line with the largest HCM-ICD registry to date.1 The specificity and negative 
predictive values of SCD risk factors to predict appropriate ICD therapy reported 
in the present evaluation should be interpreted with caution, as only an absolute 
minority of our patients presented without presence of conventional SCD risk 
factors. In addition, it should be emphasized that SCD risk factors are established 
markers and remain the cornerstone for a decision on ICD implantation in HCM 
patients.2 The present results may not be generalizable to low-risk HCM patients 
for SCD. Therefore, given its retrospective observational single-center nature, this 
report should be considered as hypothesis generating and requires prospective 
validation in a larger HCM patient cohort.
CONCLuSION
Albeit conventional SCD risk factors are the cornerstone for clinical decision-
making to implant ICD in HCM patients, these factors yield limited value to predict 
subsequent appropriate ICD therapy. Both LAVI and GLS are independent predic-
tors of appropriate ICD therapy showing incremental benefit over conventional 
SCD risk factors, mainly attributed to high negative predictive value. Therefore, in 
addition to conventional SCD risk factors, assessment of both parameters may be 
clinically useful to optimize candidate selection and timing of ICD implantation, 
particularly to identify HCM patients at low risk for appropriate ICD therapy.
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Left atrial size and function in hypertrophic 
cardiomyopathy patients and risk of new onset 
atrial fibrillation 
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Atrial fibrillation (AF) in hypertrophic cardiomyopathy (HCM) patients is highly 
prevalent, implies dismal prognosis, rendering risk stratification a priority. Whether 
LA volume and LA strain yield incremental value over LA diameter to risk stratify 
HCM patients for AF is unknown. The value of LA diameter, volume and strain to 
risk stratify HCM patients for new onset AF was explored.
Methods and results
A total of 243 HCM patients without AF history were retrospectively evaluated 
by (speckle tracking) echocardiography to assess LA diameter, volume and strain. 
New onset AF comprised the primary endpoint. During mean follow-up of 4.8±3.7 
years, 40 patients (16%) developed AF. Multivariable analysis showed LA diameter 
(HR=1.07, 95%CI 1.02-1.13, p=0.011), LA volume (HR=1.03, 95%CI 1.01-1.06, 
p=0.007) and LA strain (HR=0.91, 95%CI 0.86-0.96, p<0.001) as independent AF 
correlates. Importantly, 58% (n=23) of AF events occurred despite a baseline LA 
diameter <45mm, observed in 186 patients. In this patient subset, LA strain (AUC 
0.73, p<0.001) and LA volume (AUC 0.70, p=0.004) showed good predictive value 
for new onset AF. Furthermore, patients with LA volume <36 versus ≥36mL/m² (me-
dian value) and LA strain >23.4 versus ≤23.4% (median value) had superior 5-year 
AF-free survival of 92% versus 80% (p=0.013) and 98% versus 74% (p=0.001), 
respectively. Importantly, LA volume <36mL/m² and strain >23.4% yielded high 
negative predictive value (93% and 94%, respectively) for new onset AF. Likeli-
hood ratio test indicated incremental value of LA volume assessment (p<0.001) 
on top of LA diameter to predict new onset AF in HCM patients with LA diameter 
<45mm, which further increased by addition of LA strain (p=0.042).
Conclusion
LA diameter, volume and strain all independently relate to new onset AF in HCM 
patients. In patients with normal LA size, however, both LA volume and strain 











Primary hypertrophic cardiomyopathy (HCM), caused by sarcomeric gene 
mutation(s), encompasses increased risk for arrhythmia, heart failure and (sudden) 
cardiac death.1,2 Atrial fibrillation is more prevalent than in the general population, 
typically affecting about 20% of HCM patients at an annual incidence of over 2%. 
3-5 Importantly, one third of patients are diagnosed before the age of 50 years 
old.3 HCM patients who develop atrial fibrillation are vulnerable to symptoms, 
impaired exercise tolerance, hospitalization for heart failure and, importantly, 
are prone to dismal prognosis.3,4 Atrial fibrillation increases by 4-fold the risk of 
mortality independent of other known mortality risk factors, mainly due to heart 
failure and stroke related death.3,4,6 In addition atrial fibrillation is associated with 
an 8-fold increased risk of thromboembolism in HCM patients, occurring at an 
annual incidence of 3.75%.5,6 Early mortality or persistent neurologic disability 
are common in these patients, even more if onset of atrial fibrillation occurs at 
younger age.3 Therefore accurate risk stratification for new onset atrial fibrillation 
in HCM patients should be a priority and may have an impact on follow-up and 
management strategies.
Left atrial (LA) diameter has consistently been identified as a strong predictor of 
atrial fibrillation development in HCM patients.3,5 It has been suggested that the 
extent of atrial remodeling and therefore risk for atrial fibrillation, might be better 
reflected by 2-dimensional assessed LA volume rather than uni-dimensional LA 
diameter.7,8 Two-dimensional (2-D) speckle tracking echocardiography is a novel 
method for accurate assessment of LA function, expressed as reservoir strain, more 
sensitive than LA size or volume. To date only one small study in HCM patients 
linked impaired LA strain to atrial fibrillation requiring hospitalization.9 We hy-
pothesized that LA volume and/or LA strain may yield incremental value over LA 
diameter to risk stratify HCM patients for new onset atrial fibrillation. The aim of 
current study is to explore the clinical value of all three LA parameters in relation 
to new onset atrial fibrillation in a large HCM population.
METhODS
Patient population
Patients ≥18 years with a clinical diagnosis of HCM based on otherwise unex-
plained ventricular hypertrophy, comprising a LV wall thickness of ≥15 mm were 
selected from an ongoing echocardiographic and clinical database. Patients with 
a history of atrial fibrillation before or at the moment of echocardiography, no 
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additional clinical follow-up visit after baseline echocardiography and insufficient 
image quality to allow LA strain assessment were excluded.
Baseline characteristics including age, gender, cardiovascular risk factors, medi-
cation use, presence of implantable cardioverter defibrillator (ICD) and results of 
sarcomere mutation testing, if performed, were extracted from the departmental 
electronic patient information system (EPD-Vision®, Leiden University Medical 
Center, Leiden, the Netherlands). In addition, at baseline all HCM patients had 
12-lead electrocardiography (ECG) and 24-hour ambulatory electrocardiography 
(Holter) registration.
As recommended, patients were followed-up on a yearly basis at our and/or the 
referring institution, comprising a clinical visit and 12-lead ECG.1,2 Repeated ECG 
or Holter recordings were performed at the discretion of the treating physician 
based on symptoms, presence of enlarged LA or for sudden cardiac death risk 
stratification. Device interrogation was performed every 3 to 6 months in ICD 
recipients.
The study was approved by the internal review board that waived the need for 
written informed consent for retrospective evaluation of prospectively collected 
clinical data.
Echocardiographic analysis
Comprehensive 2-D transthoracic echocardiography was performed in all patients 
in the left lateral decubitus using commercially available ultrasound systems (Sys-
tem-5, Vivid-7 and E9, GE-Vingmed, Milwaukee, WI) equipped with a 3.5 MHz or 
M5S transducers. Conventional ECG-triggered 2-D B-mode, M-mode, pulsed wave, 
continuous wave and color-Doppler images were acquired in still or cine-loop 
format and analyzed off-line (EchoPAC version 112, GE Medical Systems, Horten, 
Norway). From a short-axis view at basal, mid and apical level the maximal LV end-
diastolic wall thickness was assessed. Septal LV wall thickness and LV diameters 
were calculated from parasternal long-axis views, as recommended.10 Simpson’s 
biplane method was used for evaluation of LV volumes and to calculate LV ejection 
fraction. Diastolic parameters, including E/A and E/e’ were assessed using pulsed 
wave Doppler at the tips of the mitral leaflets and from tissue Doppler imaging 
at the level of the lateral annulus, respectively. A multi-integrative approach was 
used to grade presence of mitral regurgitation as grade 1 (trivial), 2 (mild), 3 (mod-
erate) or 4 (severe), as recommended.11 In addition systolic anterior movement of 
the anterior mitral leaflets was evaluated from M-mode parasternal acquisition. 
Presence of LV resting intraventricular or outflow tract gradient was systematically 











LA diameter was derived from parasternal long axis B-mode view and LA volume 
was measured at end-systole with the Simpson’s biplane rule. All volumes were 
indexed to body surface area. LA 2-D speckle tracking longitudinal strain was 
measured as peak systolic reservoir strain, as previously reported.12 The small-
est region of interest was set to include the thin atrial wall. The average value of 
both the apical 2-chamber and 4-chamber views was used. Mean frame rate for LA 
strain analysis was 57 frames per second. The intra- and interobserver variability 
for LA strain analysis in our department has been previously reported.12
Endpoint
New onset atrial fibrillation at out-patient or emergency room visit, defined as 
an irregular heart rhythm without distinct P-waves documented on ECG, Holter 
registration (if duration ≥30 seconds) or after expert analysis from device record-
ings in patients with ICD, comprised the study endpoint.13 
Statistical analysis
Normally distributed and skewed continuous data are presented as mean ± 
standard deviation and median ± interquartile range, respectively, while percent-
ages are used for categorical data. Comparison between groups was based on 
Student-T, Mann-Whitney U, Fisher exact or χ2-test, when appropriate. Receiver 
Operator Characteristic (ROC) curve analysis was performed to test all 3 LA pa-
rameters (diameter, volume and strain) for prediction of the study endpoint. The 
study population was stratified based on LA diameter < or ≥45 mm, a cut-off value 
proposed by most recent HCM guidelines.2 Stratification based on LA volume and 
strain was performed by their median value, given current lack of generally ac-
cepted cut-off in this patient population. Kaplan-Meier cumulative survival curves 
free of atrial fibrillation were constructed for all LA parameters, stratified accord-
ing to their cut-off values, and compared by log-rank test. In addition sensitivity, 
specificity, positive and negative predictive values for the study endpoint predic-
tion were calculated. Subsequently Cox proportional hazards regression analysis 
was performed to identify associates of new onset atrial fibrillation. Parameters at 
a significance threshold of p<0.1 at univariable level were entered into the mul-
tivariable analysis using a backward elimination approach. Multivariable testing 
was performed for each LA parameter of interest separately (diameter, volume 
and strain). Finally, similar statistical analysis was performed, restricting the study 
population to patients with LA diameter <45 mm, generally regarded as being at 
low risk for new onset atrial fibrillation.2 In addition, likelihood ratio test was used 
to explore the potential incremental value of adding LA volume and strain on top 
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of LA diameter in relation to the study endpoint for this patient subset. SPSS ver-
sion 20.0. (SPSS Inc., Chicago, Illinois) was used for statistical analysis. A p-value of 
<0.05 was considered statistically significant, all tests being two-sided.
RESuLTS
Patient population
A total of 243 HCM patients comprised the final population after excluding patients 
for age <18 years old (n=18), history of atrial fibrillation (n=43), no follow-up visit 
(n=4) and insufficient image quality for LA strain assessment (n=54, 15%). Base-
line demographic, clinical and echocardiographic characteristics of these patients 
(65% male, mean age 53±13 years) are provided in Table 1. The patient population 
showed typical characteristics of HCM such as increased wall thickness (median 
21 mm), small LV cavities and preserved LV function (ejection fraction 68±8 %). 
In addition the presence of systolic anterior movement of the mitral valve or a 
significant LV outflow tract obstruction (≥30 mmHg) were noted in one third of the 
patients. Median LA size was slightly or moderately increased, when expressed as 
diameter [40 mm (36-44)] or volume [36 mL/m² (28-46)], respectively.10 Median 
LA reservoir function measured with speckle tracking was 23.4% (16.9-29.1). By 
definition all patients were in sinus rhythm at baseline.
Study endpoint
During a mean follow-up of 4.8±3.7 years (range 1.7-7.1) 40 out of 243 patients 
(16%) experienced new onset atrial fibrillation. Particularly, more than half of 
these events (23/40, 58%) occurred in the sub-group of 186 HCM patients with a 
baseline LA diameter of <45 mm.
Atrial fibrillation in the overall population
Patients with versus without new onset atrial fibrillation had a larger LA size (di-
ameter and volume) and more impaired LA function (strain), as shown in Table 2 
(all p<0.001). ROC curve analysis, indicated a moderately higher predictive value 
for LA volume and LA strain than for LA diameter, to predict the occurrence of new 
onset atrial fibrillation (Table 2, all p<001).
Survival free from new onset atrial fibrillation was higher in patients with an LA 
diameter <45 versus ≥45 mm yielding a 5-year atrial fibrillation free survival of 
88% versus 74%, respectively (p=0.005) (Figure 1). Similarly, survival free from 
new onset atrial fibrillation was higher in patients with an LA volume <36 versus 










>23.4 vs ≤23.4 % (5-year survival of 94% versus 75%, respectively, p<0.001). 
Table 2 shows the higher sensitivity at cost of lower specificity of LA volume and 











Age, years 53 ± 13 53 ± 13 52 ± 14 0.544 
Men, n (%) 157 (65) 108 (58) 49 (86) <0.001 
Systolic BP, mmHg 139 ± 23 138 ± 23 142 ± 21 0.432 
Diastolic BP, mmHg 81 ± 11 81 ± 10 80 ± 11 0.512 
Hypertension, n (%) 94 (39) 73 (39) 21 (37) 0.624 
Diabetes, n (%) 20 (8) 17 (9) 3 (6) 0.773 
Smoking history, n (%) 65 (27) 51 (27) 14 (24) 0.212 
Hyperlipidemia, n (%) 73 (30) 60 (32) 13 (23) 0.325 
ICD, n (%) 20 (8) 14 (8) 6 (10) 0.581
For primary prevention 14 (6) 10 (5) 4 (7) - 
For secondary prevention 6 (2) 4 (2) 2 (4) - 
Echocardiography
IVS, mm 20 ± 5 19 ± 5 22 ± 6 <0.001 
Maximal LVH, mm 21 (18-24) 20 (17-23) 24 (21-26) <0.001 
LVEDD, mm 43 ± 6 42 ± 6 47 ± 6 <0.001 
LVESD, mm 24 ± 6 23 ± 6 26 ± 7 0.001 
LV EDVI, mL/m2 51 ± 16 49 ± 14 57 ± 18 0.001 
LV ESVI, mL/m2 16 ± 7 15 ± 6 19 ± 9 0.001 
LV EF, % 68 ± 8 69 ± 8 67 ± 8 0.171 
LA diameter, mm 40 ± 6 38 ± 5 48 ± 3 <0.001 
LA volume, mL/m2 38 ± 14 35 ± 12 50 ± 15 <0.001 
LA strain, % 23.2 ± 8.0 24.6 ± 7.6 18.7 ± 7.4 <0.001 
E/A 1.0 (0.7-1.4) 0.9 (0.7-1.4) 1.2 (0.9-1.6) 0.018 
E/e’ 10 (8-15) 10 (8-15) 13 (10-17) 0.011 
Systolic anterior motion of MV, n (%) 90 (37) 62 (33) 28 (49) 0.041
MR grade  1.02 ± 0.71 0.98 ± 0.74 1.18 ± 0.69 0.075 
Resting LV outflow gradient, mmHg 9 (6-20) 9 (6-17) 10 (7-55) 0.051 
Resting LV outflow gradient >30 mmHg, n (%) 39 (16) 24 (13) 15 (26) 0.021
Sarcomeric mutation (n=119 tested), n (%) 61 (51) 43 (48) 18 (56) 0.541
BP: blood pressure, EDD: end-diastolic diameter, EDVI: end-diastolic volume index, EF: ejection fraction, ESD: end-
systolic diameter, ESVI: end-systolic volume index, ICD: implantable cardioverter defibrillator, IVS: interventricular 
septum, LA: left atrium, LV: left ventricle, LVH: left ventricular hypertrophy, MR: mitral regurgitation, MV: mitral valve
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sion analysis identified age, diabetes, E/e’, mitral regurgitation grade and all LA 
parameters (diameter, volume and strain) as univariate associates of new onset 
atrial fibrillation (all p<0.10) (Table 3). Moreover, multivariable analysis showed 
that all LA parameters were independently associated with the study endpoint: 
LA diameter (HR 1.07, 95% CI 1.02-1.13, p=0.011), LA volume (HR 1.03, 95% CI 
1.01-1.06, p=0.007) and LA strain (HR 0.91, 95% CI 0.86-0.96, p<0.001) (Table 4).
Atrial fibrillation in patients with left atrial diameter <45 mm
Although HCM patients with LA diameter <45 mm are generally considered to be 
at relatively low risk for new onset atrial fibrillation, 58% (23 out of 40) of these 
events occurred in this subset of 186 patients (Figure 2), implicating a prevalence 
LA diameter < 45 mm
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Figure 11.1
Kaplan-meier survival curves free of new onset atrial 
fibrillation for the entire study population (n=243). 
Patients are stratified according to left atrial (LA) diam-
eter (Panel A), median LA volume (Panel B) and median 











Left atrial parameters for prediction of new onset atrial fibrillation using the pre-specified cut-off values. Note 
superior sensitivity of LA volume and strain versus diameter to predict atrial fibrillation in entire study population. 
In the patient sub-group with preserved LA diameter (<45 mm, 186 patients), comprising 58% (n=23/40) of the 



















LA diameter, mm 40 ± 6 44 ± 6 <0.001 0.68 ≥ 45 43 80 30 88
LA volume, mL/m² 36 ± 13 48 ± 16 <0.001 0.72 ≥36 73 54 22 92




<0.001 0.71 ≤23.4 75 55 25 85


















LA volume, mL/m² 34 ± 11 44 ± 16 <0.001 0.70 ≥36 63 62 17 93
LA strain, % 25.4 ± 7.3 18.9 ± 7.5 <0.001 0.74 ≤23.4 74 61 21 94
Abbreviations, see Table 1. AF: atrial fibrillation. AUC: area under the curve, NPV: negative predictive value, PPV: 
positive predictive value, ROC: receiver operating curve analysis, Sens: sensitivity, Spec: specificity



























Left a rial diameter (m )
Figure 11.2
New onset atrial fibrillation according to left atrial size and function. Left atrial (LA) diameter versus volume (Panel 
A) and versus strain (panel B). Dashed vertical line represents the 45 mm LA diameter cut-off. The dashed hori-
zontal line represents the 36 mL/m² and 23.4% cut-off for LA volume (panel A) and strain (panel B), respectively. 
A significant proportion of new onset atrial fibrillation events occurs despite ‘normal’ LA diameter (<45 mm) of 
which a significant part is detected based on the cut-offs set for enlarged LA volume and impaired LA strain (light 
blue area), explaining higher overall sensitivity. Relative few events occur in patients with preserved LA diameter 




Multivariable Cox regression analysis to predict new onset atrial fibrillation for different left atrial parameters.
Univariate predictors p<0.10 in univariable model were included in the multivariable model. Separate models 







HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value
Age 1.03 (1.00-1.06) 0.071 1.01 (0.97-1.04) 0.635 1.01 (0.98-1.07) 0.732
Diabetes 1.70 (0.58-5.00) 0.332 1.78 (0.60-5.32) 0.302 1.17 (0.40-3.38) 0.779
E/e’ 1.02 (0.99-1.06) 0.207 1.03 (1.00-1.07) 0.079 1.02 (0.98-1.05) 0.440
MR grade 1.66 (0.97-2.83) 0.063 1.40 (0.72-2.73) 0.322 1.67 (1.02-2.71) 0.041
LA diameter 1.07 (1.02-1.13) 0.011 - -
LA volume - - 1.03 (1.01-1.06) 0.007
LA strain - - - - 0.91 (0.86-0.96) <0.001
Table 11.3
Univariable Cox regression analysis to predict new onset atrial fibrillation. Abbreviations, see Table 1. LVOT: left 
ventricular outflow tract.
Univariable
HR (95% CI) p-value
Age, per year 1.04 (1.01-1.07) 0.002
Male gender 0.70 (0.37-1.31) 0.266
Systolic BP, per mmHg 1.00 (0.98-1.02) 0.808
Diastolic BP, per mmHg 1.02 (0.98-1.05) 0.409
Hypertension 1.42 (0.73-2.74) 0.300
Diabetes 2.66 (1.09-6.46) 0.031
Smoking history 0.79 (0.36-1.77) 0.577
Hypercholesterolemia 0.94 (0.47-1.89) 0.855
Maximal LVH, per mm 1.02 (0.97-1.07) 0.383
E/e’ 1.04 (1.02-1.07) 0.003
MR grade 2.09 (1.38-3.15) <0.001
Resting LV(OT)gradient, per mmHg 1.01 (1.00-1.02) 0.130
Resting LV(OT)gradient >30 mmHg 1.34 (0.61-2.91) 0.464
LVEDD, per mm 0.98 (0.93-1.03) 0.389
LVESD, per mm 1.01 (0.96-1.07) 0.606
LVEDVi, per ml/m² 0.99 (0.97-1.01) 0.243
LVESVi, per mL/m² 1.01 (0.98-1.05) 0.579
LVEF, per % 0.97 (0.94-1.01) 0.112
LA diameter, per mm 1.09 (1.04-1.14) 0.001
LA volume, per mL/m² 1.05 (1.03-1.07) <0.001










of 12% (23/186) versus 30% (17/57) in patients with LA diameter <45 mm versus 
≥45 mm, respectively.2 
Within the cohort of patients with LA diameter <45 mm, LA volume was larger 
and LA strain more impaired in patients that developed new onset atrial fibrillation 
compared with patients who remained in sinus rhythm (Table 1). Using ROC curve 
analysis, LA strain (AUC 0.74, p<0.001) provided greater predictive value for new 
onset atrial fibrillation compared to LA volume (AUC 0.70, p=0.004) in this subset 
of patients. Importantly, both LA parameters were able to further discriminate risk 
for new onset atrial fibrillation in patients with LA diameter <45 mm, as illustrated 
by the survival curves free of new onset atrial fibrillation in Figure 3. Patients with 
LA volume <36 versus ≥36 mL/m² and LA strain >23.4 versus ≤23.4 % (median 
values) had better survival free of atrial fibrillation with cumulative 5-year survival 
of 92% versus 80% (p=0.013) and 98% versus 74% (p=0.001), respectively. As 
shown in Table 2 and Figure 2, both LA parameters particularly yield high negative 
predictive value for new onset atrial fibrillation in this HCM sub-population.
Likelihood ratio test indicated significant incremental value of LA volume 
(p <0.001) on top of LA diameter to predict new onset atrial fibrillation in HCM 
patients with LA diameter <45 mm (Figure 4). Interestingly, addition of LA strain 
further increased the predictive value of the model containing LA diameter and LA 
volume (p =0.042).
LA volume < 36 mL/m²
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Figure 11.3
Kaplan-meier survival curves free of new onset atrial fibrillation in patients with left atrial diameter <45 mm 
(n=186). Patients are stratified according to median left atrial (LA) volume (Panel A) and LA strain (Panel B).
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DISCuSSION
The main study findings in this HCM population can be summarized as follows: 1) 
LA size (diameter and volume) and LA function (strain) are independently related 
to new onset atrial fibrillation, 2) the burden of new onset atrial fibrillation is 
significant despite the relative young age, even in patients with LA diameter <45 
mm, and 3) adding LA volume and/or LA strain assessment on top of LA diameter 
improves prediction of new onset atrial fibrillation with both parameters yielding 
high negative predictive value in the subset of patients with LA diameter <45 mm.
Left atrial remodeling comprises structural and functional changes usually 
preceding atrial arrhythmias. In the current study, patients developing new onset 
atrial fibrillation had larger LA size (diameter and volume) and more impaired LA 
function (strain), compared to HCM patients free of atrial fibrillation. HCM patients 
are particularly prone to adverse atrial remodeling for several reasons. Increased 
filling pressures due to left ventricular diastolic dysfunction and hypertrophy, mi-
tral regurgitation and outflow tract obstruction are well known determinants of in-
creased LA size in HCM patients.14,15 Moreover, increased atrial fibrosis contributes 
to atrial enlargement and functional impairment.16 Although evidence is scarce, 
intrinsic atrial myopathy as part of the molecular disease has been suggested as 
well.5 Specific sarcomeric gene mutations have recently been described in atypical 
forms of HCM that relate to juvenile onset of atrial fibrillation in these patients.17 
Even polymorphisms in non-sarcomeric genes, encoding for proteins involved in 






























Likelihood ratio test in patients with left atrial diameter <45 mm (n=186). Subsequent addition of both left atrial 











act as HCM disease modifiers, increasing the likelihood of atrial fibrillation devel-
opment.18 Therefore it is not unexpected that atrial fibrillation often complicates 
the natural course of HCM, translating into a significant morbidity and mortality 
burden.
Increased LA size, evaluated by uni-dimensional antero-posterior diameter as-
sessment, has consistently been reported as one of the strongest correlates of 
atrial fibrillation in HCM patients.3,5 Current guidelines recommend intensification 
of diagnostic arrhythmia surveillance with 48-hour Holter 6-monthly once LA 
diameter equals or exceeds 45 mm.2 As atrial enlargement in the antero-posterior 
direction is restricted by the presence of the sternum and mediastinum (more spe-
cific), structural remodeling may be better described by evaluating atrial volume, 
often based on a 2-D approach (more sensitive).8,19 Several reports demonstrate 
that increased LA volume heralds increased risk of atrial fibrillation and might 
be preferred over LA diameter.7,8,20,21 The current study confirms this hypothesis, 
indicating higher sensitivity and negative predictive value of LA volume versus 
diameter to identify patients at risk for new onset atrial fibrillation.
Functional LA changes may coincide or even precede structural adaptations. De-
creased LA ejection fraction, evaluated by echocardiography or cardiac magnetic 
resonance imaging, has been linked to the occurrence of atrial fibrillation in HCM 
patients.7,20 Two-dimensional speckle tracking analysis allows angle independent 
assessment of LA function by measuring magnitude (strain) or rate (strain rate) 
of atrial deformation. In particular LA reservoir strain, referring to longitudinal 
deformation that occurs due to LA distention by pulmonary venous inflow dur-
ing ventricular systole (reservoir phase) is a highly sensitive technique, able to 
identify atrial changes even in patients with normal LA size.22,23 Hence, impaired 
LA reservoir strain is often noted in HCM patients.24 A recent cross-sectional report 
in a limited number of patients indicated more impaired lateral reservoir Doppler-
derived strain (rate) in HCM patients with versus without atrial fibrillation.21 One 
study in 50 HCM patients indicated that LA reservoir speckle-tracking derived strain 
independently predicts occurrence of atrial fibrillation requiring hospitalization 
(odds ratio 0.85, 95% CI 0.75-0.97, p=0.017).9 The present study, representing 
the largest cohort of HCM patients evaluated by LA strain so far, demonstrates 
higher sensitivity of LA strain compared to LA diameter to predict new onset atrial 
fibrillation and confirms its independent predictive value for this endpoint.
Importantly, 58% of new onset atrial fibrillation events in the HCM patients 
studied occurred despite a relatively preserved atrial diameter of <45 mm. This 
is of particular relevance as this subset of HCM patients is generally regarded as 
being at low risk to develop atrial fibrillation and no additional follow-up mea-
sures are recommended.2 We showed that patients with LA diameter <45 mm who 
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actually do develop atrial fibrillation have larger LA volume and more impaired LA 
function compared to patients free of atrial arrhythmia. In particular patients with 
LA volume ≥36 mL/m² or LA strain ≤23.4 % had worse survival free of atrial fibril-
lation. Presence of relatively preserved LA volume <36 mL/m² or LA strain >23.4 
% virtually excluded the risk of new onset atrial fibrillation (negative predictive 
value of 93% and 94%, respectively). Not unexpectedly, additional assessment 
of LA volume and LA strain therefore conveyed a higher predictive value for new 
onset atrial fibrillation in the subset of HCM patients with LA diameter <45 mm. 
These findings probably reflect the previously reported higher sensitivity of LA 
volume and LA strain assessment in comparison with LA diameter.
Clinical implications
Intensified monitoring to detect atrial fibrillation should indeed be offered to HCM 
patients with dilated LA ≥45 mm, as recommended.2 Based on current findings, 
however, this strategy should not be restricted to those patients only, but LA vol-
ume and/or strain assessment should additionally be performed in order to rule 
out increased risk for atrial fibrillation. In those patients with LA volume >36 mL/² 
and/or LA strain <23.4 % it might therefore be prudent to intensify follow-up aim-
ing for detection of subsequent atrial fibrillation occurrence. In addition, obser-
vational data have indicated that patients with only one atrial fibrillation episode 
have similar risk for thromboembolism versus those with repeated episodes and 
oral anticoagulation using warfarin significantly decreased that likelihood.5,6 It has 
been suggested that prophylactic anticoagulation in HCM patients with increased 
LA size should be the focus of additional research. In light of current findings it 
might prove valuable to consider additional assessment of LA volume or strain 
to facilitate such clinical decision-making. Finally ablation for atrial fibrillation in 
HCM patients is increasingly reported although the results seem less compared to 
non-HCM patients.25,26 The value of LA volume and strain rather than LA diameter 
to select candidates for ablation and predict success or recurrence of arrhythmia 
in HCM patients may be the scope of future investigation.
Limitations
Some limitations merit attention. First, this report is a retrospective longitudinal 
analysis of patients referred to a tertiary HCM center; therefore selection bias can-
not be fully excluded. Second, ICD recipients are submitted to continuous heart 
rhythm monitoring, increasing the likelihood of atrial fibrillation detection. Other 
patients were followed by annual ECG or Holter monitoring (at discretion of treat-
ing physician). Therefore the true prevalence of new onset atrial fibrillation may 











Both LA size (diameter and volume) and function (strain) are independently re-
lated to new onset atrial fibrillation in HCM patients. A significant proportion of 
atrial fibrillation events, however, occurs in patients despite relatively preserved 
LA diameter <45 mm. Assessment of LA volume and strain have incremental pre-
dictive value in this patient subset, in particular to exclude increased risk for atrial 
fibrillation development based on high negative predictive value. These findings 
might impact on provision and intensity of follow-up surveillance to detect atrial 
fibrillation in HCM patients with preserved LA size.
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In this thesis we explored risk stratification and management of patients with struc-
tural heart disease, focusing on valvular heart disease and primary hypertrophic 
cardiomyopathy. In particular the potential clinical role of advanced echocardiog-
raphy, including 3D-echocardiography and deformation imaging (strain), as well as 
clinical surrogates, were evaluated. The introduction of this thesis summarizes the 
rationale and background of our study.
The global burden of valvular heart disease such as aortic stenosis or mitral 
regurgitation is significant, and it is expected to increase due to Western popula-
tion ageing. Left untreated, valvular heart disease is associated with poor prog-
nosis. As older patients often present with several co-morbidities, interventional 
treatment tailored to their inherent high or prohibitive surgical risk is key and can 
nowadays be provided by less invasive percutaneous valve replacement or repair 
techniques, as indicated in the introduction of this thesis. Primary hypertrophic 
cardiomyopathy due to sarcomeric mutation(s), affecting about 1 out of 500 
people, is associated with increased risk of sudden cardiac death, heart failure, 
arrhythmia and thrombo-embolism. Although the absolute sudden cardiac death 
risk is rather low, its impact is substantial as it tends to occur in young patients 
and gains significant media attention when it affects young athletes during sports, 
fueling debates about preventive sport participation screening. Risk stratification 
and adequate patient selection for interventions in patients with structural heart 
disease such as valvular heart disease or primary hypertrophic cardiomyopathy 
are critical to assess the need, timing and type of therapeutic intervention and as-
sure beneficial outcomes. We elaborated how clinical risk scores or surrogates as 
well as advanced echocardiography techniques including 3-dimensional echocar-
diography and deformation imaging (strain) may be ideally suited for this purpose 
in patients with valvular heart disease and primary hypertrophic cardiomyopathy. 
In particular, the search for techniques or clinical surrogates that relate to the pres-
ence of fibrosis, a critical determinant of disease course in both forms of structural 
heart disease, is explained.
Part I: 3-Dimensional echocardiography
In the first part we explored the value of a novel clinical risk score to predict out-
come after transcatheter aortic valve implantation and studied the potential role 
of non-invasive cardiac imaging in mitral valve disease, focusing on 3-dimensional 
echocardiography.
In Chapter 2 we present a clinical risk score, the ‘TAVI2-SCORe’, that we devel-
oped to predict one year mortality after transcatheter aortic valve implantation 
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(TAVI), based on preprocedural clinical and echocardiographic characteristics of 
511 patients that underwent this procedure. Porcelein Thoracic aorta, Anemia, 
left Ventricular dysfunction, recent myocardial Infarction, male Sex, Critical aortic 
valve stenosis, Old age and Renal dysfunction, were independently related to 1 
year mortality after TAVI and comprised the constituents of the ‘TAVI2-SCORe’. 
Proportional to the hazard ratio, each constituent was assigned 1 point and 2 
points for recent myocardial infarction. We indicated better discrimination and 
calibration performance of this novel risk score compared to conventional surgical 
risk scores to predict the endpoint. The ‘TAVI2-SCORe’ is an accurate, simple and 
bed-side available score that might assist to select those patients at high surgical 
risk that may ultimately benefit form TAVI treatment.
In Chapter 3 we provided an overview of contemporary non-invasive cardiac im-
aging techniques that can be applied to study mitral valve anatomy and function, 
in perspective to potential clinical applications. In particular we highlighted the 
role of 3-dimensional echocardiography for superior mitral valve morphological 
evaluation compared to 2-dimensional echocardiography, its potential for valve 
geometry assessment and its additive value to assess valve function comprising 
mitral stenosis or regurgitation. Multidetector row computed tomography offers 
mitral valve morphology and geometry evaluation with high spatial resolution in 
addition to providing anatomical imaging of the relationship of the valve with sur-
rounding structures such as coronary sinus or circumflex artery. Such information 
may be critical when evaluating technical feasibility for indirect percutaneous 
annuloplasty techniques. The strength of cardiac magnetic resonance imaging in 
mitral valve disease involves being an accurate alternative for mitral regurgitation 
assessment, particularly in patients with poor acoustic window or contra-indication 
for transesophageal echocardiography.
Evidence is accumulating that mitral valve leaflets in patients with heart failure 
undergo active ultrastructural and structural remodeling, including larger leaflet 
area compared to normal controls. In Chapter 4 we showed, using advanced 3-di-
mensional echocardiography, that patients with functional mitral regurgitation 
indeed show larger leaflet area compared to normal subjects. More important, less 
leaflet remodeling was noted in patients with ≥ grade 3 versus < grade 3 functional 
mitral regurgitation, despite similar tethering degree. Lack of coaptation reserve 
(coaptation area ≤ 24% of the overall mitral valve leaflet area) was independently 
related to more severe mitral regurgitation. In addition we indicated that left 
ventricular function and sphericity as well as tenting volume and annulus dilata-
tion are determinants of mitral leaflet remodeling. Such findings imply that the 
mitral valve leaflets are no innocent bystanders in functional mitral valve disease 







regurgitation. Therefore the mitral leaflets in functional mitral valve disease might 
represent a biological or interventional therapeutic target.
In Chapter 5 we described the use of 3-dimensional transesophageal echocar-
diography (3D-TOE) for selecting and guiding in percutaneous mitral valve repair 
treatment using MitraClip. Evaluating technical feasibility for MitraClip therapy is 
a critical determinant of postprocedural success. 3D-TOE offers superior morpho-
logical characterization of the mitral valve and displays the presence and extent 
of morphological lesions. In addition it offers unique possibilities for evaluating 
coaptation length and depth in functional regurgitation as well as flail width and 
gap in organic disease. Furthermore, characterization of the origin and number 
of regurgitant jets as well as accurate quantification of regurgitation severity and 
leaflet area can be accomplished. During the percutaneous MitraClip procedure, 
3D-TOE is indispensable for guiding transseptal puncture, steering of the guid-
ing catheter in the left atrium, positioning and perpendicular alignment of the 
clip, mitral leaflet grasping and postprocedural evaluation, including regurgita-
tion reduction and residual valve area. Finally, 3D-TOE provides a common and 
comprehensible communication platform between imagers, interventionalists and 
cardiac surgeons.
In Chapter 6 we aimed to assess the effect on mitral valve geometry in 42 
patients that underwent percutaneous MitraClip therapy for functional mitral 
regurgitation. We showed that the mitral annulus becomes more elliptical with a 
tendency towards antero-posterior dimension reduction. Importantly, the coapta-
tion area significantly increases after MitraClip by including mainly a larger part of 
the anterior mitral valve leaflet into the coaptation, bringing the coaptation point 
more anteriorly. These beneficial effects are noted, despite no increased leaflet 
stress as no change occurred in tenting volume or annular height to intercommis-
sural width ratio. Therefore MitraClip therapy seems to affect mitral coaptation 
geometry similarly to surgical mitral annuloplasty, however, through a different 
mechanism. These geometric insights might fuel further design iterations and 
help understanding therapeutic efficacy and ultimately durability of percutaneous 
repair using MitraClip.
Part II: Echocardiographic deformation imaging
In the second part of this thesis we explored the role of risk stratification by ECG 
and myocardial deformation imaging (strain), as surrogate markers of fibrosis.
Chapter 7 comprises an evaluation of QRS fragmentation, a surrogate marker 
of fibrosis, and QTc duration on surface ECG in 195 primary hypertrophic cardio-
myopathy patients without (in)complete bundle branch block. We showed that 
the presence of extensive QRS fragmentation in ≥ 3 territories (inferior, lateral, 
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septal and/or anterior) and/or QTc ≥ 460 ms independently related to malignant 
ventricular tachyarrhythmia and sudden cardiac death in these patients. Impor-
tantly, we indicated that both surface ECG markers provide incremental value on 
top of conventional sudden cardiac death risk factors to predict the combined 
endpoint, each yielding a positive predictive value of about 30%, which is higher 
than the usually reported 10 to 20% for conventional sudden death risk factors. 
These findings implicate that QRS fragmentation and QTc duration may serve as 
additional sudden death risk markers that might optimize selection of appropriate 
candidates for implantation of automated implantable cardioverter defibrillators 
(ICD).
In Chapter 8 we documented the potential role of imaging fibrosis in patients 
with severe left-sided valvular heart disease, focusing on aortic stenosis and mi-
tral regurgitation. Focal and/or diffuse fibrosis formation is inherent to the natural 
disease course of severe valvular heart disease and relates to symptoms and 
dismal outcome. This renders imaging markers or surrogates of fibrosis a valuable 
potential tool to assist in risk stratification and decision making for the need and 
timing of valvular interventions. Delayed contrast-enhanced cardiac magnetic 
resonance imaging, T1 weighted cardiac magnetic resonance imaging, calibrated 
integrated backscatter echocardiography and several molecular nuclear imaging 
techniques provide direct fibrosis assessment. Indirect evaluation of ventricular 
fibrosis is offered by strain (rate) imaging using echocardiography or cardiac 
magnetic resonance as well as perfusable tissue fraction and index using positron 
emission tomography. Evidence for the use of imaging markers of fibrosis in left-
sided valvular heart disease is rapidly accumulating as they hold great promise for 
early risk stratification in asymptomatic patients with severe left-sided valvular 
heart disease. Whether such an approach outperforms conventional risk factors in 
valvular heart disease and ultimately can improve outcome after valve interven-
tion needs to be proven.
Volume overload in mitral regurgitation primarily affects the left atrium, making 
it an attractive potential subject for risk stratification. In Chapter 9 we explored 
the value of left atrial function assessment using 2-dimensional speckle track-
ing echocardiography in 121 patients with severe organic mitral regurgitation 
compared to 70 control subjects. We indicated that significant left atrial reservoir 
and contractile dysfunction was present in mitral regurgitation patients, particu-
larly in those subjects with indication for mitral valve surgery based on current 
recommendations. Left atrial reservoir function (strain) independently predicted 
presence of surgical indication and proved to be more sensitive than left atrial 
diameter or volume. Left atrial strain ≤ 24% identified those patients with worse 







intervention. Impaired left atrial reservoir strain provided incremental value to 
predict mortality after surgery over current guidelines-based indications for mitral 
surgery. Therefore left atrial reservoir strain might be a valuable marker for follow-
up and decision-making in patients with severe organic mitral regurgitation.
ICD device therapy improves outcome in selected primary hypertrophic cardio-
myopathy patients, but accurate predictors of appropriate ICD therapy are poorly 
documented in this subgroup of patients. In Chapter 10, global longitudinal left 
ventricular strain (GLS) and left atrial volume index (LAVI) were evaluated in 92 
primary hypertrophic cardiomyopathy patients that underwent ICD implantation. 
Both imaging markers related to appropriate ICD therapy, a combined endpoint of 
antitachycardia-pacing and/or shock for ventricular arrhythmia, independently of 
and incremental to conventional sudden cardiac death risk factors. Importantly, 
the combined presence of LAVI < 34 mL/m² and GLS < -14% adequately ruled out 
likelihood of appropriate ICD therapy, reflected by a 100% negative predictive 
value. Therefore both LAVI and GLS assessment on top of conventional sudden 
cardiac death risk factors might be helpful to optimize referral criteria and timing 
of ICD implantation in hypertrophic cardiomyopathy patients.
Hypertrophic cardiomyopathy patients with left atrial diameter ≥ 45 mm are 
considered to be at high risk for atrial fibrillation and are recommended to undergo 
at least 6-monthly arrhythmia surveillance using 24 hour Holter registration. In the 
final Chapter 11 of this thesis, we assessed left atrial diameter, volume and func-
tion (reservoir strain by 2-dimensional speckle tracking echocardiography) in rela-
tion to new onset atrial fibrillation in 243 primary hypertrophic cardiomyopathy 
patients. Although all 3 left atrial parameters were independent correlates of atrial 
fibrillation, 58% of atrial fibrillation events occurred despite left atrial diameter < 
45 mm. In those patients, we showed high negative predictive values of 93% and 
94% for left atrial volume < 36 mL/m² and strain > 23.4 %, respectively. In this 
group of patients, left atrial volume provided incremental predictive value over 
left atrial diameter, even further increased by left atrial strain. In primary hyper-
trophic cardiomyopathy patients with preserved left atrial diameter but increased 
left atrial volume (≥ 36 mL/m²) or impaired strain (≤ 23.4%), intensification of 
follow-up to detect subsequent atrial fibrillation might be warranted, in addition 
to current recommendations.
CONCLuSIONS AND FuTuRE PERSPECTIVES
As risk is a continuum rather than a dichotomous event, risk stratification will 
not be perfect. Nevertheless risk stratification is key for optimal management of 
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patients with structural heart disease in daily clinical practice, including those 
with valvular heart disease or primary hypertrophic cardiomyopathy. Advanced 
echocardiographic techniques such as deformation imaging (strain) provide a very 
sensitive tool to assess early subclinical atrial or ventricular dysfunction, related 
to fibrosis, loading conditions, contractility and geometry in patients with valvular 
heart disease or primary hypertrophic cardiomyopathy, and offer a strong biologi-
cal correlate to prognosis. In addition clinical markers, including surface ECG mark-
ers such as fragmented QRS, may yield prognostic clinical value. Whether early 
fibrosis imaging represents a hallmark for risk stratification needs to be proven, 
but ongoing research and scientific efforts in search for optimized risk stratification 
using advanced echocardiography and clinical surrogates will guarantee optimal 
outcome for patients with structural heart disease.
A clear tendency towards less invasive and more percutaneous therapies for 
valvular heart disease, including direct or indirect repair and valve replacement, 
is present and fueled by tremendous efforts of clinicians, scientists, engineers 
and medical industry. Non invasive cardiac imaging, including 3-dimensional 
echocardiography, offers unique pathophysiological insights as well as accurate 
anatomical, morphological and functional imaging of patients with valvular heart 
disease that aids in the optimal selection of candidates and procedural guiding of 
patients undergoing such percutaneous interventions. As we are just at the begin-
ning of this intriguing era of percutaneous therapies for structural heart disease, it 
is crucial to confirm and further explore the indispensable role of 3-dimensional 
















In deze thesis bestudeerden we risico stratificatie en management van patiënten 
met structureel hartlijden, met focus op patiënten met hartklepaandoeningen en 
primaire hypertrofische cardiomyopathie. Meer bepaald werd de potentiële rol 
van geavanceerde echocardiografie, waaronder 3D-echocardiografie en deforma-
tie beeldvorming (strain), evenals klinische surrogaat merkers, geëvalueerd. De 
introductie tot deze thesis vat de rationale en achtergrond van onze studie samen.
De globale belasting van hartklepaandoeningen zoals aortaklep stenose of 
mitralisklep lekkage is significant, wordt verwacht toe te nemen door vergrijzing 
van de Westerse populatie en impliceert een ongunstige prognose wanneer on-
behandeld. Aangezien oudere patiënten zich vaak presenteren met verschillende 
co-morbiditeiten, is het primordiaal behandeling aan te bieden op maat van hun 
inherent hoog of prohibitief heelkundig risico. Dit kan tegenwoordig gerealiseerd 
worden door minder invasieve percutane klep vervanging of herstel technieken, 
zoals weergegeven in de introductie van deze thesis. Primaire hypertrofische 
cardiomyopathie secundair aan sarcomerische mutatie(s) treft ongeveer 1 op 
500 mensen en is geassocieerd met plotse dood, hartfalen, arritmie en thrombo-
embolische events. Hoewel het absolute plotse dood risico eerder beperkt is, 
is de impact substantieel aangezien dergelijke events de neiging hebben zich 
voor te doen bij jonge patiënten. Plotse dood bij jonge atleten tijdens sporten 
kan daarom vaak rekenen op belangrijke media aandacht en vormt steevast 
brandstof voor het maatschappelijk debat rond sport participatie screening. Risico 
stratificatie en adequate selectie van patiënten met structureel hartlijden zoals 
hartklep aandoeningen of primaire hypertrofische cardiomyopathie zijn dan ook 
kritisch om de nood, timing en het type therapeutische interventie te bepalen en 
gunstige uitkomsten te verzekeren. In deze thesis werkten we uit hoe klinische 
risico scores en hun surrogaten, zowel als geavanceerde echocardiografische 
technieken waaronder 3D-echocardiografie en deformatie beeldvorming (strain), 
ideale kandidaten kunnen zijn om dit doel te dienen bij patiënten met hartklep 
aandoeningen of primaire hypertrofische cardiomyopathie. Meer in het bijzonder 
werd de zoektocht naar technieken of klinische surrogaten die gerelateerd zijn aan 
de aanwezigheid van fibrose uitgelegd, een kritische determinant van de ziekte 
evolutie bij beide vormen van structureel hartlijden.
Deel I: 3-Dimensionele echocardiografie
In het eerste deel exploreerden we de waarde van een nieuwe klinische risico 
score om uitkomst te voorspellen na transcatheter aortaklep implantatie (TAVI) en 
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werd de potentiële rol van niet invasieve cardiale beeldvorming bij mitralisklep 
lijden bestudeerd, met focus op 3D-echocardiografie.
In Hoofdstuk 2 presenteren we een klinische risico score, de ‘TAVI2-SCORe’, 
die we ontwikkelden om 1-jaar overlijden na TAVI te voorspellen, gebaseerd op 
de pre-procedurale klinische en echocardiografische karakteristieken van 511 
patiënten die deze interventie ondergingen. Porceleinen Thoracale aorta, linker 
Ventrikel dysfunctie, recent myocard Infarct, mannelijk geslacht (Sex), Kritische 
aortaklep stenose, Anemie, Oudere leeftijd en Renale dysfunctie waren allen onaf-
hankelijk gerelateerd aan 1-jaar overlijden na TAVI en omvatten de verschillende 
componenten van de ‘TAVI2-SCORe’. Proportioneel aan de hazard ratio werd aan 
elke component 1 punt toegekend en 2 punten aan recent myocard infarct. We 
toonden aan dat deze nieuwe risico score beter presteerde betreffende discrimi-
natie en calibratie dan conventionele heelkundige risico scores met betrekking tot 
het eindpunt. De ‘TAVI2-SCORe’ is een accurate, simpele en bed-side beschikbare 
score die zou kunnen assisteren om die patiënten te selecteren dewelke een hoog 
risico hebben voor heelkunde, maar uiteindelijk toch zouden kunnen baat hebben 
bij TAVI behandeling.
In Hoofdstuk 3 werd een overzicht geboden van hedendaagse niet invasieve 
cardiale beeldvormingstechnieken die aangewend kunnen worden om mitralisk-
lep anatomie en functie te bestuderen en in perspectief geplaatst ten opzichte 
van potentiële klinische toepassingen. Meer bepaald stipten we de rol van 3D-
echocardiografie aan met betrekking tot superieure morfologische evaluatie van 
de mitralisklep in vergelijking met 2D-echocardiografie, zijn potentiële waarde 
voor klep geometrie evaluatie en zijn toegevoegde waarde voor bepaling en 
kwantificatie van mitralisklep stenose en lekkage. Multidetector row computed 
tomography (MDCT) biedt eveneens de mogelijkheid tot geometrische en mor-
fologische evaluatie van de mitralisklep met hoge spatiale resolutie, naast de 
gelegenheid om anatomische beeldvorming te verrichten van de relatie tussen 
de klep en zijn omliggende anatomische structuren zoals de coronaire sinus of de 
circumflex coronair arterie. Dit laatste kan van kritisch belang zijn bij het evalueren 
van de geschiktheid van patiënten voor het ondergaan van percutane annulo-
plastie technieken. De kracht van cardiale magnetische resonantie beeldvorming 
bij mitralisklep aandoeningen omvat een alternatief bieden voor bepaling van 
mitralisklep lekkage, voornamelijk bij patiënten met een beperkte echogeniciteit 
of contra-indicaties voor slokdarm echocardiografie.
Meer en meer evidentie stapelt zich op dat mitralisklepblaadjes in patiënten 
met hartfalen actieve structurele en ultra-structurele remodeling ondergaan, 
waaronder een groter klepblad oppervlakte vergeleken met controle patiënten. 









grafische evaluatie van mitralisklep geometrie, dat patiënten met functionele mi-
tralisklep lekkage inderdaad een grotere klepblad oppervlakte hebben vergeleken 
met normale subjecten. Belangrijker nog, we stelden vast dat minder klepblad 
remodeling aanwezig was bij patiënten met ≥ graad 3 versus < graad 3 lekkage, on-
danks eenzelfde graad van trekkrachten op de klepblaadjes (tethering). Dergelijk 
gebrek aan coaptatie reserve (coaptatie oppervlakte ≤ 24% van de totale klepblad 
oppervlakte) was onafhankelijk gerelateerd aan meer uitgesproken mitralisklep 
lekkage. Daarenboven toonden we aan dat linker ventrikel functie en sfericiteit 
naast tenting volume en annulus dilatatie determinanten zijn van mitralisklepblad 
remodeling. Deze bevindingen impliceren dat de mitralisklepblaadjes niet zomaar 
onschuldige ‘bystanders’ zijn bij functioneel mitraliskleplijden aangezien grotere 
klepblaadjes voor dezelfde graad van tethering protectief kunnen zijn ten aanzien 
van significante mitralisklep lekkage. Daarom is het niet uitgesloten dat de mitra-
lisklepblaadjes in functioneel mitraliskleplijden een biologisch of interventioneel 
doel-op-zich zouden kunnen vormen.
In Hoodstuk 5 beschreven we het gebruik van 3D-slokdarm echocardiografie 
voor de selectie en het begeleiden van percutane mitralisklepherstel behandel-
ing door middel van MitraClip. Het evalueren van de technische geschiktheid 
van een kandidaat voor MitraClip behandeling is een kritische determinant van 
post-procedureel succes. 3D-slokdarm echocardiografie biedt superieure mor-
fologische karakterisatie van de mitralisklep en geeft adequaat de aanwezigheid 
en uitgebreidheid weer van morfologische laesies. Bovendien biedt het unieke 
mogelijkheden om de coaptatie lengte en diepte te bepalen bij functioneel mi-
traliskleplijden, alsook de opportuniteit om de breedte en de omvang van een 
flail klepbladsegment te bepalen bij organische klepziekte. Daarenboven kan de 
karakterisatie van de origine en het aantal lekkende jets bekomen worden, alsook 
accurate kwantificatie van de ernst van het kleplek en de klepblad oppervlakte. Ti-
jdens de MitraClip procedure is 3D-slokdarm echocardiografie tevens onontbeer-
lijk voor begeleiding van de trans-septale punctie, sturing van de guiding-catheter 
in het linker atrium, positionering en loodrechte alignatie van de clip, grijpen van 
de klepblaadjes alsook de post-procedurele evaluatie, waaronder bepaling van 
de kleplek reductie en residuele klepoppervlakte. Tot slot biedt 3D-slokdarm 
echocardiografie een gemeenschappelijk en inzichtelijk communicatie platform 
tussen beeldvormers, interventie cardiologen en hartchirurgen.
In Hoofdstuk 6 streefden we ernaar om het effect op mitralisklep geometrie te 
evalueren bij 42 patiënten dewelke percutane MitraClip behandeling ondergingen 
voor functionele mitralisklep lekkage. We toonden aan dat de mitralis annulus 
meer elliptisch wordt met een trend tot reductie van de voor-achterwaartse diam-
eter. Daarenboven was een belangrijke vaststelling dat de coaptatie oppervlakte 
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significant toenam na MitraClip, voornamelijk door inclusie van een groter deel 
van het voorste mitralisklepblad in de coaptatie, waardoor het coaptatie punt meer 
naar anterior komt te liggen. Deze gunstige veranderingen werden opgetekend 
ondanks afwezigheid van toename in klepblad stress, aangezien er geen wijziging 
was in tenting volume noch annulaire hoogte tot inter-commissurale breedte ratio. 
Daarom lijkt het zo dat MitraClip eenzelfde effect bekomt op mitralisklep coapta-
tie geometrie zoals bij heelkundige annuloplastie, zij het door een verschillend 
mechanisme. Deze geometrische inzichten kunnen brandstof vormen tot verdere 
design aanpassingen en helpen bij het begrip van therapeutische efficaciteit en 
uiteindelijk durabiliteit van percutaan herstel door middel van MitraClip.
Deel 2: Echocardiografische deformatie beeldvorming
In het tweede deel van deze thesis exploreerden we de rol van risico stratificatie 
door middel van ECG en myocardiale deformatie beeldvorming (strain), als sur-
rogaat merkers van fibrose.
Hoofdstuk 7 omvat een evaluatie van QRS fragmentatie, een surrogaat fibrose 
merker, en QTc duur op oppervlakte ECG bij 195 primaire hypertrofische cardiomy-
opathie patiënten in afwezigheid van (on)volledig bundeltak blok. We toonden aan 
dat de aanwezigheid van uitgebreide QRS fragmentatie in ≥ 3 gebieden (inferior, 
lateraal, septaal en/of anterior) en/of een QTc duur van ≥ 460 ms onafhankelijk 
gerelateerd zijn aan maligne ventrikel tachy-aritmie en plotse cardiale dood bij 
deze patiënten. Belangrijker nog, we stelden vast dat beide oppervlakte ECG merk-
ers meerwaarde bieden bovenop de conventionele plotse dood risicofactoren om 
het eindpunt te voorspellen. Beide merkers hebben een positieve predictieve 
waarde rond 30%, wat hoger is dan de meestal gerapporteerde 10 tot 20% voor 
conventionele plotse cardiale dood risico factoren. Deze bevindingen impliceren 
dat QRS fragmentatie en QTc duur additionele risico merkers zouden kunnen zijn 
dewelke de selectie van juiste kandidaten kan optimaliseren voor implantatie van 
een automatische defibrillator (ICD).
In Hoofdstuk 8 documenteerden we de potentiële rol van fibrose beeldvorming 
bij patiënten met ernstig linkszijdig kleplijden, met focus op aortaklep stenose en 
mitralisklep lekkage. Zowel focale als diffuse fibrose zijn inherent aan het natu-
urlijk verloop van ernstig kleplijden en zijn gerelateerd aan symptomen en on-
gunstige prognose. Daarom zijn fibrose beeldvorming merkers of surrogaten een 
waardevolle potentiële tool om te helpen bij risico stratificatie en besluitvorming 
betreffende de nood en timing van klepinterventies. Laattijdige contrast-versterkte 
cardiale magnetische resonantie, T1-gewogen cardiale magnetische resonantie, 
gecalibreerde geïntegreerde backscatter echocardiografie en verscheidene mo-









mogelijk. Indirecte evaluatie van fibrose is op zijn beurt mogelijk door strain (rate) 
beeldvorming op basis van echocardiografie of cardiale magnetische resonantie, 
alsook door perfundeerbare weefsel fractie en index gebruik makende van posi-
tron emissie tomografie. Evidentie voor het gebruik van fibrose merkers bij linkszi-
jdig kleplijden accumuleert snel, aangezien zij veelbelovend zijn betreffende de 
mogelijkheid tot vroegtijdige risico stratificatie in asymptomatische patiënten met 
ernstig linkszijdig kleplijden. Of een dergelijke aanpak daadwerkelijk conventio-
nele risico factoren in kleplijden kan overtroeven en uiteindelijk zo de uitkomst 
kan helpen verbeteren na klep interventie dient nog te worden bewezen.
Volume overbelasting bij patiënten met mitralisklep lekkage treft in de eerste 
plaats het linker atrium dat daarom een attractieve potentiële kandidaat is voor 
risico stratificatie. In Hoofdstuk 9 verkenden we de waarde van linker atriale 
functie evaluatie op basis van 2D speckle-tracking echocardiografie in een groep 
van 121 patiënten met ernstige organische mitralisklep lekkage, vergeleken met 
70 controle patiënten. We toonden aan dat significante linker atriale reservoir en 
contractiele dysfunctie aanwezig is in patiënten met mitralisklep lekkage, voor-
namelijk in patiënten die een indicatie vormen voor mitralisklep heelkunde, ge-
baseerd op de huidige richtlijnen. Linker atriale reservoir functie (strain) was niet 
alleen een onafhankelijke predictor van de aanwezigheid van een heelkundige 
indicatie, maar bleek eveneens sensitiever dan linker atriale diameter of volume. 
Linker atriale dysfunctie op basis van een strain waarde ≤24 % identificeerde 
patiënten met gedaalde overleving na mitralisklep heelkunde en dit, belangrijk, 
onafhankelijk van de symptomatische status voor de interventie. Verminderde 
linker atriale reservoir strain bood incrementele waarde om postoperatieve mor-
taliteit te voorspellen bovenop de huidige richtlijn-aanbevelingen voor mitralisk-
lep heelkunde. Daarom zou linker atriale reservoir strain een waardevolle merker 
kunnen zijn voor follow-up en beslissingsvorming bij patiënten met ernstige 
organische mitralisklep lekkage.
ICD device therapie verbetert de uitkomst van geselecteerde patiënten met 
primaire hypertrofische cardiomyopathie. Desondanks bestaat er actueel slechts 
beperkte documentatie omtrent adequate predictoren van terechte ICD therapie 
in deze patiënten subgroep. In Hoofdstuk 10 werden globale longitudinale strain 
(GLS) en linker atriale volume geïndexeerd voor lichaamsoppervlakte (LAVI) 
bestudeerd in 92 primaire hypertrofische cardiomyopathie patiënten dewelke 
ICD implantatie ondergingen. Beide beeldvorming merkers waren gerelateerd aan 
terechte ICD therapie, gedefinieerd als een gecombineerd eindpunt bestaande uit 
anti-tachycardie pacing en/of shock voor ventriculaire aritmie, en dit onafhankelijk 
en incrementeel ten opzichte van conventionele risicofactoren voor plotse dood. 
Belangrijk, de gecombineerde aanwezigheid van LAVI < 34 ml/m² en GLS < -14 % 
– 250 –
sloten adequaat de waarschijnlijkheid voor terechte ICD therapie uit, weerspie-
geld door de 100% negatieve predictieve waarde. Aldus zouden beiden LAVI en 
GLS evaluatie, bovenop evaluatie van de conventionele risicofactoren voor plotse 
dood, een hulp kunnen bieden ter optimalisatie van criteria voor verwijzing alsook 
timing van ICD implantatie bij patiënten met primaire hypertrofische cardiomy-
opathie.
Primaire hypertrofische cardiomyopathie patiënten met een linker atriale 
diameter ≥ 45 mm worden als hoog risico patiënten beschouwd voor boezem-
fibrillatie. Dergelijke patiënten dienen daarom, op basis van de huidige richtlijn-
aanbevelingen, 6-maandelijks 24 uur Holter ritme registratie te ondergaan. 
In het laatste Hoofdstuk 11 van dit proefschrift evalueerden we linker atriale 
diameter, volume en functie (reservoir strain op basis van speckle-tracking echo-
cardiografie) in relatie tot de novo boezemfibrillatie in 243 patiënten met primaire 
hypertrofische cardiomyopathie. Hoewel alle 3 atriale parameters onafhankelijk 
gerelateerd waren met boezemfibrilleren, noteerden we 58% van de boezemfi-
brillatie events bij patiënten ondanks een linker atrium diameter < 45 mm. In die 
patiënten subgroep toonden we aan dat een linker atrium volume (geïndexeerd 
voor lichaamsoppervlakte) < 36 ml/m² een negatieve predictieve waarde had voor 
het eindpunt van 93%, en gelijkaardig 94% voor een linker atriale strain waarde > 
23.4 %. In deze groep bood linker atriale volume incrementele predictieve waarde 
voor de novo boezemfibrilleren bovenop linker atriale diameter. Toevoegen van 
linker atriale strain evaluatie verbeterde het predictief model verder significant. 
Bij patiënten met primaire hypertrofische cardiomyopathie en relatief bewaarde 
atriale diameter (< 45 mm), lijkt het dus aangewezen dat wanneer er een vergroot 
linker atriaal volume aanwezig is ≥ 36 ml/m² of een gedaalde linker atriale strain 
functie ≤ 23.4 %, intensificatie van follow-up ter detectie van boezemfibrillatie 
wordt aangeraden, aanvullend op de huidige aanbevelingen.
CONCLuSIES EN TOEkOMSTPERSPECTIEVEN
Aangezien risico een continuüm is eerder dan een dichotome gebeurtenis, zal 
beslissingsvorming op basis van risico stratificatie nooit perfect zijn. Desalniette-
min speelt risico stratificatie een sleutelrol bij optimaal management van patiënten 
met structureel hartlijden in de dagelijks praktijk, inclusief patiënten met kleplijden 
of primaire hypertrofische cardiomyopathie. Geavanceerde echocardiografische 
technieken zoals deformatie beeldvorming (strain) bieden bij dergelijke patiënten 
een ongeziene mogelijkheid om vroegtijdige atriale of ventriculaire dysfunctie op 









dewelke biologisch sterk gerelateerd is aan de prognose. Bovendien kunnen 
klinische merkers zoals gefragmenteerde QRS complexen op een oppervlakte 
ECG voor eenzelfde doel worden gebruikt. Of vroegtijdige fibrose beeldvorming 
daadwerkelijk de heilige graal van risico stratificatie vertegenwoordigt, dient nog 
te worden bewezen. Wel staat het reeds vast dat doorgedreven onderzoek en 
wetenschappelijke inspanningen op zoek naar optimalisatie van risico stratificatie 
en dus therapeutische besluitvorming op basis van geavanceerde echocardio-
grafie en klinische merkers mede een garantie zullen bieden om de uitkomst te 
verbeteren van patiënten met structureel hartlijden.
Een duidelijk trend tot minder invasieve en meer percutane therapieën ter be-
handeling van hartklep aandoeningen heeft zich afgetekend, waaronder direct of 
indirect klepherstel en klep vervanging. Deze evolutie wordt verder gevoed vanuit 
enorme inspanningen door clinici, wetenschappers, ingenieurs en de medische 
industrie. Niet invasieve cardiale beeldvorming, waaronder 3D-echocardiografie, 
vormt een uniek platform om fysio-pathologische inzichten te verwerven, alsook 
accurate anatomische, morfologische en functionele beeldvorming te verrichten 
bij patiënten met hartklep aandoeningen. Hierdoor kan optimale patiënten selec-
tie en procedurele begeleiding verzorgd worden van patiënten die een dergelijke 
percutane interventie ondergaan. Aangezien we nog maar aan de wieg staan van 
dit intrigerend tijdperk van percutane therapieën voor structureel hartlijden, is het 
cruciaal om de onmisbare rol van 3D-echocardiografie en overige beeldvorming-
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